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Abstract 
Cutaneous squamous cell carcinoma (cSCC) is a common skin malignancy. Rates of cSCC in 
Australia are the highest in the world, approaching 800 cases/100 000 people per annum in 
North Queensland. Between 2-5% of cSCC will metastasise to regional lymph nodes, 
representing a higher clinical stage and requiring more aggressive and more morbid 
treatment, principally surgery and radiotherapy. Little is known of the molecular mechanisms 
of metastasis in cSCC, which makes a stratified method of appropriate surveillance 
challenging.  
Patients with biopsy proven metastatic cSCC to lymph nodes of the head and neck were 
identified and recruited for fresh tumour and whole blood harvest. DNA extracted from 19 
nodal metastases of cSCC was sequenced using whole genome sequencing. Following quality 
control, in particular verification of tumour cellularity, this number was reduced to 15 for the 
purposes of the study. Tumour DNA was compared to DNA from whole blood (germline) to 
establish the pattern of somatic variation.  
Approaching 98% of the somatic short variants observed were in the noncoding regions of 
the genome in all samples. A mutational burden (207/Mb) greater than any other malignancy 
previously described underpinned the mutational landscape, characterised by UV implicated 
C>T single nucleotide variation in known oncogenes and tumour suppressor genes, a highly 
amplified genome and significant structural variation, particularly involving TTC28. 
Recurrent high impact short variants were seen in known cancer associated genes including 
TP53, CDKN2A and NOTCH1, but also in less well described but emerging genes of interest 
including MECOM, PTPRD, PLCB4, PCLO, CSMD3 and FAT4.  Non-coding variants were 
particularly evident in the TERT promoter region identifying a variant pattern not previously 
found in cSCC. Significant amplification of microRNA miR-3147 was seen in all samples. 
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Prominent amplification of cancer associated long non-coding RNAs not previously 
identified in cSCC was observed. These included PVT1, MALAT1, HULC and NORAD.  
Expression changes resulting from somatic mutation were explored using co-extracted RNA 
on the NanoString platform. Prominent overexpression of key genes in cancer progression 
and metastasis was observed such as NDRG1, PIK3CA and SOX2. 
This work has catalogued the extent and pattern of somatic variation in metastatic cSCC and 
has provided potential new targets that can now be investigated for their utility as biomarkers 
of progression and metastasis. 
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 1 
1 Introduction 
The perfect storm for cutaneous malignancy would be for a fair-skinned people to occupy a 
land with extreme ultraviolet radiation for most months of the year, to serially avoid sensible 
preventive strategies to avoid excessive solar skin damage, and to have an excellent health 
system which means the majority of the inhabitants live beyond 80 years of age. This perfect 
storm is the public health and clinical scenario that has given rise to the tsunami of cutaneous 
Squamous Cell Carcinoma (cSCC) in Australia, New Zealand and the US.  
For at least 40 years, Australia has been at the forefront of public health campaigns to 
promote preventive sun exposure strategies. It is likely these efforts will eventually lead to a 
decrease in the incidence of cSCC. But aside from a few examples, our research has centred 
on elegantly describing what we see in the clinic and observe during follow up. Very little is 
known about the molecular basis of advanced cutaneous squamous cell carcinoma. The era of 
massive parallel sequencing has allowed for a deeper understanding of the molecular biology 
of many cancers. The accessibility of such processing lead to our employing whole genome 
sequencing to further explore the mutational profile of metastatic cSCC. Our challenge, and 
responsibility, was to use the opportunity afforded us by our clinical workload to progress the 
understanding of the molecular and genetic basis of metastatic cSCC. 
1.1 Clinical context 
Cutaneous squamous cell carcinoma (cSCC) is the second most common malignancy, after 
basal cell carcinoma (BCC), affecting up to 500 000 people in the United States (US) 
annually (American Cancer Society 2018). The non-melanoma skin cancers (NMSC) are 
more common than all other cancers combined (Fransen, Karahalios et al 2012). The burden 
of NMSC is so great that central cancer registries in both the US and Australia specifically 
exclude the collection of data on their incidence.   Though absolute incidence of NMSC and 
cSCC in Australia is simply unknown, current estimates are >176,000 cases per year (Perera 
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et al 2015) . In a 2017 review of Australian Health Insurance Commission billing items and 
tissue subtypes (Pandeya et al 2017), the incidence of primary cSCC was estimated at 270 per 
100 000 person-years.  
 
Figure 1-1. 29 year old male with left lower lip cSCC with metastasis to ipsilateral 
upper cervical lymph nodes. Treatment entailed radical excision of lower lip cSCC and 
selective neck dissection followed by adjuvant external beam radiotherapy (Ashford 
patient).  
The highest incidence is observed in Queensland, Australia where the annual age adjusted 
incidence of cSCC was determined to be 573/100 000 in males (Pandeya et al 2017). 
Lymph node metastases occur in approximately 2-5% of cSCC (Venebles, Autier et al 2018, 
Forest, Clark 2010).  The majority of cSCC arising in the scalp and face generally show a 
predictable pattern of spread predominantly to intraparotid, level II (upper jugular) and 
perifacial lymph nodes (Forest, Clark et al. 2010) see also Figure 1-1 and Figure 1-2. 
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Figure 1-2.  Lymph node levels of the neck. Taken from chapter “Advanced 
Developments in Neck Dissection Technique: Perspectives in Minimally Invasive 
Surgery” in “Neck Dissection- Clinical Application and Recent Advances” Lee and 
Chung (2012)  
 
 
The pattern of lymph node metastasis from varying regions of the head and neck was first 
described in a landmark survey of 209 patients with metastatic cSCC from known primary 
locations (Vauterin, Veness et al 2006). Of particular note was the importance of the nodal 
basins of the parotid gland and the drainage along the external jugular vein lymphatics 
(Figure 1-3). This was the first detailed description of this pattern of metastasis in cSCC in an 
Australian cohort.  
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Figure 1-3 Patterns of spread to regional lymph nodes depending upon location of 
primary, noting the predilection for parotid and external jugular drainage (From 
Vauterin, Veness et al 2006) 
 
Limited progress has been made in the management of regionally advanced disease over the 
last 15 years. Most patients are managed with parotidectomy, neck dissection and adjuvant 
external beam radiotherapy depending on the site and stage at diagnosis (Veness 2005). 
Treatment failures are usually locoregional.  Durable salvage following locoregional failure 
is rarely achievable as there are no effective second line therapies. Options for retreatment in 
this setting principally include radical surgical resections and are highly morbid, with 
profound physical, functional and psychosocial effects that greatly affect the quality of life 
for both patients and their carers. The ageing Australian population also means that there will 
be an increase in the incidence of cSCC, principally neglected head and neck cutaneous 
primary disease and metastases to the parotid and the regional lymph nodes.   
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The Sydney Head and Neck Cancer Institute manages advanced/metastatic cSCC in a 
multidisciplinary setting and treats in excess of 80 cases per annum and has published 
extensively on the staging, clinicopathological features and outcomes of metastatic cSCC 
(Ch’ng 2013, Forrest 2010, Gore 2016).  My clinical practice in Wollongong included more 
than 30 cases of metastatic cSCC/year over the years 2013-16. 
 
Unfortunately, despite high-level prospective data, the best predictors of nodal metastases 
such as tumour thickness and perineural invasion are not sufficiently discriminatory to 
change clinical practice because the majority (>85%) of ‘high risk’ tumours will not develop 
metastases. In addition, the ‘high risk’ predictors for nodal metastases do not address the 
critical group with medium to low-risk local disease where early intervention for nodal 
metastases will impact on survival (Ch’ng, Clark et al 2013). This was clearly demonstrated 
in the largest series of sentinel node biopsies for ‘high risk’ cSCC where mortality due to 
local recurrence out-weighed any beneficial effect (see Gore et al 2016 below). 
 
1.2 Aetiology of cSCC 
Ultraviolet (UV) radiation exposure and immunosuppression are the key factors in the 
development of cSCC (Alam, Ratner 2001).  UVB (280-315nm wavelength) is the dominant 
environmental risk factor for cSCC (Armstrong, Kricker 2001).  Long term sun exposure 
implies an increased risk, particularly in individuals with skin photosensitivity and lower 
melanin content as determined by the Fitzpatrick classification of skin phenotypes. This is 
more frequent in males and increases with age. UVB induced p53 loss of function is the 
index event in cSCC carcinogenesis. 
Immunosuppression is a critical risk factor for both the development and metastasis of 
cSCC(Euvrard, Kanitakis et al. 2003).  Nearly 82% of Australian transplant recipients will 
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develop skin cancers 20 years post transplant (Veness, Quinn 1999). The immunosuppressed 
population shows higher recurrence rates of cSCC. The rates of metastasis are ten times 
greater than immunocompetent individuals.  The degree of immunosuppression also confers 
greater risk for development of cSCC following transplant. For example, heart transplant 
recipients and those who suffer from rejection events within the first year generally require 
greater levels of immunosuppression and have higher rates of cSCC than the wider transplant 
population (Veness, Quinn 1999). 
Rare inherited genetic conditions such as Xeroderma pigmentosa, an autosomal recessive 
disorder of DNA repair following UV induced injury, lead to cutaneous malignancy and  
death due to melanoma and cSCC (Soufir 2000). 
 
1.3 Staging of cSCC 
Staging of solid organ malignancies is according to the American Joint Committee on Cancer 
(AJCC) Cancer Staging Manual, currently in 8th edition. This Manual stratifies disease in 
clinical and pathological stages in terms of primary Tumour, Lymph Nodes and distant 
Metastasis (TNM). The current version for SCC of the head and neck is presented in 
Appendix 1. Nodal metastasis confers a five year survival ranging from 55 to 75% (Brunner, 
Veness 2013). 
 
It is worth noting that there is no discrimination between mucosal and cutaneous disease, 
which has led to criticism as to the utilities of the staging system to act as a prognostic tool 
(Liu, Ebrahimi 2017). The limitations of the 8th edition of the AJCC Cancer Staging Manual 
with respect to cutaneous head & neck SCC are indicative of our relative lack of 
understanding of this disease.  
 
 
 7 
1.4 Conventional methods for assessment of metastatic potential of cSCC 
Traditional means of assessing risk of metastasis in primary cSCC include clinical features 
such as location of the primary (lip and ear) and immunosuppression, and histopathological 
features such as tumour thickness, poor differentiation, lymphovascular invasion and 
perineural infiltration (Peat, Insull et al. 2012). These semiqualitative factors are highly 
unreliable predictors of metastatic potential.  
 
Immunohistochemistry (IHC) is a cost effective method of detecting protein expression that 
can be easily integrated into the routine clinical diagnostic workup of patients. Differential 
protein expression secondary to mutations or post translational changes could be explored in 
patients with cSCC. 
 
Currently, there are no reliable immunohistochemical stains that can be used for evaluation of 
metastatic potential in routine diagnostic work up of any organ system. Various experimental 
stains including focal adhesion kinase (FAK) are being evaluated in gynaecologic and 
urologic malignancies with promising results in estimation of metastatic spread (Aust, Auer 
2014).   Other experimental immunostains such as wingless type receptor homolog 6 (FZD6), 
pleiotropin (PTN), cathepsin and matrix metalloproteinases (1,10,13) have been evaluated in 
research settings but are not used in clinical practice. 
 
In a well-designed prospective study (Brantsch, Meisner et al. 2008), thickness, 
immunosuppression, location on the ear and maximum tumour dimension were identified as 
significant predictors of metastasis. Factors predicting for nodal metastases are often 
interchangeable with prognostic factors. In a review of 239 patients with established nodal 
metastases from cSCC (Ch’ng, Clark 2013), multivariate analysis of the primary tumour 
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including tumour differentiation, margin status, tumour size and thickness found that only 
poor tumour differentiation of the primary was associated with shorter disease free survival. 
Similarly, Brantsch et al identified thickness >6.0mm and poor differentiation as significant 
factors for metastasis. Our study outlined below (Gore, Shaw et al 2016) reporting a large 
series of sentinel node biopsies for high risk cutaneous SCC supports the importance of 
tumour thickness. Nodal metastases only occurred in tumours more than 4mm thick and the 
number of high risk factors (4 or more) was the best predictor of nodal metastases, rather than 
any individual clinicopathological variable. 
 
We are not the first group to attempt to establish a link between types of primary tumours and 
the likelihood of metastatic disease. Sentinel node biopsy (SNB) is used in numerous 
malignancies including breast and penile carcinoma, as well as in melanoma to stage nodal 
disease in higher risk primary tumours (Giuliano, Kirgan et al 1994, Kelley, Ollila et al 
1998). Sentinel node biopsy allows for the detection of low volume nodal metastasis in the 
most likely first echelon node immediately downstream of the index lesion. The facility of 
detailed examination of a single lymph node is to allow for multiple and serial sectioning of a 
single node not possible in the multiple lymph nodes seen in a larger sample harvested in a 
formal neck dissection. The examination of sentinel nodes in high risk cSCC might allow for 
the alignment of risk factors beyond those previously described for metastasis.  
 
Our group has published the largest prospective series of sentinel node examination in high 
risk cSCC (Gore, Shaw et al 2016). Patients with high risk primary cSCC were prospectively 
enrolled to undergo sentinel node biopsy. Full clinicopathological status was documented and 
the patients were followed for recurrence and also emergence of occult nodal disease despite 
negative sentinel node status (false negative biopsy). 
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Inclusion criteria comprised at least one of these characteristics in a patient with cSCC: 
1. Tumour size > 2cm  
2. Invasion into subcutaneous fat or tumour thickness >5 mm 
3. Poorly differentiated tumour 
4. Perineural invasion 
5. Lymphovascular invasion 
6. Local Recurrence in the setting of adequate prior resection margins 
7. Ear or lip location 
8. Immunocompromise (post-organ transplant, chemotherapy) 
9. Carcinoma in pre-existing scar 
 
Enrolled patients received treatment based on the nature of their presentation. Patients who 
presented with a high-risk primary or recurrent cSCC were offered wide excision of the 
tumour and concurrent SNB. Those who presented following excision of a cSCC that was 
subsequently confirmed (by pathological or clinical criteria) to be high-risk were offered 
secondary SNB, either alone or along with a wider excision if that were deemed appropriate.  
 
Identification of the likely sentinel node was achieved using both radio-isotope and 
intraoperative mapping. Pre-operative lymphoscintigraphy was performed according to local 
nuclear medicine department protocols. Intra-operatively patent blue dye or isosulfan blue 
was injected intradermally at four points around the middle of the scar, tumour or the edge of 
a small skin graft or flap.  
 
SNB was typically performed prior to primary tumour excision, unless the location of the 
primary tumour hampered the detection of the sentinel node field in which case the primary 
tumour site was resected first. Incisions for SNB were made in appropriately planned sites for 
inclusion in potential completion lymph node dissections. Sentinel nodes were identified by 
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the combination of the pre-operative lymphoscintigram, the visually identified “blue” node 
and the use of a hand-held gamma probe.  
 
Primary tumour resection margins were individualized according to clinicopathological 
criteria, in all cases aiming for macroscopic tumour clearance and histologically clear 
margins. Wound closure was at the discretion of the operating surgeon. 
 
All Sentinel nodes were cut along their longitudinal axis in 3 mm thick slices and embedded 
entirely in paraffin blocks following tissue processing. Four sequential 5μm tissue sections 
were cut from each block and stained with haematoxylin and eosin (sections 1 and 4) and 
cytokeratins for immunohistochemistry (sections 2 and 3). Each section was examined 
microscopically for the presence of metastatic tumour cells by an experienced 
histopathologist. 
 
SNB was undertaken in 45 patients (79%) at the time of cSCC resection, of which 17 (30%) 
were recurrent tumours. In 12 cases (21%) pathological analysis of the primary tumour 
following excision prompted SNB and further wide local excision was performed to achieve 
adequate margins.  
 
The mean tumour diameter was 25mm (range 6 - 65mm) and mean depth of invasion was 
9.2mm (range 1.0 – 22mm). In 44 cases the tumour was over 5mm thick or was at least 
invading to Clark level 4. In 22 patients previous surgery had been performed in the region of 
the tumour and 31 patients had been treated for prior non-melanoma skin cancer. The mean 
number of sentinel nodes identified on pre-operative lymphoscintigraphy was 2.2 (range 0-6). 
Two cases underwent immediate selective neck dissection because of the finding of 
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macroscopic tumour whilst the remaining 55 cases had only sentinel nodes resected. In the 55 
SNB cases the number of resected nodes was slightly higher than those identified on 
lymphoscintigraphy (mean 2.7, range 0-7). In four cases no nodal tissue was identified on 
histopathology despite confirmation with blue dye and intra-operative gamma probe. This 
occurred exclusively in patients with prior radiotherapy and scalp primaries with drainage to 
retroauricular or occipital nodal basins. 
 
In total, seven patients (12.3%) had subclinical nodal metastasis detected at the time of 
planned SNB. In five cases (8.8%) micro-metastatic SCC was detected on pathological 
examination and in two cases (3.5%) macroscopic tumour was discovered at the time of 
sentinel node biopsy exploration. All seven patients proceeded to therapeutic 
lymphadenectomy; the five SNB cases were performed as completion lymphadenectomies 
following histopathology results whereas the two patients with macroscopic disease 
proceeded to immediate selective neck dissection. Of five patients who had nodal micro-
metastasis and proceeded to CLND, two had further metastatic disease identified in the neck 
dissection specimen (one further positive node in each of these cases).  
 
Median follow up was 19.4 months (range 2.4 - 41 months). At the time of analysis nine 
(15.8%) patients had developed recurrence, of which three had subclinical metastasis 
detected by SNB. There were six (10.5%) patients who had died of cSCC, of which two had 
subclinical metastasis detected, giving a three-year disease specific survival rate of 82%. 
There were eight local failures (SNB +ve n=2), two regional failures (SNB +ve n=1) and 
three distant failures (SNB +ve n=2)  One patient developed regional recurrence after failed 
sentinel node biopsy increasing the true number of patients with subclinical nodal metastasis 
to eight (14%). This patient underwent preoperative lymphoscintigraphy but although nodal 
tissue was removed this was not confirmed to be the sentinel node by standard criteria (blue 
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dye / gamma probe count). The patient developed recurrence at the site of exploration. In 
addition, one patient developed in-field regional recurrence after positive sentinel node 
biopsy, bilateral neck dissection and postoperative radiotherapy. This patient subsequently 
died of disease and was the only patient to die with established regional recurrence following 
positive SNB. The other five patients who died of disease during the follow-up period 
suffered local recurrence (n=4) and /or distant disease (n=2). No episodes of distant 
recurrence in the absence of local or regional recurrence have been noted. Patients with 
confirmed subclinical metastatic disease had a significantly higher mortality rate than those 
whose SNBs were negative for disease (p=0.0082).  
 
In this study the factors associated with a high risk (>20%) of nodal metastasis were depth of 
invasion ≥10mm, lymphovascular invasion, perineural invasion, poorly differentiated 
tumours, location on the lip, nose or ear, and four (or more) factors combined. On 
multivariable analysis the strongest predictors of metastasis were the number of high risk 
tumour factors present, the presence of perineural invasion and also the presence of 
lymphovascular invasion. Depth of invasion remains an important consideration as all 
patients with metastasis had primary tumours more than 5mm thick.  
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Figure 1-4. Kaplan-Meier survival analysis of patients with (‘Nodal_Metastases = Y’) 
and without (‘Nodal_Metastases = N’) nodal metastasis. Patients with metastasis had 
significantly worse survival than those without (p=0.0082). 
 
Our group has recently updated the data on this study to include a total of 105 SNB 
procedures were performed on 104 patients, with one patient undergoing two SNB’s for 
metachronous lesions 32 months apart (currently under consideration for publication).  The 
average age at time of SNB was 65 years with a strong male preponderance (male:female = 
90:14). The SNB was performed at the time of initial lesion excision on 41 occasions (39%), 
after pathological examination of the lesion, with or without further excision to achieve 
adequate margins, on 31 occasions (30%) or at the time of recurrent lesion resection on 34 
occasions (32%).  
 
In total, 15 patients (14.3%) had subclinical nodal metastases, including 10 patients with a 
positive sentinel node (9.5%) and an additional five patients (4.8%) who developed nodal 
recurrence on follow up). Macroscopic disease was identified at the time of SNB in four 
cases and CLND was undertaken at the time of SNB. Microscopic disease was identified on 
pathological examination of the sentinel nodes in six cases with three having CLND as per 
protocol. The remaining two patients underwent post-operative radiotherapy and one declined 
any further intervention. This patient developed recurrence 11 months after SNB and 
subsequently underwent a level II-V neck dissection with 3 of 26 nodes positive. Of the 
seven patients who underwent either immediate or staged neck dissection as per protocol, the 
median number of nodes removed was 35 (range 6-60) and the median number of involved 
nodes was 2 (range 1-14), including nodes removed with the SNB. The negative predictive 
value of SNB was 94.7%. Overall sensitivity for SNB was 66.7% with a 100% specificity.   
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Median follow up as was 26.2 months (range 0.3-78 months). At the time of analysis there 
were 13 local recurrences (four SNB positive), eight regional recurrences (three SNB 
positive) and four distant metastases (three SNB positive). One patient developed nodal 
metastases more than five years after SNB in the context of multiple subsequent cutaneous 
SCC excisions and this was not believed to be related to the index lesion for which the SNB 
was performed. Another patient developed distant disease (L2 vertebra deposit) in the 
absence of local or regional recurrence. In total, 10 patients died from cSCC during follow up 
with a 5-year disease specific survival rate of 83.1%.  Patients with subclinical nodal 
metastases had a significantly higher mortality compared to those without nodal metastases 
(p<0.0001). Of the deceased, death was due local failure in three, regional failure in two, 
distant failure in two, local and regional failure in one, local and distant failure in one, and 
one patient died with local, regional and distant failure.   
 
On univariable analysis the only significant predictor of subclinical nodal metastases was 
depth of invasion. The rate of nodal metastases in patient with DOI ≥ 5mm was 19.7% 
compared to 0% in patients with DOI < 5mm (p=0.01). The rate of nodal metastases in 
patient with DOI ≥ 10mm was 25% compared to 0% in patients with DOI < 5mm (p=0.001). 
However, in patients with both a depth of invasion ≥ 5mm and perineural invasion, the rate of 
nodal metastases was 28% compared to 8.2% in patients who did not fulfil both criteria (p= 
0.02) The median number of inclusion criteria for patients with subclinical nodal metastases 
was four as compared to three for patients without nodal metastases (p= 0.036). 
 
No individual high-risk feature (i.e. inclusion criteria) was significant in predicting 
subclinical nodal metastasis on multivariable analysis using logistic regression. Using a 
backward elimination method, only the number of inclusion criteria was statistically 
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significant (p= 0.035; OR 3.3 for 4 or more compared to 3 or less). When the number of 
inclusion criteria was excluded from the model and the depth criteria was set to greater than 
10mm (as all positive SNB lesions were greater than 5mm), then the only significant 
predictor of subclinical nodal metastases was depth greater than 10mm (p = 0.043; OR 3.2). 
Once again the survival data underlines the significant negative prognostic impact of nodal 
metastasis. 
 
 
Figure 1-5. Expanded survival data for patients undergoing sentinel node biopsy. Nodal 
metastasis (N=15), no nodal metastasis (N=89). Data taken from Mooney, Martin 
manuscript (listed in publications cited earlier) 
 
 
1.5 Genomic observations 
As discussed above, the conventional clinicopathologic prognostic markers in cSCC have 
been shown to be highly unreliable predictors of metastasis in our own prospective study of 
SNB.  Metastasis driver mutations may exist in cSCC that could be used to more reliably 
predict metastasis risk in primary high risk cSCC at the time of initial presentation. However, 
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relatively little is understood of the molecular and genetic basis of metastasis in cSCC. 
Clinically relevant and reproducible molecular signatures that can predict metastatic potential 
in the primary cSCC at initial presentation have not been described.  An understanding of the 
molecular and genetic pathways of metastasis in cSCC has the potential to positively 
influence countless lives affected by cSCC in countries with high solar exposure by allowing 
for better stratification of risk, more efficient surveillance and the delivery of targeted 
therapies that may have lower toxicity and increase potency in patients with recurrent 
disease. 
 
Within the genomic examination of cSCC have been papers utilising targeted next generation 
sequencing (NGS) and whole exome sequencing (WES) (discussed further below). There are 
currently no reports of whole genome sequencing (WGS) being employed in cSCC (primary 
or metastatic) and there is no WGS data for cSCC in The Cancer Genome Atlas (TCGA) 
(https://portal.gdc.cancer.gov). Reference will be made throughout this introduction to the 
techniques used as applicable.  
 
Skin is our first line of defence against environmental assault. The established model for 
carcinogenesis (Hanahan, Wienberg 2011) involves genomic instability, cell cycle 
dysregulation, induction of telomere maintenance mechanism and an angiogenic switch.  
Normal, sun-exposed skin harbours many of the key driver mutations that are seen in cSCC 
(Martincorena 2015). This study used targeted NGS and highlighted the breadth and 
frequency of UV associated mutations in macroscopically normal skin excised in the course 
of blepharoplasty. Common gene mutations included those within the NOTCH family and 
TP53, at a frequency about 10% of that seen in cSCC. This underlines the continuum 
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between early genotypic changes tolerated in “normal” skin and the phenotypic expression of 
atypia, dysplasia and ultimately cSCC. 
 
One of the few publications to cite genetic abnormalities in cSCC highlights the density of 
mutations (Durinck, Ho et al. 2011).  These authors performed WES of eight primary cSCC 
and found approximately 1300 somatic single-nucleotide variations per cSCC exome 
(1/30000 base pairs). This is amongst the highest degree of mutation observation for any 
cancer described. The authors hypothesize that the constant reinjury to the basal epithelial 
cells by UV radiation is at the root of the multiple mutational events in cSCC, including 
significant TP53 (100% of samples) and NOTCH1,2 mutations. Variation in established 
cancer associated genes are outlined below for cSCC. These include TP53, NOTCH, RAS, 
CDKN2A and PTPR. 
 
1.5.1 TP53 family 
In cSCC, UVb exposure is implicated in gatekeeper TP53 mutation. This hypothesized 
initiating mechanism is seen in both pre-neoplastic actinic keratosis as well as in invasive 
SCC in UV exposed skin changes (Benjamin and Ananthaswamy 2006). TP53 (chr17p13.1) 
encodes the protein p53 which belongs to a family of transcription factors comprising p53, 
p63 and p73. p53 impacts transcription regulation via effects on cyclin dependant kinase 
activity. UV-induced mutation of TP53 has long been thought to be critical in loss of 
programmed cell death in abnormal squamous cells (Armstrong, Cricker 2001) and 
inactivating TP53 mutation has been understood since the 1990s as a cause of cutaneous 
malignancy (Basset-Seguin, Moles et al 1994). 
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TP53 family mutations can give rise to measurable decreases in expression of other putative 
tumour suppressor factors such as IFR6, a member of the Interferon Regulatory function 
transcription factors. IFR6 is involved in skin development, due in part to its interaction with 
p63. A study comparing cSCC with normal matched skin (Botti, Spallone et al. 2011) found 
subsequent downregulation of IFR6 in 71% of cSCC (cell line A431). This analysis 
correlated downregulation of IFR6 expression with poor differentiation and increased 
invasive potential. Altered expression probably also infers loss of intercellular adhesion, and 
perhaps, metastatic potential. Mutation of another tumour suppressor, DICER, has been 
suggested to augment the deleterious effect of TP53 mutation (Su, Chakrvarti 2010 and Lyle, 
Hoover et al 2014). 
 
1.5.2 NOTCH family 
The NOTCH signalling pathway is crucial to epidermal development and maturation. 
(Moriyama, Durham et al. 2008).  There are 4 families of NOTCH receptors (1-4). The genes 
are located at NOTCH1 (chr9q34.3), NOTCH2 (chr1p12), NOTCH3 (chr19p13.12) and 
NOTCH4 (chr6p21.32). NOTCH is a transcellular membrane molecule that once activated 
transfers its intracellular domain into the nucleus.  Intranuclear activation of various genes 
are reliant on NOTCH. 
NOTCH receptor activation or signalling, depending on the cellular context, can have either 
an oncogenic or tumour suppressing role.  Whole exome sequencing of head and neck 
mucosal SCC demonstrated that up to 15% of tumours show mutation in NOTCH1 receptors 
(Agarwal 2011) and loss of NOTCH1 is associated with disease progression. Thus whether it 
is inactivation of oncogene action, or loss of tumour suppression function, changes in 
NOTCH activity has implications in epithelial maturation and differentiation. NOTCH 
expression and activity can be manipulated by commensal human papilloma virus (HPV). 
 
 19 
 
1.5.3 RAS Family 
The RAS gene family comprise 3 RAS genes (H-, K- N-RAS) which encode a family of 
small GTPases (Marshall 1996).  These genes map to chromosome 11p (HRAS), 12p 
(KRAS) and 1p(NRAS). The active form exists with bound GTP (rather than GDP in the 
inactive state). RAS activation leads to downstream effects on cellular regulating molecules 
such as RAF, MEK and MAPK.  Some mutations of RAS can lead to prolonged activation 
due to insensitivity to processes that dephosphorylate GTP.  Activators of RAS, eg 
RASGRP1, a guanine nucleotide exchange factor, have been shown in mouse models to 
promote spontaneous cutaneous tumours when overexpressed (Sharma, Fonseca et al. 2014). 
Knockout mice also resist tumour formation. 
 
Activating RAS mutations are expected in up to 9% of cSCC. HRAS mutation is more 
commonly associated with cSCC than NRAS and KRAS. In a recent German study assessing 
focused sequencing analysis of FFPE extracted DNA, only 1/31 cSCC showed a RAS 
mutation (Mauerer, Herschberger et al. 2011). Again, the pattern of tumour suppression loss 
rather than oncogene activation that typifies cSCC was observed. 
In a study of targeted sequencing of DNA from cSCC in 21 patients on the various 
vemurafenib trials (Su, Viros, 2012), activating RAS mutations were identified in 60% of the 
cancers indicating that the MPAK altering repercussions of BRAF inhibition seem to have a 
potent oncogenic influence. In this study, HRAS mutations were most prominent. 
1.5.4 CDKN2A 
CDKN2A maps to chromosome 9 and encodes for two cell cycle regulatory proteins p16 and 
p14, which act via retinoblastoma and p53 pathways respectively. Mutations of CDKN2A 
lead to loss of function, and subsequent loss of expression. 
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Primary and metastatic cSCC were compared in a study investigating the prognostic 
significance of TP53, CDKN2A and HPV status in metastatic cSCC (Kusters-Vandevelde, 
Van Leeuwen et al. 2010). This study examined formalin-fixed, paraffin embedded 
specimens from both primary and metastatic cSCC, and normal tissue from 35 patients. 
Normal tissue was included for exclusion of germline mutations. Highly targeted sequencing 
was followed by PCR amplification from extracted DNA to assess TP53 and CDKN2A (both 
p16 and 14) mutations.  They observed an increased rate of CDKN2A mutation (31%) in the 
metastatic tumours when compared to sporadic primary cSCC (Soufir, Daya-Grosjean 2000), 
but at similar levels to Xeroderma pigmentosa primary cSCC. 
 
1.5.5 Protein tyrosine phosphatase receptors 
PTPRs are cell surface, transmembrane receptors involved in cell signalling via tyrosine 
phosphorylation. There are 21 PTPR. Some members of the family of PTPRs function as 
tumour suppressors. Loss of function due to mutation may have flow on effects on 
downstream signalling.  PTRP mutations have been observed in mucosal SCC, and a recent 
publication (Lui, Peyser et al. 2014) hypothesizes a role for loss of function of PTPRT 
leading to elevated levels of phosphorylated (activated) STAT3(oncogene) in head and neck 
(mucosal) SCC. There is no data to support or refute the role of this group in cSCC. 
This early exploration of genomic mutations associated with cSCC development barely 
begins to explain the complex pathway interaction dysfunction in cSCC. Some of these 
mutant pathway modifications will no doubt be responsible for not just cutaneous 
carcinogenesis, but will be implicated in the metastatic process, by altered expression of 
factors that enhance proliferation, extracellular stromal interaction and ultimately escape 
from the primary site. 
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1.5.6 More recent genomic observations for cSCC 
Pickering et al (Pickering, Zhou et al. 2014) have recently progressed the survey of the 
genetic landscape of high risk cSCC. Their group performed WES of DNA extracted from 
high risk head and neck cSCC fresh tissue.  Their aim was to establish the mutation pattern 
and frequency, and to identify driver mutations. They identified a high rate of mutations with 
a common pattern of UVB induction (C>T transition), and a strong preponderance toward 
inactivating mutations of tumour suppressor genes. Predictable loss of function mutations in 
tumour suppressor genes including TP53, NOTCH1 and NOTCH2 were observed. New driver 
gene mutations were observed in RIPK4 and RASA1. However, the identification of 
actionable mutations in cSCC was thwarted by the predominance of tumour suppressor gene 
inactivation as opposed to oncogene activation.  Detailed differential mutational patterns in 
primary and metastatic cSCC were not explored. 
 
Li, Hanna et al. (2015) examined single nucleotide variation and copy number variation in 29 
formalin fixed, paraffin embedded lymph node metastases of cSCC using a 504 cancer gene 
panel and categorized mutations as belonging to any of 4 categories: the RAS/RTK/PI3K 
pathway, cell cycle pathway (TP53, CDKN2A), squamous differentiation pathway (TP63, 
NOTCH) or epigenetic (chromatin remodelling) genes.  This is the first genomic analysis 
published addressing nodal metastases and offers valuable information. The most recurrently 
altered genes seen were TP53 (79% of cases), CDKN2A (48%) and NOTCH 1/2/4 (69%). 
They observed activating alterations in the RAS/RTK/PI3K pathways in 45% of samples. An 
association was observed between this activation and shorter progression free survival in 
their cohort of 29 cases. Other activating mutations in various tyrosine kinase / kinase 
pathways, upstream of known significant cell survival augmenting mediators such as MEK 
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and mTOR were observed. These included KIT, KRAS and BRAF. All specimens were judged 
as HPV negative by p16 IHC and analysis of HPV E6/7 genes. Interestingly, these authors 
reported no adverse effects from the challenges of nucleic acid extraction, processing and 
interpretation in the setting of formalin fixed specimens. 
 
The substantial mutation rate in the PIK3/Akt/mTOR pathway in the study by Li et al (2015) 
suggests a role for this central cascade in the metastatic spread of cSCC. This has been 
previously described as a point of difference between gastric cancers with and without 
peritoneal metastatic spread (Liu 2010). Using RT-qPCR on extracted RNA they 
demonstrated a 5x and 2x higher rate of mutation of the PIK3CA (encoding the catalytic 
subunit of p110alpha) in normal gastric and primary gastric cancers, respectively. This 
disordered regulation of the PIK3/Akt/mTOR pathway is a potential site of action on 
mutations enhancing metastasis. 
 
The identification of deleterious mutations likely to be drivers of carcinogenesis, and 
potentially metastasis, is hampered by the high level of background mutation in sun exposed 
skin as mentioned above (Martincorena 2015). A prospective study of sentinel node analysis 
on high risk cSCC (Gore, Shaw et al. 2016) confirmed non-metastatic cSCC with proven 
negative sentinel nodes and long clinical follow-up. In a related collaborative study using 
DNA from FFPE primary cSCC using a 48 cancer gene panel a surprising number of likely 
deleterious mutations in key driver genes (eg PIK3CA, NRAS, APC) were found when 
compared to uninvolved lymph node for germ line control (Zilberg, Lee et al,  2018). 
 
In an analysis of the mutational landscape of metastatic tumour deposits (total n=10000) from 
multiple malignancies, Zehir et al included 27 cases of metastatic nodal cSCC all with DNA 
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extracted from FFPE samples and subjected to targeted NGS (Zehir, Benayed et al. 2017). 
The custom panel of genes targeted included 410 genes that included known oncogenes and 
tumour suppressor genes, as well as key non coding regulatory areas like the TERT promoter. 
Overall, only 6 % of their samples had insufficient DNA yield to be used, and their average 
coverage for the panel was 718X. They found the most frequently observed variant in 
metastatic cSCC (indeed in all tumours analysed) was TP53. They did note 32% of patients 
harboured TERT promoter variants, albeit in a pattern different from that described by Huang 
et al (Huang, Hodis et al 2013) in melanoma.  
 
A recent reanalysis of 40 cSCC (Inman, Wang et al 2018), predominantly in 
immunocompromised patients (mostly solid organ transplant recipients) found a new suite of 
significantly mutated genes. These included the often reported TP53, NOTCH 1 and 2 and 
CDKN2A, but also identified HRAS, MAP3K9, PTEN, SF3B1, VPS41 and WHSC1 as well as 
deletion of HRAS. The key finding of this paper was the description of a new mutational 
signature (based on the Catalogue of Somatic Mutations in Cancer (COSMIC) signature 
patterns) within cSCC related to therapy with the immunosuppressant azathioprine.   
 
 
1.6 Non-coding RNA – microRNA and lncRNA 
There has been emerging interest in the role of both micro RNA and other non-coding but 
regulatory RNA elements in cancer. The research interest stems from not just their potential 
role in carcinogenesis and progression of malignancy, but also their potential for use as 
biomarkers. MicroRNAs are small (22 nucleotide) RNAs transcribed in the nucleus in a 
primer form to be activated by Dicer after transport into the cytoplasm (Reinhart, Slack et al 
2000). There they act on mRNA to block translation (Almeada, Reis et al 2011).  
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In cSCC, a number of studies have examined the role of microRNA (miR). Perhaps the first 
of these was an examination of miR in cSCC cell lines, normal skin, actinic keratosis and 
frank cSCC (Xu, Zhang et al 2012). By RT pCR and immune fluorescence hybridization, the 
authors reported up-regulation of 4 miR (31, 135b, 21 and 223) as well as down-regulation of 
54 miR, including 125b, in both cSCC and cell lines when compared to both actinic keratosis 
and normal skin which they found by microarray analysis targeted MMP13. They identified 
that miR-125b suppressed proliferation and colony formation as well as the migration and 
invasive capacity of cSCC cells and that down regulation reduced the deactivation of 
MMP13. 
 
miR-203 was found to be inversely correlated with tumour differentiation in cSCC samples 
and cell lines (UT-SCC-7 (metastatic) and A341), and was active against c-MYC, effectively 
having a tumour suppressor effect (Lohcharoenkal, Harada et al 2016).  
 
Using qPCR on RNA from in situ and invasive cSCC, miR-21, miR-103a, miR- 186, miR-
200b, miR-203, and miR-205 expression levels were compared (Stojadinovic, Ramirez et al 
2016). They found between invasive and in situ disease, both miR-21 and 205 were 
significantly upregulated, proposing a role in a more advanced state, by action of down-
regulation of genes MEIS1, KAT2B, and BLMH.  
There is evidence for upregulation of miR-31 in invasive cSCC compared to both actinic 
keratosis and normal healthy skin (Wang, Landen et al 2014). miR-31 is thought to oppose 
ITGA5, RDX and WAVE3 and RhoTBT1 (Lin, Zhou et al 2017).  With the exception of the 
inclusion of the (incompletely characterised) metastatic cell line UT-SCC-7, none of the 
aforementioned studies of microRNA have examined the metastatic stage of cSCC. 
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There is limited evidence for the role of long non-coding RNA (lncRNA) in metastasis of 
cSCC. Pipponen et al (2016) analysed the role of the long intergenic ncRNA LINC00162 in 
both cSCC and normal skin cell lines. They identified is overexpression in tumour cells (by 
RNA in situ hybridization) and not in normal skin cells. Knockdown resulted in suppression 
of growth of the tumour cells. They theorised LINC00162, which they renamed PICSAR 
(p38 inhibited cutaneous squamous cell carcinoma associated lincRNA), to act by regulation 
of ERK1/2 via DUSP6 downregulation.  
 
 
 
1.7 Epigenetic changes in cSCC 
Epigenetic changes reflect alterations in the histone supports of the nucleic acids. A recent 
report identified methylation profile differences in key CpG promoter sites between 
metastatic and non metastatic SCC and BCC (Darr, Colacino et al. 2014).  DNA extraction 
and methylation analysis using formalin fixed and paraffin embedded specimens of 37 
primary cSCC (and 5 BCC) showed hypermethylation at CpG sites and thus silencing of 
FRZB, TFAP2C and ASCL2 (Goldengate Cancer Panel) in cSCC that developed metastases 
as opposed to the cSCC that did not.  Pickering et al (Pickering, Zhou et al. 2014) showed an 
inactivating mutation of KMT2C in 39 cSCC, which encodes a histone methylation complex 
to alter transcriptional regulation. This mutation has been identified in other malignancies and 
was associated with increased incidence of bone invasion and a shorter time to recurrence in 
cSCC.  
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Chromatin accessibility as a result of genomic variants is an important area of interplay 
between genomic and epigenomic analysis. An example of this is in the promoter region of 
TERT where alteration in ETS binding site motifs with resultant increased affinity for the 
transcription factor as a result of somatic variants leads to an increase in histone methylation 
and chromatin opening(Liu, Yuan et al. 2016).  
 
1.8 Stromal influences and EMT in the tumour microenvironment 
Tumour-stromal interaction is key to the metastatic process.  Early invasion in cSCC is 
characterized by a desmoplastic stromal reaction. Fibroblasts from the stroma associated with 
cSCC have architectural and behavioural differences when compared to normal dermal 
fibroblasts (Commandeur, Ho et al. 2011).  Increased expression of vascular endothelial 
growth factor C has been shown in supraglottic (mucosal) SCC to be predictive of lymph 
node metastases (Baek et al 2009). Similarly altered expression of VEGF is seen in the 
stromal microenvironment in cSCC (Moussai, Mitsui et al. 2011) 
 
Phenotypic changes may result from pluripotent subpopulations of cells that behave as cancer 
stem cells. These cells can exhibit both epithelial-mesenchymal transition (EMT) and 
mesenchymal-epithelial transition (MET).  The transition between epithelial and 
mesenchymal phenotypes may be partial and may also be reversible (Lamouille et al 2014). 
The normal junctional integrity and polarity of epithelial cells in skin can, when exhibiting 
EMT, be characterised by a loss of E-cadherin expression and an abundance of expression of 
N(neural)-cadherin. Even this simple observation and explanation allows an appreciation of 
the altered function mediated by transcription factors that are either under or overproduced in 
the tumour microenvironment. Transcriptional repressors of E-cadherins include the 
mesenchymal markers Snail, Slug and Twist (Thiery et al 2009). Expression of these 
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repressors has been shown to be increased in poorly differentiated cSCC when compared to 
benign or well differentiated tumours. (Chen, Takahara et al. 2013). Overexpression of the 
mesenchymal proteins Twist, Zeb1, Vimentin, beta-catenin and Podoplanin was observed in 
metastatic when compared to non-metastatic cSCC (Moussai, Mitsui et al. 2011). TGF-ß 
through SMAD activation and intranuclear transport can upregulate EMT by activating 
transcription factors and inhibiting repressors, either directly, or through SNAIL to effect E-
cadherin expression (Lamouille et al 2014). 
 
Mesenchymal stem cells (MSCs) probably constitute a percentage of tumour associated cell 
population but may be attracted by tumour cells into the tumour-stromal interface 
(Chamberlain, Fox 2007). Karnoub, Dash et al (2007) described paracrine inducement of 
MSCs in the presence of breast tumour stroma, with increased metastasis. The urokinase-type 
plasminogen activation (uPA) system is a key component of extracellular matrix and 
basement membrane degradation and is overexpressed in more aggressive malignancies 
(Ranson, Andronicos 2003). The activation of this system allows for fibrinolysis via the 
conversion of plasminogen to plasmin and involves genes including PLAU, PLAUR 
SERPINE2 and SERPINB2. 
 
Recently, Laurenzana, Biagioni et al (2015) showed the effect of TGF-ß (canonical SMAD 
activation) on uPAR mediated mesenchymal expression within melanoma cells incubated 
with MSCs in vitro, as an upregulation of N-cadherin, a-SMA and vimentin, a decrease in E-
cadherin and enhanced expression of the E-cadherin transcriptional repressors SNAIL1/2. In 
vivo, when bone marrow stem cells were co-injected with melanoma cells in a mouse model, 
tumour progression was rapid, however, animals were euthanized due to tumour burden prior 
to the exhibition of established metastatic disease. Such growth factor induced altered 
 
 28 
expression with upregulation of pro-EMT mechanisms will be a focus of future research in 
metastasis, particularly with the emergence of organotypic culture models. 
 
We have previously published (Morosin et al 2016) a pilot study investigating the presence of 
circulating tumour cells (CTC) in the blood of patients with known metastatic cSCC. In this 
study, peripheral blood was drawn from patients, with resectable lymph node disease 
peripheral circulation prior to any manipulation of the tumour at the time of 
lymphadenectomy. Ep-CAM and cytokeratin markers were used to positively identify CTC 
after exclusion of circulating cells expressing CD45 (lymphocytes). CTC were identified in 
8/10 patients with metastatic cSCC, with tumour microemboli found in 3/10 samples. 
Notwithstanding technical considerations around cell surface expression in different EMT 
states, this study identified a potential role for CTC analysis in surveillance of patients post 
therapy to detect early recurrence. 
 
1.9 Differential expression in cSCC 
In a study comparing 2 cell lines of cSCC with a Bowen’s disease (carcinoma-in-situ) cell 
line, disease stage dependency dictated the expression of 1895 genes by using organotypic 
cultures and IHC, ISH and microarray (Serewko, Popa et al 2002). They found 
overexpression of EGFR, but reduced expression of FRA-1, MAPK and MAPKK.  
 
More recently, the predictive utility of inositol polyphosphate 5-phosphatase (INPP5A) was 
analysed and measured against biological behaviour in cSCC (Cumsky, Costello et al 2019). 
This was built upon earlier work using gene array, FISH and IHC showing loss of INPP5A 
may occur early in cSCC evolution (Sekulic, Kim et al 2010). They theorised that deletion of 
the short arm of chr10 contributed to the loss. Using IHC, Cumsky et al showed that reduced 
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INPP5A expression was also more consistent in more aggressive disease, including in worse 
differentiation, LVI and those that metastasised.  
 
The landmark study comparing both transplant requiring immunosuppression induced cSCC 
and actinic keratosis with that of normal skin in both the transplanted and other non-
transplanted patients (Nindl, Dang et al 2006) compared 22283 genes by microarray and 
identified 9 genes over expressed in the tumours. These genes were CDH1, MAP4K4, IL-
1RN, IL-4R, NMI, GRN, RAB31, TNC, and MMP1. There were 4 genes that were under 
expressed including ERCC1, APR-3, CGI-39 and NKEFB. 
 
Garcia-Diez et al (2019) identified underexpression of NEK10 and overexpression of both 
FOSL1 and BNC1 when comparing cSCC, actinic keratosis and normal skin in 10 matched 
pairs of immunocompetent patients.  
 
Expression of cyclin D1, a member of a family of cell cycle regulatory proteins, increases 
proliferation and disorganization of epithelium and is increased in both pre-neoplastic and 
malignant skin changes (Burnworth, Arendt et al. 2007). These authors describe a difference 
in p16 expression levels between pre-neoplastic and invasive carcinoma in their study cohort, 
hypothesizing that decreased p16 was an essential trigger for these preliminary changes to 
allow for the invasive progression. They also identified increased telomerase reverse 
transcriptase (hTERT) expression in both AK and SCC. 
 
The search for biomarkers of progression in cSCC has thus far borne limited fruit. In a  
review of analysis of their own cell lines and FFPE specimens, Kivisaari and Kahari (2013) 
highlight extracellular proteases and inhibitors including MMP-7 and SerpinA1 as potential 
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candidates. Using genome wide expression profiling comparing cSCC cell lines with normal 
keratinocytes they were able to identify expression differences between malignant and benign 
conditions ( Farshchian, Kivisaari et al 2011, Kivisaari, Kallajoki et al 2008). They then 
utilised rtPCR to validate the expression observations and ultimately used Western blot to 
confirm the translated protein effects of these. Primary cSCC FFPE samples were used for 
both IHC and also for tissue microarray construction.  
 
Erythropoietin-producing hepatocellular Type B2 (EphB2) is a ligand for a class of receptor 
tyrosine kinase.  It has been shown to have altered expression in metastasis in  colorectal 
cancer (Guo, Zhang et al 2006), wherein loss of EphB2 is associated with a more aggressive 
phenotype using tissue microarrays from adenomas, colon cancers and their metastases. 
Farshchian, Nissinen et al (2015) conversely showed that EphB2 expression promotes 
carcinogenesis, invasion and migration in cSCC cell lines and xenografts suggesting it could 
be used as a biomarker. This study did not make specific observations of the metastatic 
context.  
Using two datasets from the Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/)	
comprising normal skin/cell lines and primary cSCC, Wei, Chen et al (2018) determined that 
only EGR3 was consistently and significantly differentially expressed.  EGR3 encodes a 
transcription factor of the EGR family and impacts up to 330 genes some of which may lead 
to progression of malignancy through inflammatory mediators including IL-6 and 8 (Baron, 
Pio et al 2015).  Once again, the datasets used by Wei, Chen et al did not include any 
metastatic tumours or cell lines.  
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1.10 Project design, rationale and aims 
The design of this project was in response to a clinical question. An ongoing effort within our 
clinical research group is to identify the key determinants of metastasis and recurrence in 
cSCC. Annually we see more than 100 patients with metastatic cSCC. These patients had all 
had primary cSCC, often treated absolutely as per protocol, and yet they had recurred, 
commonly presenting with multiple lymph node metastases to the neck. The required 
treatment would usually include both surgery and adjuvant external beam radiotherapy, at 
significant quality of life cost to the patient, and significant financial cost to the community. 
As outlined above, our group had previously published a prospective study investigating the 
role of sentinel node biopsy in high risk cSCC with an interest in identifying which types of 
primary lesions were most likely to result in metastasis (Gore, Shaw et al  2016) Depth of 
invasion and perineural invasion were identified as key predictors of risk of metastasis, 
although the actual numbers of metastatic cases were low (15/104 patients enrolled). 
Nonetheless, the potential of interrogating the primary lesion by established clinical and 
pathological means to determine risk had been surveyed. 
 
In addition to our focus on the primary lesion in a bid to understand the metastatic process in 
cSCC, it became an emerging question as to whether looking at the metastatic deposit for 
clues would shed further light on a means to establish risk. The theory behind this was that 
the clone responsible for metastasis must in part persist as one of the dominant clones in the 
metastatic deposit. Sequencing options available for this project included targeted NGS, WES 
and WGS. Each modality has advantages and disadvantages including technical and logistic 
demands, depth and breadth of coverage and cost of both sequencing and bioinformatic 
analysis. Given the discovery nature of the project and the availability of fresh tissue for 
sequencing, a determination was made to proceed with WGS. The benefits that were 
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anticipated by this choice included the coverage of non-coding and regulatory regions of the 
genome and the ability to make genome wide assessments of mutational burden. Ultimately 
this assessment proved valid. To understand the genomic profile of the metastasis, the aim 
was to analyse fresh, viable tumour DNA by WGS, as this had never been reported in 
metastatic cSCC. We felt that to use this investigative process in a disease which dominated 
our clinical practices constituted sound clinical research and offered us an opportunity to 
describe for the first time the mutational landscape of this disease. 
 
1.10.1 Aims of this project 
Overall aim – to describe the overall pattern of somatic variation in metastatic cutaneous 
squamous cell carcinoma and to define particular regions of the genome, patterns of variation 
and genes for further analysis in order to facilitate identification of potential biomarkers of 
risk for metastasis. 
 
Specific aims 
1. Collection of matched samples of blood (germline) and nodal metastatic cSCC 
(tumour) and extraction of nucleic acids for downstream analysis 
2. Undertake WGS of quality controlled DNA to greater than 60X coverage for tumour 
and greater than 30X for germline 
3. Subject raw data to manipulation and then bioinformatics analysis to assess overall 
somatic mutational burden, structural variation, copy number variation and to detect 
short variants across both coding and non-coding regions of the genome. 
4. Analyse genes or regions that are either amplified or deleted, or genes that exhibit 
high impact or recurrent short variants for altered expression.  
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2 Methods 
2.1 Patient Recruitment 
Patients were recruited according to the protocol contained in the approved ethics application 
14/397 UOW/ISLHD HREC and LH 15.047 RPA/LH HREC. The ethics process involved 
about 4 months of work and 2 revisions to enable the approval to be granted and the study to 
commence.  
 
Recruitment commenced in February 2015. Patients with biopsy proven metastatic cutaneous 
SCC scheduled for surgery with a curative intent were eligible for inclusion of tissue for this 
study. All patients were initially seen in the consulting rooms of the surgeon and were then 
discussed at the local Head & Neck Cancer Multidisciplinary Team (MDT) meeting. 
Informed consent for both the procedure and for the collection of blood and tumour samples 
was obtained separately and, as per ethics approval, no patients had any parts of their 
treatment altered if they were unwilling to be involved in the study. 
 
Recruiting patients was not an issue for the same reason the project was conceived; the 
burden of disease is nearly overwhelming. So it was that the flow of patients willing to 
contribute to the research effort was plentiful. In the first 18 months of collection of samples, 
the patient accrual target of 60 cases had been achieved. 
 
Two centres were involved in sample collection. The Chris O’Brien Lifehouse at RPA 
(Camperdown) was the secondary site for sample collection and has had a tumour bank in 
place for some time. This is a formal process with a separate consent that allows for a 
standardized collection of key tissues, including demographics and sample handling. This is 
the ideal arrangement for a study such as this. The primary site for sample collection was 
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Wollongong Hospital. This was on the basis of proximity to our wet laboratory facilities and 
was particularly useful for the purposes of establishing a cell culture from freshly resected 
metastatic cSCC (J.Perry PhD Candidate UOW (Ranson)). At the commencement of the 
study, no formal tissue banking arrangement was in place in the Illawarra and Shoalhaven 
Local Health District (ISLHD). This meant that the quality control, clerking and storage of 
most of the tissue samples for the study fell to us and required a significant amount of time 
and technique critical detail. This requirement has now been usurped with the involvement of 
the Wollongong Hospital in the CONCERT (Centre for Oncology Education Research 
Translation) Biobank (http://concert.org.au/research/research-capabilities/concert-biobank). 
This facility is based at the Ingham Institute, but now runs a full service at the Wollongong 
Hospital. 
 
Regular reports to the HREC were delivered and there was no departure from the 
promulgated protocol. No patients withdrew consent from the study and there were no 
complaints identified by our research team pertinent to the research protocol.  
 
Patients were identified for inclusion in the study if they had biopsy proven metastatic cSCC. 
Most of these patients had a historical index lesion that had been excised or biopsied.  All of 
our patient’s index lesions were from head and neck sites.  
 
Resources allowed for the whole genome sequencing of 20 matched whole blood: tumour 
pairs to the 30X and 60-90X respectively. Prior to nucleic acid extraction, a snap frozen 
tumour sample was subjected to Pathologist review to determine tumour cellularity. Samples 
deemed > 30% tumour cellularity were then further processed. Clinicopathological data for 
 
 35 
the patients with metastatic disease from which DNA was used for sequencing is presented in 
Table 2.1. 
Examples of haematoxylin and eosin histopathological assessment of cellularity are presented 
in Figure 2.1. 
  
  
 
Figure 2.1. Pictures clockwise from upper left (i) 2 x magnification of 35% cellularity 
sample moderately differentiated cSCC revealing islands of tumour separated by non-
tumour fibrous tissue, (ii) Same tumour at 20 x magnification showing more cytological 
detail, (iii) 2 x magnification of 70% cellularity sample with less fibrous tissue, (iv) 20 x 
magnification of same tumour as (iii) showing cytological detail including higher grade 
(poorly differentiated) features. 
 
i ii 
iii iv 
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Table 2.1 Clinicopathologic data for  samples originally included for WGS analysis. Staging is according to AJCC 8th edition. LNY: Lymph 
node yield – total number of nodes resected. LNR: Lymph node ratio – number of positive nodes /total number of nodes. ECS: presence of 
extracapsular (nodal) spread. R Status: R0 – microscopically clear margin, R1 – Microscopically involved margin, R2 – macroscopically involved 
margin. Other: CLL- chronic lymphocytic leukaemia. Liver Txplant- liver transplant recipient on immunosuppression. RA Immunomodulation- 
rheumatoid arthritis on immunomodulation therapy. 
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Neck dissection for metastatic cSCC involves not simply the removal of the diseased node/s, 
but rather clearance of anatomical regions (levels) of lymph nodes allowing for the capture or 
harvest of occult metastases in more distant echelons.  This allows for a lymph node yield 
that maximizes the accuracy of pathologic staging and is likely to deliver the best curative 
effort. Following surgery and pathological reporting, all patients were then again considered 
by the local MDT. Herein recommendations were made to the patient about adjuvant 
treatment which in most cases consisted of radiotherapy. Following definitive treatment, 
patients had regular surveillance in the rooms of the treating doctors. 
 
There was no departure from established protocols for managing metastatic cSCC. 
Preoperative blood was drawn at the time of intravenous cannulation, usually by the 
attending Anaesthetist. At least 2ml of whole blood was collected in EDTA tubes that were 
then transferred to the laboratory for storage at -800C.  
 
2.2 Tissue Handling  
On the day of surgery, a sample of the metastatic deposit, approximately 10mm3 was 
preserved for storage and downstream analysis.  It was critical that the specimen retrieval did 
not compromise the work of the Pathologist.  The aim was to sample a section of the 
metastatic deposit from an area free of macroscopic necrosis and at the leading edge of the 
tumour:stromal interface. The specimen was then restored in overall arrangement by suturing 
and submitted to normal histopathological processing initially involving fixation in buffered 
formalin. 
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The harvested fresh sample was stored in cold buffered PBS for transport to the wet 
laboratory. Once received at the laboratory, the sample was divided into 30mg cubes and 
snap frozen in liquid nitrogen to be stored at -800C.  
 
Prior to any nucleic acid extraction, samples were formally assessed by a Consultant 
Pathologist experienced in cutaneous malignancy. One of the 30mg blocks was delivered to 
the pathology laboratory on dry ice. Once received, the sample was treated as a normal frozen 
section; embedded in medium and sectioned on a cryotome. An estimate of the cellularity of 
the specimen (that component comprising viable tumour cells) was made. An arbitrary cut-
off of 35% cellularity was used to determine is a sample was to be submitted for further 
processing. Almost half of our cases satisfied this cellularity threshold. 
 
2.3 Nucleic Acid Extraction 
Samples identified as having adequate cellularity were identified for nucleic acid extraction. 
Preparatory experiments for the nucleic acid extraction included comparing automated 
techniques of tissue homogenization. Following the homogenization and nucleic acid quality 
control application, the Miltenyi Gentle MACS™ system using the RNA01 program was 
selected for use with frozen tissue samples.  No specific homogenization program for DNA 
extraction is supplied on this platform. Tissue was processed in M tubes (a proprietary 
canister with an internal blade that is driven by the housing on the Gentle MACS processor), 
after the application of 600µl of RLT buffer. The post processing emulsion was then 
centrifuged at 4000 rpm for 5 minutes at 4oC. 
 
The resultant solution was then processed to extract both DNA and RNA using the AllPrep 
DNA/RNA/Protein Mini Kit (80004, Qiagen), according to the manufacturer’s instructions. 
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All resultant DNA and RNA samples were quantified using the NanoDrop (ND1000, 
Thermoscientific). The aimed absorbance levels for DNA and RNA were 260:280 ratios of 
1.8 (+/-0.1) and 2.0 (+/-0.1), respectively. The results of nucleic acid extraction are presented 
in Appendix 2. DNA samples were further analysed using 1% TAE agarose gels. Results of 
gel electrophoresis are included in Appendix 3. 
 
2.3.1 Germline (blood) nucleic acid extraction 
Whole blood was used for germline DNA. Some samples acquired initially as serum 
delivered insufficient DNA even using a kit specifically design for same. It was decided that 
whole blood (as per the initial protocol) was the preferred germline source and the 
PureLink® Genomic DNA Mini Kit was employed. Samples were quality controlled 
quantitatively with Nanodrop and gel electrophoresis.  
 
2.4 Sequencing 
The staging of funding allocation necessitated the sequencing of DNA through 2 laboratories. 
Both the Macrogen service outsourced through the Australian Phenomics Facility at the 
Australian National University and the inhouse sequencing provided by the Kinghorn Centre 
for Clinical Genomics (KCCG, Garvan Institute of Medical Research) utilised an Illumina Hi 
Seq X platform. 
Specifically, the process at Australian Phenomics Facility (ANU) included: 
1. Sample initial QC using nanodrop, agarose gel electrophoresis and Picogreen 
assay and sample final QC check using SNP arrays. 
2. WGS reads were generated on HiSeq X (Illumina Inc, San Diego, CA) as 
follows: 
a. Library Kit Type: Truseq Nano DNA kit 350bp insert 
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b. 150bp Paired End; 60X mappable and 45X mappable (sequencing depth) 
c. Expected Output: >100Gb per lane at raw data level 
3. Raw data was delivered in FASTQ, although both BAM and VCF were 
available. 
The KCCG service only differed in the sequencing depth, this being 90X for tumour DNA 
and 30X for germline DNA. 
 
2.5 Bioinformatic Workflow 
The process of turning WGS raw data into interpretable events is always complex. This is 
made moreso by an increased mutational burden. Prior to this study, melanoma had been 
identified as having the highest mutational burden, averaging in the order of 49 mutations per 
megabase for cutaneous melanoma (much greater than for variants including uveal and acral 
lentiginous) (Hayward, Wilmott et al. 2017).  
 
The process from sequencing to files able to be interpreted by a non-bioinformatician is long 
and expensive. For a single matched (tumour and germline) DNA sample undergoing WGS, 
the cost from eluted DNA to output data in 2018 was in excess of $10000. And beyond 
output files, significant bioinformatic interpretation and formatting for presentation is 
required.  
 
The pipeline consists broadly of variant calling from aligned reads, establishing the effect of 
variants, determining copy number (ploidy) of individual spans of reads, and interrogating 
break points to determine structural variation. 
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Seave, a bespoke Gemini-based program for searching and collating genomic variation across 
all forms had been previously used by co-workers to investigate the mutational landscape of 
lung cancer (Gayevskiy, Roscioli et al 2019). This set of applications runs in-series analysis 
across multiple bioinformatic file types and allows the user to dictate not just what type of 
variant is being sought, but also the parameters of confidence and incidence required for 
reporting.  
 
2.5.1 Sequencing outputs 
Sequencing provides short reads (up to 200 bases long) as an output FASTA file (Pearson,  
Lipman 1988). When the FASTA also includes quality data in the form of a Phred score, it is 
termed FASTQ. This is the usual output form for subsequent alignment to the reference 
genome. 
 
Following alignment to the reference genome (in our case GRCh37/hg19) files are in 2 
forms, SAM (Sequence Alignment Map) (Li, Handsaker et al. 2009) and BAM (the binary 
form of SAM). Both file types include sequencing data aligned to the genome from which 
can be made an index file to tag the relative positions of sequence within the entire genome. 
BAM is the input used for the Integrated Genome Viewer (IGV) (Broad Institute). IGV is the 
basis for confirming a mutation or anomaly seen on some other platform. It allows for 
assessment of the entire genome and can also enable very localized assessment and can 
review reads/point mutations and even breakpoint areas. To navigate around IGV using BAM 
files, the Index file (.bai) must be loaded concurrent with the .bam.  IGV is not a discovery 
tool, but rather a means by which outputs from bioinformatics analysis can be checked for 
veracity.  
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Sequenza (Favero, Joshi et al. 2015) was employed to calculate cellularity and copy number 
variation, a process dependant on adequate read depth in the region of interest. Less 
confidence in the output, as always, is the result of analysis of regions with poor coverage.  
 
Manta was the principle program utilized for structural variant analysis. Like Sequenza, it 
uses BAM files to look for breakpoints, and identifies insertions, deletions, inversions and 
translocations. SV analysis was further interrogated by using Mobile Element Locator Tool 
(MELT) (Gardner, Lam et al 2017). This tool enables the identification of somatic 
breakpoints built upon local sequence identifiers and the degree of confidence of the call for 
Mobile Element Insertions (MEI).  
 
Maftools (Mayakonda, Koeffler 2016) was used to derive Mutation annotated format (maf) 
files from Variant Calling Format files (see below). Thereafter, visual representation of short 
variants, and copy number variants were delivered in oncoplot form.  
 
Circos plots were generated to display an overall genomic variant profile, including structural 
variants using Purple. PURPLE is a purity ploidy estimator. It uses the read depth and 
tumour BAF to estimate the purity of a sample and generate a copy number profile. 
(https://github.com/hartwigmedical/hmftools/tree/master/purity-ploidy-estimator). PURPLE 
is one of a number of tools that can be utilised to provide relatable information as a function 
of copy number and sample purity. The 5 basic steps in the computation of values form 
PURPLE include (Preistley, Baber et al 2017)  
1. Calculate BAF in tumour at high confidence heterozygous germline loci  
2. Determine read depth ratios for tumour and reference genomes  
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3. Segmentation – the division of the genome into uniform Copy Number (CN) regions, 
within the limits of breakpoints and chromosomes 
4. Purity Fitting – relates ploidy and BAF to determine reliability of CN calls 
5. Smoothing – reduces outlying small variances in CN to related regions not including 
those broken by segmentation 
Diagrammatic representation of bioinformatic outputs were conceived in collaboration with 
and refined by Bioinformatician Dr M Gauthier. 
 
2.6 Scoring Variant Effects 
Variant calling, and subsequent variant effect prediction is the process whereby the aligned 
reads are subtracted from the germline, within ascribed confidence limits to identify somatic 
variants. Strelka was used as the variant caller (Saunders, Wong et al 2012) . The output of 
Strelka is a .vcf file (variant calling format). The effect of the variant can be measured (or 
scored) by algorithms, including SIFT, Polyphen and CADD, to provide evidence regarding 
the likely impact of variants to help understand the biological effect. 
 
2.6.1 SIFT (Sorting Intolerant From Tolerant) 
SIFT (Ng, Henikoff 2001) predicts the likely impact of an amino acid substitution due to a 
somatic variant in the coding genome. It uses the genomic information of a missense variant 
as input. SIFT scores range from 0-1 and a score less than 0.05 means the amino acid change 
is likely to be damaging, based on probability. Between 0.05 and 0.1, the biological effect of 
the change in protein function due to the amino acid change is judged to be possibly 
damaging. 
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2.6.2 PolyPhen 
PolyPhen (Adzhubei, Schmidt et al 2010) uses a similar mechanism to predict the effect of 
missense variants in the coding genome. It uses protein information to arrive at an assessment 
of biological effect. The possible outputs are probably damaging, possibly damaging and 
benign, all given with a confidence score, where closer to 1.0 is the highest level of 
confidence.  
 
2.6.3 CADD (Combined Annotation Dependent Depletion) 
CADD (Kirsher, Witten et al 2014) is a more recent addition to the predictive tools for 
genomic variants. CADD combines other scoring systems (including SIFT and PolyPhen) 
with integration with both large genomic datasets (such as 1000 Genome) to cover both 
coding and non-coding regions. CADD scores imply that for a score of 10, the variant is in 
the most damaging 10%of variants, and a score of 20 means the variant is in the highest 1% 
of damaging variants. Both raw and scaled CADD scores may be derived. Raw CADD scores 
are best to compare overall effect between 2 groups, eg control and study, whereas scaled 
scores are more useful for looking between small groups or individuals.  
 
Without translated data, these numerical interpretations of implied biological effect are not 
entirely accurate as identified in a recent review of this topic (Misoge, Field et al 2015). 
Nonetheless, these parameters serve as an independent measure of risk of biological impact. 
 
For each significant short variant reported, IGV was used to confirm the coverage in the 
region and the true nature of the variant in a given sample to trust the finding. Some GC rich 
areas seen in our samples had problems with coverage due to the challenges of genome 
assembly on the Illumina platform. Because coverage effects the reporting of variant allele 
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fractions and because coverage can be affected by such bias, high variant areas, or areas that 
we would expect to show variation but didn’t need to be reviewed for each sample to 
establish the reliability of the individual call. This is a manual process and took some time to 
learn and subsequently complete.  
 
2.7 Gene Expression Analyses 
Gene expression was explored using the NanoString nCounter Sprint system using the 770 
gene PanCancer Progression panel with 25 ng of RNA extracted as above from fresh frozen 
tumours as per the manufacturer's instructions (NanoString Technologies). Nanostring uses a 
hybrid probe to allow RNA in solution to be identified with a capture probe and subsequently 
reported by a reporter probe. This highly automated process delivers molecule counts for 
each gene of interest as a measure of expression. The molecule counts are compared and 
calibrated to that of housekeeping genes. Results were analysed using NanoString nSolver 
4.0 and Advanced Analysis Module, which normalizes gene expression to a set of positive 
and negative controls genes built into the platform. The housekeeping genes selected for 
Content Normalization are selected based on low level of overall change in reads across the 
samples and also represent low, medium, and high expression levels. Differential expression 
of key gene pathways was compared between specimens. The parameters for constructing 
heatmaps were derived in NSolver Basic Analysis program. These included background 
subtraction of the geometric mean of negative controls and including only those 
housekeeping genes with an average numerical count of greater than 50. Variation in 
expression between samples for given genes was expressed across Z-scores (how many 
standard deviations below or above the population mean a raw score is). 
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3 Clinicopathological characteristics and broad genomic 
characterisation 
 
3.1 Tumor cellularity and clinicopathological parameters  
As outline in Methods, funding allowed for 20 matched pairs of blood and tumour to undergo 
WGS. Despite review of case notes and pathological specimens, 1 of the 20 cases identified, 
processed and sequenced was ultimately found to have be inaccurately categorised, and was 
actually a large primary tumour which had no nodal spread following neck dissection. This 
left us with 19 sequenced blood; tumour pairs. Initial bioinformatic analysis using Sequenza 
to derive cellularity (as part of the overall bioinformatic pipeline “Refynr”) revealed 
significant variance between the histopathological yield (purity) and the bioinformatic (Table 
3.1) Furthermore, despite attention to quality control, ultimately 4 of the 19 specimens were 
not useful for somatic variant analysis due to poor cellularity as judged by Purple. The 
discrepancy between the histopathological yield, that derived by Sequenza and that derived 
by Purple was the subject of much analysis.  
 
So far as the difference between the yield determined by the Histopathologist and Sequenza, 
the specimen used for DNA extraction can never be the same as that used by the Pathologist 
for cellularity estimation, they can at best be adjacent, which invites microscopic variance 
between the two. As a result, the potential exists for a specimen used for DNA extraction to 
have less viable tumour, more stroma or even non-cellular areas of necrosis.  
 
Strategies for decreasing the likelihood of this in future experiments of this kind could 
include using a block tissue as samples for cellularity estimation on either side of the block of 
tissue used for nucleic acid extraction, or by using a SNP array to identify suitability of the 
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tumour tissue for downstream processing. The SNP array would incur further processing 
costs, but perhaps only 10% of the costs associated with WGS.  
 
Table 3.1 : Variance between histopathological cellularity and that defined by Sequenza 
100% = tumour only. 0% non tumour only. * no histopathological cellularity estimate 
measured. 
 
Furthermore, in samples where the true cellularity was very low (in the order of 10-20%) 
Sequenza tends to overcall variation. In these cases, Purple was a more reliable determinant 
of the true cellularity, ultimately exhibited by almost no somatic variation, either as short 
variants or CNV.  
 
The 4 cases that were judged by Purple to be of inadequate cellularity had all passed quality 
control measures as part of the routine initial assessment of cases worthy of inclusion in that 
tissue quality and tumour cellularity within the specimen was assessed as adequate by a 
Specialist Histopathologist highly experienced in cutaneous malignancy. Nonetheless, 
ultimately it became clear that the cellularity as determined by the bioinformatics algorithms 
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was significantly different to the clinical and histopathological assessment, and these tumours 
were judged as having cellularity that was too low (less than 20%) to allow for calling of low 
variant allele mutations, and therefore could not be relied upon to faithfully represent the true 
mutational status of the original tumour. The clinicopathologic data of these 15 cases is 
summarised in Table 3.2. 
 
Table  3.2. Clinicopathologic data of 15 specimens cleared for bioinformatic analysis. 
Staging according to AJCC 8th edition: (Grade 1: Well differentiated; Grade 2: Moderately 
differentiated; Grade 3. Poorly differentiated. Tumour mutational burden is genomic. Units 
mutations/Megabase.)  
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One sample initially designated as metastatic was found at a later time to have been from a 
primary cSCC with no evidence of metastasis. This specimen, and its matched whole blood, 
underwent WGS to 60X/45X prior to its status being understood. As such, it was not included 
in this analysis, but the variant calls and all data from this analysis will be used by a 
collaborator who is mirroring this overall study design, but in the primary cSCC setting.  
 
3.2 Sequencing coverage  
Of the 15 samples that passed quality control, sequencing coverage is presented in Table 3.3. 
Overall tumour coverage was 78.5X and germline was 34.4X. Coverage and tumour 
cellularity combines to enable confidence in variant calling, and the ability to also identify 
low VAF variants.  
Table 3.3 Sequencing coverage for each sample tumour and blood(germline).
 
3.3 Mutational burden and signatures 
Across the 15 cases with matched metastatic cSCC and matched whole blood for germline, a 
striking incidence of mutational burden was observed (Figure 3-2) with an average mutation 
load of 207.8 mutations/Mb. This is greater than previously published data from primary 
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cSCC where the mutational burden was 45.2 mutations/Mb(Chalmers, Connelly et al. 2017). 
No mutational burden data for a cohort of metastatic cSCC has previously been published.  
Mutational burden of our cohort compared to previously published data is presented in figure 
3.1 and is now also published (Mueller et al 2019). 
 
 
Figure 3-1. A comparison of tumour mutational burden across a variety of tumour 
types. SKCM – skin cutaneous melanoma. LUSC – Lung small cell. LUAD – lung 
adenocarcinoma. BCLA – breast lobular carcinoma. This figure is derived from data 
from Chalmers et al (2017) and data herein. 
 
The scale of the variants identified within this cohort is significant. In total, WGS identified 
14681149 variants. Of these, 5801 were classified High Impact (including Stop gained, 
Splice site, Frame shift or Stop lost) on the basis of either functional or algorithmic (CADD, 
SIFT, Polyphen) implication. A further 74612 were classified as being of medium impact. Of 
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these, 45067 had a CADD > 15. A CADD score of 20 means the variant is within the top 1% 
of deleterious variants in the entire genome, a CADD of 30 put the variant in the top 0.1% of 
the most deleterious variants (Kircher, Witten et al. 2014). All high and medium impacts 
were in the coding genome, as non-coding variants are classified low impact on the 
established scoring systems.  
 
For each specimen, it was possible to report on the percentage of nucleotide variants that best 
fit one of the 30 COSMIC mutational signatures (Alexandrov, Nik-Zainal et al. 2013) (Figure 
3-2). Cosmic signatures are derived from major catalogues of cancer associated exome and 
genome level sequencing. Where tumours are predicted to have a clear aetiological 
relationship with some known or unknown factor, they are grouped on the basis of 
predominant nucleotide variants. For some of the mutational signatures, the aetiological agent 
is known and ascribed, for other groups of tumours with a recurrent pattern of mutations, the 
agent is unknown. For instance, Signature 4, seen in tumours of the head and neck (mucosal), 
liver, lung and oesophagus, which is characterized by C>A mutations, and CC>AA 
dinucleotide substitutions has tobacco mutagens as its proposed aetiological agent. Signature 
7, seen in skin cancers, is characterized by C>T, and CC>TT dinucleotide substitution, and is 
ascribed ultraviolet radiation as its proposed aetiology. The predominant mutation signature 
in our disease cohort was Signature 7 (Figure 3-2). As predictable as this may sound, this 
finding has not been reported in metastatic cSCC and confirms the metastatic process does 
not overly influence the underlying likely mechanism and pattern of nucleotide variation. 
Compared to other tumour groups, the percentage of mutations showing concordance to the 
underlying signature is striking. On average, greater than 65% of variants seen in our cohort 
were C>T, or CC>TT. The fit with Signature 7 is somewhat clouded by the similarity 
between it and Signature 11, ascribed to the exposure to alkylating agents (first described in 
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exposure to temozolomide). Temozolomide acts by its ability to alkylate or methylate DNA, 
particularly on guanine residues. This effect triggers apoptosis.  
 
Figure 3-2 Mutation density and signature analysis across the cohort of 15 cSCC lymph 
node metastases. (Top) Base change mutation distribution at single base level shows 
predominance of CàT transitions. (Middle) Boxplot showing median number of 
mutations per megabase (Mb) in the coding and non-coding DNA. Mutation burden per 
patient in coding and non-coding DNA.  (Lower) Signature profiles using the updated 
signature repertoire by Alexandrov et al. (Alexandrov et al., 2018).  
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3.4 Discussion 
Tumour mutational burden is a complex and potentially confusing descriptor. Traditionally, 
TMB has been described as the rate of mutations/Mb of the coding regions, either as a 
percentage of the total coding region, or as a percentage of the entire genome. This rule is not 
universally followed. The melanoma genomic analysis paper (Hayward, Wilmott et al 2017) 
cites TMB for various subtypes of melanoma. The authors used TMB in a genomic context, 
ie looking at mutation across the entire genome. This is different to most previous TMB 
papers, although truly is a measure of genomic instability. In our paper describing TMB in 
metastatic cSCC (Mueller, Lauthier et al 2019), TMB is reported as both non-coding (non-
coding mutations/Mb of the entire genome) and coding (coding mutations/Mb of the entire 
genome) to illustrate the predominance of non-coding variants within our samples. In this 
paper, we report coding TMB as 1.2 mutations/Mb and non-coding TMB as 206.6 
mutations/Mb. If we report the same dataset as TMB of the coding region with the total Mb 
of the coding region as the denominator, the result is 43.0 mutations/Mb. Similarly, if we 
report non-coding TMB with the non-coding genome as the denominator, the result is 212.5 
mutation/Mb. It is therefore important to compare like with like, and to establish the 
parameters of TMB prior to drawing conclusions. 
 
Whilst we suspected the genomic mutational burden in metastatic cSCC (total mutations of 
any type across the entire genome) would be high, at an average of 207.8 mutations/Mb, this 
figure vastly eclipses the rates of any other malignancy, including metastatic melanoma and 
primary cSCC. UV associated melanoma and primary cSCC had the highest rate of 
mutations/Mb described. In a study outlining the genomic landscape of subtypes of 
melanoma, sun exposed skin occurring melanoma had an overall tumour burden averaging 49 
mutations/Mb. Non UV associated tumours (uveal and acral) showed far lower rates of 
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overall mutational burden(Hayward, Wilmott et al. 2017). Rates for a mixed cohort of cSCC 
(including 7 cases of metastatic cSCC) were 61.2 mutations/Mb (Pickering, Zhou et al. 2014) 
 
The UV associated signature of pyrimidine substitution (C>T) was strikingly consistent 
throughout our samples. This confirms the penetration of the UV associated genomic base 
substitution through EMT, with subsequent genotype of the metastatic clone/s closely 
mirroring the predicted effect.  
 
We assume that the increased mutational load in metastatic cSCC is due to the ongoing and 
prolonged burden of UV associated damage. However, it is clear from analysis of  
microsatellite instability (MSI) in non-polyposis colorectal cancer, that mutation rates are 
higher in so called MSI-High (MSI-H) tumours (Pawlik 2004). These cancers in HNPCC are 
the result of germline mutations in mismatch repair genes, in particular MSH2, MLH1, 
MSH6, PMS2, and PMS1.  
 
The unprecedented level of mutational burden seen in our tumours makes the case for the use 
of checkpoint inhibitors as probable therapeutic agents in this disease. Whilst the 
consideration of therapies is well beyond the scope of this project, the utility of any therapy 
needs to be based on scientific observation, and it is established that tumours with a greater 
mutational burden should respond with greater effect to checkpoint inhibition (Yarchoan, 
Hopkins et al. 2017). The authors describe response rates to checkpoint inhibition as a 
function of coding (exomic) TMB. According to the formula established by Yarchoan et al 
for assessing predicted response rate to PD-1 inhibition, Response rate = 10.8 x loge(X)-0.7, 
where “X” is the mutational burden (mutations/Mb), our cohort should have a 39.6% 
response rate. The results of the phase 2 EMPOWER CSCC-1 trial of a monoclonal antibody 
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to PD-1 Cemiplimab which showed that about half of patients responded to therapy with a 
mean follow-up of 7.9 months, have lead to the release of this drug in the US in the advanced 
cSCC setting, for both metastatic and locally advanced disease (Midgen, Rischin et al 2018). 
Our mutational burden findings support the use of PD-1 inhibitors in metastatic cSCC.  
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4 Major structural variation including copy number 
variation 
 
4.1 Overview 
Structural variation (SV) covers major chromosomal events including inversions, 
translocations, large deletions and amplifications. Visual representation of SV events can be 
figuratively exemplified in Circos plot format - a means by which multiple data points and 
types can be represented on a single figure able to recreate the full, in this case, genomic 
picture. Each circus plot is built upon data derived from variant and structural analysis 
through the bioinformatic pipeline. Each circus plot thus also contains information relating to 
short variants including allele frequency, copy number variation as well as major structural 
variants. Such a format allows for a comparison within a cohort of the extent of genomic 
variation, and for each sample, can guide areas of the genome for interrogation with respect 
to a given category of variation.  After exploring a number of formats to represent our 
structural variant data in circos, Purple, a bioinformatics program that estimates purity and 
copy number by using read depth and tumour variant allele frequency, was chosen. This 
allowed for the most accurate visualisation of all the elements deemed useful. 
 
4.2 Major structural variation 
4.2.1 Results 
As outlined above Circos plots provide an overall impression of the somatic genome of an 
individual sample, in comparing between samples, or identifying congruence between 
versions (tumour, cell line, passages) of a single sample. An annotated example of a circos 
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plot derived by Purple is presented in Figure 4-1. Circos plots of all 15 specimens, with a 
clinicopathologic summary are presented below.  
 
 
 
Figure 4-1 Circos plot sample 4699. Cellularity 52% 
 
The utility of the circos plot is to enable an overview of all categories of variants within a 
sample’s genome. Sample 4699 is from a 78 year old male who had a right pinna cSCC 
treated with cryotherapy only and developed ipsilateral nodal disease. The patient eventually 
developed contralateral neck disease from a forehead cSCC moderately differentiated with no 
LVI or PNI, treated with surgery and adjuvant RT. He eventually succumbed to soft tissue 
recurrence within the RT field and developed lung metastasis (DOD).  
1. Chromosome 
2. Purity adjusted allele 
frequency of SNV by 
colour 
3. Type of indel 
(deletion:red, 
insertion:yellow) 
4. Copy number changes, 
both focal and 
chromosomal. Copy 
number losses are red, 
green shows copy 
number gain. A dot 
above green shows 
CN>6 
5. Minor allele copy 
number, losses orange, 
gain is blue. Scaled 
from 0 (LOH) to 3, 
high level gain  
6. Structural variants – 
translocations in blue, 
deletions in red, 
insertions in yellow, 
duplications in green 
and inversions in black. 
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The overwhelming majority of the second shell (SNVs) of the circos shows C>T (red). When 
compared to Figure 5-1, detailing Indels, shell 3 in the circos appears mostly insertions. The 
contrast between these colours could be improved to allow for greater resolution. CNV is 
demonstrated in the 4th shell and is able to be constrained by block size. The minor allele CN 
in shell 5 here shows, for example, amplification of both major and minor allele in 5p. The 
proximity of 4q and 5p are useful for displaying a copy number gain despite the loss of the 
minor allele(4q) and a copy number gain of both major and minor allele (5p).  In 8p, a CN 
neutral LOH is seen due to loss of the minor allele. The inner shell herein shows both 
inversions and translocations. Particular concentration is seen in the proximal long arm of 15 
and in 8q. 
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Figure 4-2: Circos plot of sample 9120. Cellularity 27%. 
Sample 9120 is from a 66 year old male.  The patient initially had an excision of recurrent 
scalp tumour of 8.5mm thickness, moderately differentiated with clear margins and no LVI or 
PNI. The patient developed metastases in the draining posterior scalp lymph nodes and 
posterior triangle 12 months following the initial excision. Currently the patient is alive with 
no evidence of disease 2 years post lymphadenectomy. 
Striking within this circos plot is the deletion of chr3p, chr4, chr11 and chr18 and loss of 
copy number. There was an oscillating CN artefact identified during SV analysis. This 
artefact resulted in, within established parameters as above, an excessive CNV count which 
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was not consistent with the actual CN and can be seen in the difference between Figures 4-1 
and 4-2 in the green track.   
 
 
 
Figure 4-3: Circos plot sample 33432. Cellularity 70%. 
Sample 33432 is from a 69year old male with a background of rheumatoid arthritis treated 
with pharmacologic immunosuppression (Azathioprine). The patient in initially had a 
temporal scalp SCC. He underwent surgery and adjuvant RT and then had recurrence of 
poorly differentiated metastatic cSCC. This patient died of disease. The lack of significant 
CNV and SV in this sample is striking.  
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Figure 4-4: Circos plot of sample 34366. Cellularity 26%. 
Sample 34366 is from an 86 year old male. Metastatic cSCC to parotid treated with surgery 
and then adjuvant RT. Thereafter recurred in soft tissues within radiated field. Died of 
disease. 
Prominent loss of minor allele copy is demonstrated across much of the genome in this 
sample, as well as areas of very high overall CN gain (chr2q and chr18p). Inversions are 
more common than translocations in this sample.  
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Figure 4-5: Circos plot sample 34934. Cellularity 73%. 
Sample 34934 is from an 87 year old male who previously had a maxillary mucosal SCC. 
Subsequently he developed a scalp cSCC and left parotid metastasis. Surgery revealed a 
single metastatic deposit. He underwent post operative radiotherapy and was alive with no 
evidence of disease 2 years later.  
Once again, despite being high cellularity there is relatively less amplification in this sample. 
CN loss is once again the predominant CNV despite some area of amplification (chr14). This 
sample has a very low indel incidence (shell 3). 
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Figure 4-6: Circos plot sample 35562. Cellularity 46%. 
Sample 35562 is from a 66year old male, 15 years post liver transplant on tacrolimus and 
prednisone for immunosuppression. He initially had excision of 20mm forehead skin lesion 
(moderately differentiated cSCC 7mm thickness, with both LVI and PNI) with right neck 
dissection. Neck dissection 2/29 lymph nodes in parotidectomy and neck dissection. Post 
operative radiotherapy. Alive with no evidence of disease at 2 years.  
Whether the formal immunosuppression has impacted the CNV in this case is not clear. Apart 
from chr8q, there are not large scale amplifications, but areas of CN loss and LOH.  
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Figure 4-7 Circos plot sample 35649. Cellularity 46%.  
Sample 35649 was from a 63 year old male with chronic lymphocytic leukaemia. Recurrent 
scalp cSCC with metastases to parotid and neck. Primary mod differentiated 8.5mm thick 
with LVI but not PNI. Post operative  radiotherapy with early recurrence. Died of disease. 
Again this sample, although having more areas of amplification, including with very high CN 
in an isolated area of chr4p, is more characterised by CN loss with LOH. A focus of 
translocation is in chr19.  
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Figure 4-8 Circos plot sample 35818. Cellularity 69%. 
Sample 35818 is from a 69 year old male. Underwent a right radical parotidectomy 
(including sacrifice of facial nerve and reconstruction) and then had post operative 
radiotherapy. Late recurrence ipsilateral lymph node level Ia/b junction. Clinically very high 
risk for recurrence but alive with no evidence of disease.  
This circos is more typical of the trend with widespread CN gain with some areas of CN 
neutral loss of minor allele (chr8p, chr5q). Most of the areas of CN gain have contribution to 
overall CN by amplification of the minor allele (blue in shell 5). Note also the concentration 
of inversion in chr1q and chr5p.  
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Figure 4-9 Circos plot sample 38532. Cellularity 24%.  
Sample 38532 is from a 78 year old male with Protein S deficiency. Nasal cSCC with 
prominent PNI. Metastasis to left parotid and eventually right neck. Post op radiotherapy. 
Alive with evidence of disease 1year post op.  
Isolated regions of amplification can be seen with total CN>10 in chr3 and 7. Overall limited 
amplification across the genome. Prominent CN loss with LOH in chr3, 8, 12 and 15. 
Amplified area of chr3 also corresponds to a concentration of both inversion and 
translocation. 
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Figure 4-10 Circos plot sample 48585. Cellularity 28%. 
Sample 48585 is from a 78 year old female (note sex chromosomes) with multiple recurrent 
cSCC bilateral forehead and face. She had an acceleration of cSCC over the last 5 years of 
her life without formal immunosuppression. This patient developed bilateral neck node 
metastases from different primaries. This invites the potential for her having a predisposing 
germline or acquired immunodeficiency.  She eventually succumb to left sided recurrence at 
skull base post salvage surgery and radiotherapy. 
This is a heavily amplified sample. Some of the amplified regions have minor allele loss. A 
focus of translocation in chr22 is typical of that seen with the TTC28 transposon (see below).  
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Figure 4-11 Circos plot sample 183410. Cellularity 35%. 
Sample 183410 if from a 30 year old male with limited UV exposure history. Left lip cSCC 
excised with emergence of ipsilateral Level Ib metastasis. Post operative chemoradiotherapy. 
He developed tinnitus with cisplatin and was switched to cetuximab. Alive with no evidence 
of disease 2 years post treatment.  
This sample had an average ploidy of 4. This is a heavily amplified genome, with only very 
few areas of minor allele loss. This sample has the highest incidence of CN >10 (4th shell 
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with circle on top of green CN gain). Additionally, significant SV with again a focus of 
translocation in chr22.  
 
Figure 4-12 Circos plot sample 184577. Cellularity 60%. 
 
Sample 184577 is from a 78 year old male. Right ear cSCC to ipsilateral parotid. Nodal 
deposit 45mm poorly differentiated with positive margin on facial nerve. Post op RT. Alive 
with no evidence of disease beyond 3 years. 
This is a similar plot to 183410 except for the extent of translocation. Some areas of LOH 
(chr10q and 13). Again some concentration of SV in chr22 (TTC28) is observed.  
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Figure 4-13 Circos plot sample 193958. Cellularity 34%.  
Sample 193958 (Parent tumour of cell line UW01- Jay Perry) is from a 74 year old male.  
cSCC from right ear excised. Eight months later emergence of parotid metastasis. 50mm 
deposit with PNI and 2 other positive nodes. Clear margins. Post op radiotherapy. Alive with 
no evidence of disease 3 years post treatment. 
This circos shows significant amplification across most of the genome. There is widespread 
loss of the minor allele, often occurring as CN neutral, but often with an overall CN gain. A 
focus of SV (both inversion and translocation) can be seen in the short arm of chr7.  
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Figure 4-14 Circos plot sample 200971. Cellularity 34%.  
Sample 200971 was from a 65 year old male who initially had a lower lip cSCC (6mm 
moderately differentiated) with metastasis to level Ib at 14 months post surgery to the 
primary. Moderately differentiated disease. Post op radiotherapy. Succumbed to pulmonary 
metastases within 3 years. 
This sample shows isolated regions of CN gain with even more isolated regions of loss of 
minor allele.  
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Figure 4-15 Circos plot sample 321773. Cellularity 33%.  
Sample 321773 was from a 78 year old male who initially had a Left forehead cSCC with 
widespread PNI. Post op radiotherapy to the primary site but not to draining nodal basins. 
Metastasis to left parotid 19 months post surgery. Parotidectomy and neck dissection with 
adjuvant radiotherapy to left neck and parotid bed. Alive with no evidence of disease at 3 
years.  
Loss of minor allele and CN loss entire chr13. Otherwise a significantly amplified genome. 
SV including chr22 (TTC28) and complex pattern of SV in chr8.  
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4.2.2 Discussion 
Just as for short variants, the identification and characterization of structural variants in a 
highly mutated genome is challenging. As stated earlier, the mutational burden of our 
samples is greater than any previously published series, at 207.8 mutations/Mb. Complex 
bioinformatics and computational analysis is required to overcome this genomic noise, and to 
filter spurious findings.    
 
Structural variants may be between non-coding or coding regions. They may involve large 
scale deletions or duplications, or breakpoints which then reconnect with a remote part of the 
genome, either intrachromosomal (inversion), or interchromosomal (translocation). Large 
deletions may include areas coding or impacting on transcription of tumour suppressor genes, 
thus promoting a carcinogenic stimulus. In addition, and often as well, large duplications 
(usually with overall CN >5 and block size >5000 base pairs) may include regions coding for, 
or impacting the transcription of oncogenes, once again with potential for malignant genomic 
effect.  
 
In addition to simple descriptions of SV events (inversion, translocation, deletion, 
duplication), more complex patterns of structural rearrangement have been described.  In a 
cohort of prostate cancers, Baca et al (2013) describe a pattern of translocation associated 
with deletion breakpoints, but also giving rise to observed deletion bridges from one 
chromosome to another. They termed this phenomenon “chromplexy” (pleko : “to weave” or 
“to braid”).  Chromoplexy is thought to occur throughout the progression of a cancer and is 
characterized by tens of chromosomal structural variants, effecting different loci and 
probably occurring at multiple timepoints. Such large scale chromosomal rearrangement is 
relatively common, particularly in prostate cancer (Shen 2013). This is in contrast to 
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chromothripsis. Chromothripsis entails a very localized disruption of the genome, often 
entailing hundreds of structural variant events, and is thought to occur as a once off 
phenomenon (Stephens 2011). Such a massive genomic crisis event gives rise to oscillating 
copy number states between one or only a few chromosomes and may include cancer causing 
fusions.  
 
Within our structural variant analysis, there are no convincing episodes that can be easily 
labelled chromothripsis. This observation may be clouded by the volume of SV events, and it 
is possible that both chromoplexy and chromothripsis are occurring in the same samples, both 
inferring a tumour clonal evolution by different means and chronologies.  
 
4.3 Gene fusions   
4.3.1 Results 
Break points within coding regions of the genome can lead to fusions with other genes or 
non-coding regions. Such coding impacts are called gene fusions and may have unpredictable 
effects on the transcribed RNA. We identified 2004 gene fusion events structural variants 
having any gene involvement (gene:intron  or gene:gene) across our 15 cases. Break points 
(including those leading to gene fusions) occurred in more than 1 sample in only 5 genes as 
listed below. By far the most frequently involved gene was TTC28 which showed significant 
structural variation in the first intron.  
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TTC28 
Ten of fifteen samples (66%) had a SV in TTC28. In our series, the TTC28 first intronic 
transposon (between coordinates 22:29064630-29066160) is inserted into a number of genes 
as depicted in Figure 4-16.  
 
Figure 4-16 TTC28 transposon structural variants 
 
Additionally, the following genes had break points in their coding regions: MYLK (2/15 
samples); PDE4D (3/15 samples); EPHB1 (2/15 samples).PTK2:SLA2 gene fusion occurred 
in 1/15 samples.  
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4.3.2 Discussion 
TTC28 (chr22:28,374,002-29,075,853) is described having recurrent chromosomal 
translocations in colorectal, small cell lung and liver cancer (Fujimoto et al  2016). The 
pattern of the structural variants we have observed involving TTC28 is most in keeping with a 
phenomenon known as somatic retrotransposition. The resulting genomic feature is an 
example of a retrotransposon in the form of a Long Interspersed Element 1 (LINE-1 or L-1). 
A known retrotransposon is within the first intron of TTC28. Retrotransposon insertion may 
also happen in the germline.  
 
It is unusual for the same region in a chromosome in the same sample to be widely dispersed 
in a structural variant or translocation event. The model of a LINE-1 dispersion to “random” 
locations, even within one sample was identified and characterized during the assessment of a 
new bioinformatics application (MELT) looking at data from 1000 Genomes Project 
(Gardner, Lam et al 2017). This tool identifies and characterises LINE-1, Short interspersed 
nuclear elements (SINEs) and other major and structural variant events caused by mobile 
elements.  The use of MELT with our data supports this hypothesis of LINE-1 transposon 
“rearrangement”.  
 
In our study, the only gene to show a fusion with TTC28 is ESRRG. ESRRG has recently been 
identified as playing a role as a tumour suppressor gene in gastric cancer (Kang, Choi et al 
2018) by its impact as a suppressor on the Wnt signaling pathway, as evidenced by the down 
regulation of key Wnt genes in ESRRG overexpressing tumours.  
 
Otherwise there appear no key known cancer genes in our observed structural variants 
interacting with TTC28. This process of somatic retrotransposition has been questioned by 
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others (Pitkanen, Cajuso et al 2017) as potentially over-calling the role of such LINE-1 
elements, particularly so since in the oesophageal SCC series, no demonstration of an 
expression change was demonstrated. Nonetheless, this pattern is repeated in numerous 
cancers, and it will be illustrative to review once we have completed a parallel project 
looking at WGS within primary cSCC, and also to examine the transcriptome affect once our 
RNA Seq project is complete across cSCC cohorts. 
 
MYLK; Functionally MYLK has transferase activity, transferring phosphorus-containing 
groups and protein tyrosine kinase activity. MYLK and MYL9 were found in NSCLC to be 
downregulated in Stage 1 and II cancers but upregulated in III and IV cancers (Tan, Chen 
2014). This suggests not only a role in carcinogenesis, but also in metastasis.  
 
PDE4D;  a phosphodiesterase that degrades cAMP thus disrupting activation of the cAMP 
pathway. Interaction with Focal Adhesion Kinase (FAK) (which we did not see as a gene 
fusion) may promote melanoma invasion (Delyon, Servy et al 2017) and conversely the 
blocking of this interaction reduces invasion.  
 
EPHB1; This gene codes for a receptor tyrosine kinase. Decreased expression of EPHB1 has 
been identified in renal cell carcinoma (Zhou, Wang 2014) 
 
PTK2:SLA2 translocation occurred in only 1 sample. PTK2 is a protein tyrosine kinase 
which if activated is an important promoter of downstream signalling processes. SLA2 is a 
member of the SLAP family of proteins, that play a role in downregulating inflammatory 
cascades, but that are also active in cancer. Silencing of SLAP promotes tumour progression 
in colorectal cancer, while overexpression inhibits tumour growth and invasiveness (Marton 
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2015). Indeed, one of the SLA2 protein domains actively binds to phosphorylated tyrosine 
residues.  
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4.4 Copy Number Variation 
4.4.1 Results 
Copy Number Variation detection was principally derived by Sequenza (as described earlier). 
Sequenza walks through the genome in 50Mb segments to identify copy number variation 
and variant allele frequency and is highly dependent on cellularity. Low cellularity specimens 
(where tumour yield was ultimately found to be low), or areas of low coverage can both 
impact on reliability of CNV data.  
 
Chromosomal amplification and deletion across the entire cohort is presented in Figure 4-17. 
Amplification is predominant although some areas of the genome do not show amplification, 
and other areas are commonly and recurrently deleted.  
 
Figure 4-17 All samples genome view of amplification vs deletion as percentage of 
samples (y axis) for each chromosomal arm (x axis). Amplification shown as blue bars; 
Deletions shown as red bars. 
 
 
An output of Sequenza includes the genome view of copy number and allele frequency. An 
example output of a single sample with high frequency alterations is shown in Figure 4-18. 
Obvious alterations in this example include a large CN gain in the long arm of Chr3 (with a 
 
 80 
CN of 1 in the beta allele), and a CN neutral (CN = 2) loss of heterozygosity (B allele CN=0) 
in the long arm of Chr5.  
 
 
Figure 4-18 Genome view of CNV sample 4699. Chromosomes are listed on the X axis. 
Copy number along the Y axis. The colours within each chromosome represent the total CN 
(red) and the CN of the minor variant allele (blue). 
 
Figure 4-19 shows CNV of a low cellularity specimen. CNV is essentially non-existent and 
resembles the genome of normal (blood), and thus this specimen most likely represents 
mainly normal tissue DNA (only minor changes from the germline). A genome view with 
little departure from the normal is thus one of the clues to low cellularity.  
 
Figure 4-19 Genome view of CNV of low tumour cellularity sample 4777 
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Figure 4-20 shows CNV for commonly effected samples with total events for each gene at 
the top of the figure. Amplification events were recognised if they had adequate size (base 
pairs > 104 ) and with total copy number >5. Deletion events were also of the same minimum 
size and either had loss of both alleles or a loss of heterozygosity event with complete loss of 
minor allele regardless of total CN. 
 
Below are listed common gene (Fig 4-20) and chromosomal band (Fig 4-21) CNV across as 
many samples as they are shared by. This is the reason not all samples are included as there is 
a tail of less common events which are not shared by many samples. Common genetic and 
chromosomal amplification is a relatively more common phenomena, as compared to 
commonly occurring deletion, a can be seen by only DCC and SMAD4 reaching any common 
threshold across samples that also shared common amplification. This is also mirrored by the 
overall finding of combined samples in Fig 4-17, which demonstrates the prominence of 
amplification in CNV analysis.  
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Figure 4-20 Genes with most frequent Copy Number Variation with minimum 
Duplication (CN>4) and Deletion (CN=1) for 10 samples with common shared CNV. 
Histogram at top: number of events for each sample for the group of genes. Histogram 
at right: number of samples (of 10) with CNV for given genes.  
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Figure 4-21 Recurrent CNV of chromosome bands. Histograms as per Figure 4-20. As 
per Figure 4-20, represented are common chromosomal band CNV with CN>4 or =1.  
 
 
Specimen 9120 was unable to be included in CNV analysis due to an oscillating CN artefact 
identified during SV analysis. This artefact resulted in, within established parameters as 
above, an excessive CNV count which was not consistent with the actual CN when inspected 
using Integrated Genome Viewer. This is most instructively seen in Figure 4-22 below, when 
comparing the CN track (green) of the circus plots of samples 4699 versus 9120. 
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Figure 4-22 Circos plots of samples 4699 (left) and 9120 (right). A comparison of the CN 
track (green) and also the minor allele CN (blue/orange) track in circos plot for 9120 
shows an oscillating artefact represented by smaller blocks of CNV. This disallowed 
9120 to be included in the CNV analysis.  
 
4.4.2 Discussion 
Overall picture is of a highly somatically amplified genome. Gene amplification has been for 
some time regarded as a driver of both carcinogenesis and of clonal expansion within 
tumours (Albertson 2006). A recent study of amplification of driver genes across multiple 
cancer types identified a group of 6 genes (from a total of 138 candidate oncogenes (n=64) 
and tumour suppressor genes (n=74)) commonly amplified across multiple cancer types (not 
including cSCC) (Ohshima, Hatakeyama et al 2017); MDM2, MYC, MYCL, MYCN, NKX2-
1and SKP2.  
Recurrent CN amplification of 3q and 5p were identified across various SCC sub types in a 
recent review comparing TCGA data and mutational signatures (Campbell, Yau et al 2018). 
Within 3q, which showed frequent CNA in our samples are included PIK3CA, TERC, TP63 
and TP73, and SOX2 (see below). 5p includes TERT, TRIP13 and FASTKD3. The role of 
TERT (in the context of TERT promoter variants) in our cohort is detailed in Chapter 6. 
 
 85 
TRIP13 can promote error prone non homologous end joining, cell proliferation, survival, 
and resistance to cisplatin in head and neck (mucosal) SCC. Twelve of 15 samples in our 
cohort had copy number gains of TRIP13 with an average CN of 4.8 across the amplified 
samples. FASTKD3 has prosurvival affects probably via inhibition of the intrinsic 
mitochondrial cytochrome-mediated cell death pathway (Simarro, Gimenez-Cassina et al., 
2010) was amplified again in (the same) 12/15 samples as TRIP13, with an average CN of 
4.6. With an average block size of 1900Mb, the amplifications encompassing these 2 genes 
were the same events. Notwithstanding the observed 5p and 3q amplification, in our cohort, 
there were also consistently amplified segments in 7p, 8q, 14q and 20q (Figure 4-17). 
In a census of amplified and overexpressed genes in cancer, the gap between amplification 
and over expression is highlighted (Santarius, Shipley et al. 2010). An amplification may be 
within a gene, or, given a cutoff of not less than 5000 BP, more often includes multiple genes 
over upward of 100 000BP. Within such regions, driver genes may be identified, but co-
amplified genes (eg DDX1 in the amplification of MYCN) could potentially play a role in any 
expression effect.  
 
4.4.2.1 Recurrently amplified genes 
The following genes were amplified in percentage of samples outlined in Figure 4-20.  
NDRG1 (N-Myc Downstream Regulated 1) chr8:134,249,414-134,314,265 encodes a 
cytoplasmic protein involved in stress response. It is generally regarded as a tumour 
suppressor, but levels of the protein are prognostically unfavourable in liver, renal and brain 
malignancy (proteinatlas.org).  
 
PIK3CA chr3:178,865,902-178,957,881 is a key participant in cellular signalling in response 
to the binding of numerous ligands to receptor tyrosine kinases. Whilst hotspots for mutation 
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at codons 542/545 and 1047 are described (Vorkas, Poumpouridou et al 2010), we did not see 
any examples of this SNV. Only 2 samples had missense mutations. By far the greatest likely 
impact on PIK3CA was amplification, which, in keeping with its role as an oncogene with 
AKT and mTOR pathway impacts, offers an opportunity for potential therapeutic 
intervention.  
 
SOX2 chr3:181,429,712-181,432,224 involved in embryonic development, stem cell 
maintenance in the central nervous system and for expression of gastric epithelial expression. 
There is no clear role for its amplification being a driver in cancer, although it thought to 
have a role in adult stem cell differentiation (Karamboulas and Ailles 2013). With 11/15 
samples showing amplification, with an average CN of 4.3, SOX2 is a good example of the 
3q amplification characteristic across various subtypes of (non-cutaneous) SCC(Campbell, 
Yau et al. 2018) 
 
ABL1 chr9:133,589,268-133,763,062 encodes a protein (non-receptor) tyrosine kinase and is 
a proto oncogene, highly expressed in many cancers (proteinatlas.org). We observed no 
major structural variations in ABL1 as described in other cancers including the BCR-ABL1 
fusion in chronic myeloid leukaemia (CML).  
 
ASXL1 chr20:30,946,147-31,027,122 encodes a chromatin-binding protein which binds and 
then disrupts chromatin in specific regions to enhance transcription. Its expression in 
endometrial cancer in a negative prognostic indicator, and conversely provides a favourable 
prognosis in head and neck (mucosal) SCC (proteinatlas.org) (Chung, Guthrie et al 2015). 
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BAI1/ADGRB1 chr8:143,530,791-143,626,370 encodes a protein which acts as an inhibitor 
of angiogenesis, perhaps as a member of the secretin receptor family. Its transcriptional 
regulation is by p53. It has low levels of expression in cancer (proteinatlas.org). 
 
CAP2 chr6:17,393,447-17,558,023 probably plays a role in actin binding and ectoderm 
differentiation. It is not normally expressed in skin (proteinatlas.org). There is no reported 
association with skin malignancy although overexpression in hepatocellular carcinoma may 
indicate a poor prognosis (Fu, Li 2015).  
 
COL5A1 chr9:137,533,620-137,736,689 encodes for collagen type V alpha chain. Type V 
collagen is found with type I collagen (fibrillary collagen found in most tissues) and this gene 
helps regulate fibre assembly (proteinatlas.org).  
 
CYC1 chr8:145,149,930-145,152,428 encodes a protein involved in mitochondrial respiratory 
chain electron transfer, Upregulation of this process may help the cell overcome the 
deleterious effects of oxidative phosphorylation and overexpression has been identified in 
breast cancer cell lines as a marker of worse prognosis and metastasis (Han, Sun et al. 2016).  
 
DSP chr6:7,541,808-7,586,950 encodes a protein that anchors desmosomes in the internal 
surface of the cell membrane. Mutations are associated with keratoderma, or abnormal 
thickening of the skin. It has been shown to be underexpressed in some Non small cell lung 
cancers (NSCLC) and its antitumoural properties might be the result of its impact on the 
expression of Wnt/ß-catenin genes Axin2 and MMP14(Yang, Chen et al. 2012).  
 
EPPK1 chr8:144,935,822-144,952,632 encodes a protein which is a member of the plakin 
family, generally involved in cytoskeletal architectural organisation, exclusively in epithelial 
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cells. This enables normal epithelial differentiation but may also effect cell migration in 
injured tissues as part of repair (Yoshida, Shiraki et al 2008).  
 
EDN1 chr6:12,290,529-12,297,427 encodes a preprotein that is then converted to a 
vasoactive peptide, enabling vasoconstriction. Its is overexpressed in colorectal cancer 
probably by interaction with ß-catenin (Kim, Xiong et al 2005).  
 
EGFL7 chr9:139,553,308-139,567,130 also encodes for a vasoactive peptide. Most 
malignancies show expression and overexpression carries an unfavourable prognosis in 
colorectal and renal carcinoma (proteinatlas.org). 
 
PLEC chr8:144,989,321-145,050,913 Plectin is an important cytoskeletal structural protein. 
It is known to be expressed in skin cancers, and its expression predicts a worse prognosis in 
renal, lung and colorectal cancer (proteinatlas.org). 
 
MYC chr8:128,747,680-128,753,680 encodes a proto-oncogene that complexes with MAX to 
act as a transcription factor and impacts cell cycle, apoptosis and cellular transformation. It 
may also bind to VEGFA promoter to drive transcription and subsequent angiogenesis.  
Known to be amplified in cancers, can also shows translocation in both Burkitts Lymphoma 
and Multiple myeloma. Samples from both proteinatlas.org and from COSMIC from TCGA 
skin cancer (melanoma samples) suggest that overexpression is not universal or profound. 
 
4.4.2.2 Recurrently deleted genes 
DCC (Deleted in Colon Cancer) encodes for a protein which is a membrane receptor for 
netrin-1 (dependence receptor). When not activated by netrin-1, DCC has a pro-apoptotic 
effect. Once bound, it can block apoptosis by activation of MAPK pathway and by Caspase 
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3. As outlined above DCC in our cohort was most significantly effected by LOH events in 
8/15 samples.  
 
 
 
SMAD4  
SMAD4 is a member of a family of signal transduction proteins and is a tumour suppressor. 
Activated by TGF-ß binding to serine protein kinases on the cell surface, the products of 
SMAD4 accumulate in the nucleus to regulate target gene transcription.  Deletions have been 
associated with pancreatic malignancy, neuroendocrine tumours (Simbolo, Vicentini et al. 
2018), juvenile polyposis syndrome, and hereditary haemorrhagic telangiectasia syndrome. 
Alternative splicing which also leads to decreased expression due to the predominance of an 
inactivated isoform has recently been described in a keratinocyte cell line subject to UVB 
radiation exposure (Ullah, Liao et al. 2018).  
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5 Short Variants 
 
5.1 Results: Short variants 
The overwhelming number of short variants detected were single nucleotide variants (SNV) 
in non-coding regions (including introns, 5’ and 3’ UTR and regulatory regions) (See Figure 
3-2). The overwhelming majority of coding SNVs were missense mutations, where the 
resultant codon encodes for an alternate amino acid (Figure 5-1). The next most common 
class of short variant was a nonsense mutation, where the altered codon results in premature 
shortening of the resultant transcribed and translated protein (eg due to the introduction of a 
stop codon). This class of mutations represents less than 5% of the missense class. 
 
The predominant pattern of SNV was C>T (refer to Figure 3.2). This made up more than 
80% of SNV and is consistent with the dominant effect of UV radiation on pyrimidine bases, 
in keeping with our general findings on mutational signature (Section 3.3) and recently 
published (Mueller, Gauthier et al 2019).  
 
 
Figure 5-1: Coding short variant classification. Short coding variants were assessed for 
rates of recurrence and likely impact on the basis of various predictors using SIFT, PolyPhen 
and CADD (see Chapter 2.6). These tools provide evidence of the likely impact of variants 
on biological activity and are best used in combination. 
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A gene list was collated that included known tumour suppressor genes, oncogenes, other 
genes falling within genomic hotspots in other cancer surveys (Gonzalez-Perez, Perez-
Llamas et al. 2013) and genes of specific relevance to surveys of cutaneous malignancy(Su, 
Viros et al. 2012). In total, 1365 genes comprised the list that was used to assess for variants 
within genes (coding and non-coding regions) using the Seave platform. The gene list used 
for identifying short variants, copy number variation and structural variant effects of the 
coding genome is listed in Appendix 3. Other lists of specific non-coding regions, including 
specific promoter regions, long non-coding RNA and micro-RNA are described separately 
below.  
 
5.2 Highly recurrent somatic mutations 
The most highly recurrent short somatic variants with scaled CADD >10 are represented, 
combined with concomitant CNV in Figures 5-2 and 5-3. Two figures are presented 
combining single nucleotide variation and copy number variation in the same samples for the 
same genes/chromosomal bands. These two figures differ in thresholds for calling of variants 
and the filtering applied in Figure 5-3  to include those genes with at least 4 COSMIC 
variants and to exclude larger genes (eg MUC16, CSMD3) where variant frequency is high 
but may not be as meaningful (Lawrence, Stojanov et al. 2013).  
.  
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Figure 5-2 Recurrent short variants in genes also subject to CNV– including PCLO, 
CSMD3 and MUC16. Top histogram: short variant events per sample colour coded. 
Histogram at right: Number of samples effected. Colour coding shows type of 
alteration.  
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Figure 5-3 Common short variants (and co-existent CNV) excluding PCLO, CSMD3 and 
MUC16. Histograms as per Figure 5-2. 
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Following is a detailed description of the types of mutation for each of the genes listed in 
Figures 5.2 and 5.3. 
  
TP53 (chr17:7,565,097-7,590,863). In our cohort, a mixture of high impact variants as well 
as copy number events were observed. A total of 79 SNV were identified across the cohort, 
31 with a CADD >20.  
 
CDKN2A (chr9:21,967,751-21,995,300). Eight samples showed high impact (mostly stop-
gained) SNV, all within the coding region and in 4 cases occurring in multiple samples. All 
of these high impact variants had COSMIC IDs and had an average scaled CADD of 36. A 
further 6 examples of medium impact SNV were seen in CDKN2A including a missense 
variant occurring in 3/15 samples.  
 
MECOM chr3:168,801,287-169,381,563). The predominant pattern of variation in MECOM 
was amplification. It was also the most highly amplified oncogene with 10 samples (66%) 
harbouring a CNV with average CN of 4, and no evidence of any LOH. Of the 6 samples 
with high and medium impact SNVs, one sample (4699) had a stop gained (COSMIC IDs 
COSM1420480, COSM4948202, COSM5829617) and the others were missense mutations. 
Of these variants, the average scaled CADD was 20.53. 
 
NOTCH1 chr9:139,388,896-139,440,314 Like MECOM the predominant pattern of variation 
in NOTCH1 was amplification. Notwithstanding this, numerous high impact SNV were 
observed including 5 samples with stop-gain mutations in the second half of the gene 
(negative strand), and numerous significant medium impact missense and splice region 
variants. 
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PTPRD chr9:8,314,246-10,612,723 In our series, PTPRD showed a mixture of variants, 
dominated by high impact (inactivating) SNV, and CNV, predominantly by deletion and 
LOH. When filtered for impact, SNV in PTPRD were the most plentiful of any in our study, 
with 293 variants with a CADD > 20 across all samples.  
 
PLCB4 chr20:9,049,410-9,461,889 Within our cohort, one specimen had both a stop gained 
and a splice acceptor SNV with high impact. In total, 56 SNV with a scaled CADD > 20 were 
identified across all samples. We identified amplification in 9 of 15 samples, to an average 
CNV of 4. Two samples had LOH with CN =1.  
 
PCLO chr7:82,383,321-82,792,246). The predominant pattern of variation for this gene was 
SNV, with a single sample showing amplification. Of the SNV, 4 samples displayed stop 
gained, while one other sample had a high impact splice variant as well as two high impact 
frameshift deletion events.  
 
PPP6C chr9:127,908,852-127,952,218 A single stop-gained SNV and 5 other missense SNV 
were identified in our series for PPP6C. 
 
FAT4 chr4:126,237,554-126,414,087). FAT4 SNVs were observed in 5 samples. Of these 
short variants, there was a single high impact stop-gain, and 57 other mutations with a 
minimum scaled CADD of 20. CNV analysis revealed 2 samples with LOH (CN =1), both 
samples also harbouring missense SNV.  
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CSMD3 chr8:113,235,157-114,449,328). Five samples had a stop gained SNV in this gene, 
effecting codons 22-67/71. One stop gain mutation effected 2 samples. This mutation has 2 
COSMIC IDs: COSM1721763, COSM1721764. These catalogue to melanoma and rectal 
adenocarcinoma, across 5 curated samples. A further 152 SNVs with a minimum scaled 
CADD of 20 were identified. These included both coding and non-coding regions.  
 
SYNE1 chr6:152,442,819-152,958,936 A single sample in our study showed 3 high impact 
mutations in this gene, including a stop gained and 2 splice acceptor variants. A further 
sample had a stop gained (high impact). In total 50 SNVs were identified in 12/15 samples 
with a CADD > 20. A single LOH event effecting SYNE1 was noted in one sample. There 
were 8 amplification events, only one of which had a CN >4.  
 
PTCH1 chr9:98,205,262-98,279,339  PTCH1 mutations were common, but it was the least 
effected by high impacting variants. Only 3 variants with a CADD > 20 were identified, all 
were missense SNV, and none were classified as “probably damaging”.  
 
DCC chr18:49,866,542-51,062,273 In our cohort, SNV in DCC was prominent with a stop 
gained truncating mutation in one sample, but in all other samples another 60 variants with 
scaled CADD >20. Of particular note, DCC in our cohort was most significantly effected by 
LOH events in 8/15 samples.  
 
AMPH chr7:38,423,297-38,671,167 We observed prominent amplification of this gene with 
10 samples having duplications with CN form 3-5. 
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MUC16 chr19:8,959,520-9,092,018).  MUC16 was subject to a high rate of inactivating 
mutations, including a stop gained in 8/15 cases, and another 9 cases of coding variants with 
CADD >20, including a missense SNV 9:8997432 (glutamate to lysine) effecting 2 samples 
with COSMIC ID COSM4546866/7, catalogued by COSMIC in the context of aggressive 
cSCC (Pickering, Zhou et al. 2014, South, Purdie et al. 2014), although not mentioned in 
these publications. We identified 6 samples with duplication events. 
 
NRXN1 chr2:50,145,643-51,259,674 High impact missense variants were identified in 8/15 
samples, including with COSMIC ID COSM 4475612 seen in high risk cSCC (Pickering, 
Zhou et al. 2014). 
 
USH2A chr1:215,796,236-216,596,738). Three samples with a total of 5 stop gained SNVs 
were identified for this gene with another 46 missense variants with CADD > 20 evident. 
Within cutaneous malignancy, USH2A variants have been documented in multiple COSMIC 
samples, predominantly melanoma, but also in a cSCC (COSM4547692) (Pickering, Zhou et 
al. 2014). COSMIC data shows an overwhelming proportion of variants of USH2A to be C>T 
(94% of 15408). We would have expected this to be the same, but only 25/46 (54%) were 
C>T. This anomaly, given the overwhelming nature of SNV being C>T in the overall cohort, 
is difficult to account for. 
 
SEMA3D chr7:84,624,869-84,816,171 Only one sample had a stop gained and splice 
accepter high impact variant, and another 6 samples exhibited 10 separate missense SNV, 
including 7:84628811 C>T which is shared by 4 samples. This variant has a COSMIC ID 
COSM170328, seen in cSCC (Pickering, Zhou et al. 2014), melanoma, prostate and bowel 
carcinoma. It has a scaled CADD of 29 and is probably damaging as assessed by PolyPhen. 
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NAV3 chr12:78,224,685-78,606,790 One sample had a stop gained, 8 samples showed 
missense SNV (19 SNV events ie most samples had more than 1 missense variant) and a 
further 15 non-coding short variants of high impact (CADD > 20), 6 of which were short 
deletions for this gene. CNV revealed 2 samples with large deletion events.  
 
5.3 Other genes of interest based on known association with metastasis 
PLAU chr10:75,668,935-75,677,259 encodes the protein urokinase plasminogen activator 
which converts plasminogen to the broad spectrum serine protease plasmin responsible for 
the degradation of extracellular matrix and tumour migration and proliferation (Ranson and 
Andronicos 2003). There were no coding short variants in PLAU in any sample. There were 
numerous large amplification events on Chr10 spanning the entire gene (Figure 4-17) and see 
also circos plots 4699, 9120, 35649, 35818, 48585, 183410, 184577, 193958, 321773 
above.  
 
FGFR2 chr10:123,237,844-123,357,972. FGFR2 encodes for a cell surface growth factor 
receptor, which when upregulated can activate both the RAS-MAPK pathway and the PI3K-
AKT pathway. FGFR2 variants with scaled CADD scores > 20 were largely missense 
variants. Coding SNV resulting in codon changes were seen at codon numbers: 
216 – S > L (Sample 9120) within the Ig-like C2-type 2 domain 
572 – G > E (Sample 4699) within protein kinase domain 
591 – H >Y (Sample 183410) within protein kinase domain 
654 – S > F (Sample 48585) within protein kinase domain 
778 – S > L (Sample 9120) within the cytoplasmic domain 
All were assessed as Deleterious on Provean and Damaging on SIFT. 
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RIPK4 chr21:43,159,529-43,187,266 RIPK4 has been postulated as a potential driver gene in 
cSCC (Pickering, Zhou et al. 2014), by activation of Wnt/Hedgehog/Notch signalling 
pathways. Five samples (33%) showed medium impact SNV, including COSM21051 which 
annotates a C>T substitution at 21:43176851 with a scaled CADD score of 28.6. 
 
RASA1 chr5:86,563,705-86,687,748). RASA1 probably acts as a tumour suppressor gene by 
its inhibitory regulation of the Ras-cyclic AMP pathway (Pickering, Zhou et al. 2014). Three 
samples (20%) showed inactivating missense SNV with scaled CADD scores >25 for this 
gene. 
 
HRAS (chr11:532,242-537,287). See above in Chapter 1.5.3. Four samples (27%) showed 
damaging and deleterious missense SNV. Only 1 sample harboured an amplification CN >= 
5. 
 
PARD3 chr10:34,398,488-35,104,253 High impact short variants (1 stop gained and 1 splice 
acceptor region variant) were identified in 2 samples for this gene. Five samples showed 
missense SNV (all with scaled CADD > 20), with one of these samples also showing an 
inframe deletion. One of the missense SNV had a COSMIC ID catalogued to BCC. All 
samples showed at least one non-coding but scaled CADD > 10 SNV. There were no 
examples of amplification in this cohort and two samples had large scale deletion events. 
Neither of these large deletions were in samples with inactivating missense coding SNV. 
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Table 5-1 Mismatch repair gene SNV/Indel and CNV 
 
5.4 Mismatch repair genes 
To identify susceptibility to microsatellite instability (MSI) due to mutations in mismatch 
repair genes, we analysed variation in a subset of genes included in a review of MSI in 
melanoma (Chae 2016). These genes were the top 10 mutated DNA repair genes when 
comparing COSMIC and TCGA data for diseases including lung, breast, liver, large intestine 
and skin(melanoma). The variant data for these 10 genes is presented in Table 5-1. All genes 
had some degree of inactivating variant. A large and significant amplification of TP53BP1 
was seen in a single specimen (4699). 
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5.5 Discussion 
5.5.1 Short Variants 
The overwhelming majority of short variant events in metastatic cSCC are non-coding (Figure 
3-2). This underlines the utility of WGS in this study compared to the largest previous study 
of aggressive and high risk cSCC which employed WGS(Pickering, Zhou et al. 2014), and a 
recent major work using targeted NGS analysis of 10 000 tumours including metastatic cSCC. 
The conclusion could be drawn from our findings that it is simply our ignorance of the non-
coding genome that limits the application of WGS to this disease and has little to do with the 
mutational landscape.  
 
5.5.2 Recurrent SNV 
Somatic SNV identification was one of the key aims of this project. We were interested in a 
metastatic cohort to establish the mutational landscape of cSCC. As with BRAF v600e, we 
wondered whether a single variant might be recurrent and provide an avenue for therapy in 
this disease. Of note, there were no BRAF coding SNV in our series. 
 
The extent of somatic variation in  “normal” UV exposed skin (Martincorena 2014) is 
significant. Nonetheless, the burden of mutation and variants seen in cancer associated genes 
is different between their cohort and ours, being at either end of the range of sun exposed and 
UV implicated pathologies. What is to be made of the extent of SNV and how can we best 
make sense of short variants in the face of the mutational burden in metastatic cSCC? The 
answer is obviously to more mindfully interrogate hotspots of impact in the non-coding 
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genome, some of which are known, and some will depend on findings from transcriptome 
analysis of our cohort. 
 
The short variants that were recurrent and high impact (coding, scaled CADD >10) included 
many known tumour suppressors or other genes previously described in the cancer context. 
These genes and their known roles in carcinogenesis and metastasis include: 
 
TP53 was the gene in which most mutations occurred. TP53 encodes a protein (p53) that acts 
as a tumour suppressor, with effects on apoptosis and cell cycle regulation, including by p21, 
GADD45 and 14-3-3 activation. Germline mutations cause Li Fraumeni Syndrome, 
characterized by early onset of many varieties of malignancy. Somatic variations in TP53 are 
seen in all cancer types. Mode of variant may be large scale impact such as frameshift or 
premature stop codons, or by missense mutation.  
 
CDKN2A– Cyclin-dependant kinase inhibitor 2A (p16) acts as a tumour suppressor, acting 
by inhibiting cyclin-dependant kinases. It is capable of inducing cell cycle arrest in G1 and 
G2. Its actions are many and can be related to its effect on p53 degradation (by binding to 
MDM2), or independent of p53 (by activation of cyclin complexes).  The usual mechanism 
of inactivation is via deletion, but this was not the case in our series, whereby SNV was 
predominant.  CDKN2A (p16) expression acts as a surrogate marker for HPV infection and is 
of particular interest in mucosal oropharyngeal SCC. It is thought that p16 expression may be 
a marker of disease more sensitive to therapy. The application of this theory is currently the 
subject of numerous clinical trials. Its role in cutaneous malignancy is less clear. There is 
good evidence that p16 expression in the lymph node metastases of cSCC is common 
(Beadle, William et al. 2013). Practical application of this finding supports a sceptical 
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approach to the routine attribution of p16 +ve SCC in cervical lymph node metastases to an 
occult mucosal primary. 
 
MECOM– a gene involved in haematopoiesis. It has at least three transcribed isoforms, 
MDS1-EVI1, EVI1 and EVI1Δ324. Generally MDS1-EVI1 behaves as a tumour 
suppressor, whereas EVI1 and EVI1 324(commonly co-expressed with EVI1) act as onco-
proteins, binding as transcription factors to ETS binding sites(Sayadi, Jeyakani et al. 
2016), and are associated with aggressive cancers with poor prognosis. MECOM is a 
transcriptional regulator and oncogene which plays a role in development, cell proliferation 
and differentiation. It has anti-apoptotic effects by suppressing the JNK-1 mediated 
phosphorylation of c-Jun. c-Jun is usually activated (phosphorylated)  in response to UV to 
protect against UV associated apoptosis. The role of an amplification (and therefore over-
expression) of MECOM could be to decrease c-Jun activity in UV exposed cells and to 
impact on normal apoptotic regulation. MECOM overexpression is associated with worse 
prognosis in glioblastoma multiforme (Hou, Zhao et al. 2016). Translocations of this gene 
with AML1 can occur in Acute Myeloid Leukaemia. In a study of irinotecan resistant 
colorectal cancer cell lines, MECOM was identified as a differentially expressed gene, acting 
through evasion of apoptosis and the MAPK pathway, to worsen prognosis in this therapy 
resistant group.   
 
NOTCH1 encodes a transmembrane protein with EGF like receptors which, once ligand 
bound, releases an intracellular component which has numerous roles in the regulation of 
transcription and subsequent proliferation, differentiation and apoptosis. The Notch signalling 
pathway is upregulated in murine mammary oncogenesis, and increased expression of Notch 
receptors has been associated with many malignancies.   
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PTPRD encodes a protein of the protein tyrosine phosphatase receptor family, that have roles 
in cell growth and differentiation and oncogenic transformation, their action opposing that of 
the tyrosine kinases. Large scale genomic events impacting CDKN2A can also affect PTPRD 
due to their proximity. PTPRD dephosphorlyates STAT3, deactivating its tumourogenic 
activity. STAT3 hyperactivation is associated with decreased survival and resistance to 
EGFR-targeted therapy (Peyser, Du et al. 2015). PTPRD inactivation was demonstrated to 
significantly increase levels of STAT3 in HNSCC. PTPRD is a tumour suppressor that 
exhibits putative inactivating somatic variants in >50% of GBM and between 10-20% of head 
and neck mucosal SCC (Veeriah 2009).  
 
PLCB4 encodes for a protein that catalyses the formation of inositol 1,4,5-trisphosphate and 
diacylglycerol from phosphatidylinositol 4,5-bisphosphate. Amplification of PLCB4 and 
subsequent overexpression has been associated with overall more aggressive disease and 
worse prognosis in primary GIST (Li et al 2017). PLCB4 is also one of a group of genes 
frequently mutated in uveal melanoma.  
 
PCLO encodes Piccolo, which is a presynaptic cytomatrix protein. There is evidence for its 
role stabilising and preventing breakdown of EGFR, and in the progression of disease in 
oesophageal SCC (Zhang 2017). In. this study, in both a knockdown mouse model, as well as 
using a monoclonal antibody targeting PCLO, tumour progression was inhibited. As such, in 
oesophageal SCC it behaves as an oncogene.  
 
PPP6C encodes a catalytic subunit of the protein phosphatase that regulates IL2 receptor 
stimulation by removing phosphate groups and activating the cytoplasmic receptor tyrosine 
kinase. This gene was recently identified as altered in review of BCC, occurring in 15% of 
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primary tumours(Bonilla, Parmentier et al. 2016). Herein it is cited as an inhibitor of Cyclin 
D1. Loss of regulation or inhibition of Cyclin D1, and its overexpression is established in 
many cancers, including head and neck SCC (mucosal). 
 
FAT4 encodes a protocadherin that plays a role in regulating planar cell polarity, the Hippo 
signalling pathway, the Wnt signalling cascade and the expression of YAP1. In gastric cancer 
cell lines and in a mouse xenograft model, FAT4 downregulation increases lymph node 
metastasis and worse survival, and increases growth and invasion of gastric cancer cells, with 
over expression of mesenchymal markers and decreased epithelial phenotype (Cai, Feng et al. 
2015).  
 
CSMD3 encodes a transmembrane protein with CUB and Sushi Multiple Domains. Available 
data from multiple sources supports a tumour suppressor role for CSMD3 and the other 
CSMD genes.  Loss of function mutations of CSMD3 were identified in a knockout airway 
epithelial cell line model to increase cell turnover and probable role in lung tumourogenesis 
in a non-small cell lung cancer model(Liu, Morrison et al. 2012).  
 
SYNE1 encodes for a spectrin repeat containing protein that localises to the cell membrane 
and assists in maintaining subcellular spatial organisation. It has influence in both meiosis 
and cell cycle pathways. Cutaneous melanoma exhibits SYNE1variants in 24% of samples, 
while HNSCC shows SNV in 18% (Intogen : Barcelona Biomedical Genomics 
Lab(Gonzalez-Perez, Perez-Llamas et al. 2013)).  
 
PTCH1 encodes a transmembrane protein receptor (Patched) for Sonic Hedgehog (SHH). 
Unbound, it suppresses the activity of Smoothened (and keeps it cytoplasmically bound 
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within and endosome), but once bound by SHH, it releases SMO to promote cell proliferation 
by nuclear GLI gene activation. Indeed, upon SHH binding, Patched is degraded. PTCH1 is a 
key component of the Hedgehog pathway, and its protein’s action on SMO is the key event in 
contemporary Hedgehog pathway inhibition. Indeed, vismodegib acts to bind and inhibit 
SMO in effect, similar to the action of Patched.  
 
DCC encodes for a protein which is a membrane receptor for netrin-1 (dependence receptor). 
When not bound, DCC has a pro-apoptotic effect. Once bound, it can block apoptosis by 
activation of MAPK pathway and by Caspase 3.  
 
AMPH encodes a protein (amphyphysin) associated with the cytoplasmic surface of synaptic 
vesicles. There is a potential role for AMPH expression changes in cancer. A subset of 
patients with Stiff-Person Syndrome and breast cancer have autoantibodies to amphyphysin.  
 
MUC16 encodes CA-125, which is a transmembrane 0-glycosylated protein which helps to 
protect the apical aspect of epithelial cells. MUC16 interacts with mesothelin (MSLN) to 
activate matrix metalloproteinases to enhance invasion in pancreatic cancer (Chen, Hung et 
al. 2013). CA-125 is used as a marker of disseminated disease in the blood of ovarian cancer 
patients, and its role in other malignancies is emerging. Its cancer association is generally 
assumed to be by overexpression, probably as a result of amplification. Given the role of 
MUC16 in invasion is likely to be by amplification, expression of MUC16/CA-125 and 
MSLN relative to MMP is likely to determine any role in this disease.  
 
NRXN1 encodes for neurexin-1-beta, which is a cell-surface protein that binds to neuroligins 
and is involved in synapse communication between cells, and likely plays a role in cell 
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adhesion interactions. Deletions in this gene are associated with neurodevelopmental and 
neurobiological abnormalities (genecards.org). 
 
USH2A encodes for a protein involved in hearing development. It has been implicated 
(perhaps as a tumour suppressor) as a result of observations of missense mutations of this 
gene in HCC, and its related genes GPR98, PCDH15 and MYO7A in a review of 88 HCC by 
WGS. (Kan, Zheng et al. 2013).  
 
SEMA3D encodes a protein involved in axon guidance in neural development and diseases 
associated with SEMA3D deactivating SNV include Meniere and Hirschsprung Disease.  
 
NAV3 is another gene involved in axon guidance and neurone development and impact IL2 
production by T cells (Karenko, Hahtola et al. 2005) and in neural regeneration. Additionally, 
it plays a role in microtubule regulation and in a breast cancer xenograft model with NAV3 
knockdown, metastasis was increased, and patients with breast cancers expressing normal 
levels of NAV3 show longer survival.  
 
FGFR2 encodes a critical receptor tyrosine kinase, one of four for FGFR. FGF plays a role in 
cell division, regulation of growth and maturation, angiogenesis and wound healing. Targeted 
next generation sequencing in a cohort of non-metastatic primary cSCC identified variants in 
FGFR2 to be exclusively seen in tumours with perineural infiltration (PNI) of tumour cells 
(Zilberg, Lee 2018). Histopathology of lymph nodes infrequently displays PNI due to the 
absence of neural tissue which makes this finding difficult to correlate in our cohort. 
 
RIPK4 encodes a key serine/threonine protein kinase involved in keratinocyte and stratified 
epithelial differentiation. It is involved in both NK-kappaB signalling interactive and 
 
 108 
Wnt/Hedgehog/Notch signalling pathways. Five samples (33%) in our series showed medium 
impact SNV, including COSM21051 which annotates a C>T substitution at 21:43176851 
with a scaled CADD score of 28.6. This variant was also seen in a series of RIPK4 in primary 
head and neck cSCC (Pickering, Zhou et al. 2014). In that series, RIPK4 variants were 
identified in 28% cases. They found variants only in exon 2 and 8, whereas in our cohort, 
they included 2, 5,7 and 8. 
 
RASA1 encodes an inhibitory regulator of the Ras-cyclic AMP pathway, acting via weak 
GTP-ase action to derive the inactive GDP bound RAS on the cytoplasmic extent of RTK. It 
thus acts as a tumour suppressor. In our cohort, three samples showed inactivating missense 
SNV with scaled CADD scores >25. This is in keeping with previously reported findings in 
cSCC (Pickering, Zhou et al. 2014). 
 
HRAS encodes for one of the Ras activating genes, involved in signal transduction and the 
MAPK pathway. It is classified as an oncogene. 
 
PARD3 encodes an adaptor protein involved in asymmetrical and cell polarization processes. 
It is involved in epithelial tight junctions (Chen, An et al. 2017) and may also targets PTEN 
to the same tight junctions. Inherited defects have been implicated in neural tube defects as a 
result of the disruption of neuroepithelial morphogenesis. Its role in cancer has mostly been 
described as a tumour suppressor in breast cancer. Recently, evidence for a role of decreased 
expression of PARD3 in facilitation of the invasion of malignant cells within the breast 
tumour microenvironment by enhancing the sliding property of tumour cells within 
stroma(Milano, Ngai et al. 2016). In our samples, high impact short variants (1 stop gained 
and 1 splice acceptor region variant) were identified in 2 samples. Five samples showed 
missense SNV (all with scaled CADD > 20), with one of these samples also showing an 
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inframe deletion. One of the missense SNV had a COSMIC ID catalogued to BCC. All 
samples showed at least one non-coding but scaled CADD > 10 SNV. There were no 
examples of amplification in this cohort and two samples had large scale deletion events. 
Neither of these large deletions were in samples with inactivating missense coding SNV. 
These data support a high incidence of inactivating short variants potentially enhancing the 
metastatic process.  
 
With such a range of high impact short variants (as well as CNV and SV) within our cohort, 
the question is how to interpret this against what we understand to be drivers of cancer. A 
recent update to the COSMIC database is the Cancer Gene Census (Sondka, Bamford et al 
2018). This is not new data but a review and representation of existing COSMIC data and 
revision of the original paper (Futreal, Lachlan et al 2004).  
 
Within the census, genes are categorised according to Tiers. Tier 1 genes possess documented 
activity relevant to cancer, along with evidence of mutations in cancer which change the 
activity of the gene product in a way that promotes oncogenic transformation. COSMIC also 
reviewed the existence of somatic mutation patterns across cancer samples in COSMIC. For 
instance, tumour suppressor genes often show a broad range of inactivating mutations and 
dominant oncogenes usually demonstrate well defined hotspots of missense mutations. Genes 
involved in oncogenic fusions are included in Tier 1 when changes to their function caused 
by the fusion drives oncogenic transformation, or in cases when they provide regulatory 
elements to their partners (e.g. active promoter). 
 
Tier 2 genes are those that, whilst being implicated in cancer, have less robust evidence and 
often relate to genes that are more recent targets of interest.  
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Within our cohort, Table 5-2 represents those genes for which we observed either significant 
SV, CNV or high impact SNV compared to the same genes annotation within the Cancer 
Gene Census. 
Of note is that for our reported SNV, we have a minimum scaled CADD of 10 for 
predominantly missense variants. Other higher impact short variants including stop gained, 
frameshift and splice donor or acceptor variants are also present. The same is not the case for 
the data from the CGS. No such minimum impact is required. Rather, for each gene, 
following a search of the COSMIC database and the available literature, data is compared 
from multiple reported series (at least 2), and each piece of evidence must satisfy at least 2 
expert (post-doctoral scientists) reviewers. The gene is then ascribed a Tier.  
Within the CNV/SV group, concordance in this comparison is seen within SOX2, MYC, 
DCC, SMAD4, PDE4D. Additionally, most of our high impact (missense) SNV share this 
observation with the CGS annotations.  
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Table 5-2 Comparison of metastatic cSCC CNV/SV genes and high impact SNV with 
annotations from COSMIC Cancer Gene Census. 
 
GENE Met cSCC CGS (Tier) GENE Met cSCC CGS (tier) 
NDRG1 Amp Trans (1) TP53 FS Splice 
Mis SNV 
Mis/Non SNV 
FS Trans (1) 
PIK3CA Amp Mis SNV(1) CDKN2A FS Mis SNV Del/FS/Splice/ 
Mis/Non SNV 
(1) 
SOX2 Amp Amp (1) MECOM Mis SNV Trans (1) 
ABL1 Amp Mis SNV/ 
Trans (1) 
NOTCH1 Mis SNV Trans Mis 
SNV (1) 
ASXL1 Amp FS, Mis/Non 
SNV (1) 
PTPRD FS Mis SNV Del Mis/Non 
SNV (1) 
BAI1 Amp - PLCB4 Mis SNV - 
CAP2 Amp - PCLO Mis SNV - 
COL5A1 Amp - PPP6C Mis SNV Mis/Non SNV 
(1) 
CYC1 Amp - FAT4 Mis SNV Mis/Non SNV 
(1) 
DSP Amp - CSMD4 Mis SNV - 
EPPK1 Amp - SYNE1 Mis SNV - 
EDN1 Amp - PTCH1 Mis SNV FS/Splice/ 
Mis/Non SNV 
(1) 
EGFL7 Amp - AMPH Mis SNV - 
PLEC Amp - MUC16 Mis SNV Mis SNV(2) 
MYC Amp Amp/Trans 
(1) 
NRXN1 Mis SNV - 
DCC Mis SNV 
/Del 
Mis/Non 
SNV Del (1) 
USH2A Mis SNV - 
SMAD4 Del FS Mis/Non 
SNV Del (1) 
SEMA3D Mis SNV - 
   NAV3 Mis SNV - 
TTC28 Trans - FGFR2 Mis SNV Mis SNV (1) 
MYLK Trans - RIPK4 Mis SNV - 
PDE4D Trans Trans RASA1 Mis SNV - 
EPHB1 Trans - HRAS Mis SNV Mis SNV(1) 
PTK2 Trans - PARD3 Mis SNV - 
CNV/SV SNV 
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5.5.3 Mismatch repair genes 
Mismatch repair defects give rise to microsatellite instability (MSI) due to hypermutation. 
Microsatellites are small recurring repeats, usually one to six base pairs in length. MSI was 
originally described in Lynch syndrome, a non-polyposis colorectal cancer, the phenotype 
having mainly right sided cancers occurring in the 6th decade and having a signet ring 
histopathology (Thibodeau 1993). This disease is characterised by germline mutations in the 
MSI genes MSH2, MLH1, MSH6, PMS2, and PMS1 (Pawlik 2004). In particular SNPs in 
MSH2 and MLH1 were seen most frequently in tumours exhibiting MSI.  
A comprehensive review of somatic mutations, CNV and expression frequencies of DNA 
repair genes within COSMIC identified recurrently somatically varied genes in melanoma 
(Chae 2016). The top 10 genes associated with subsequent MSI in melanoma were TP53, 
KMT2C, POLQ, ATM, ATR, BRCA2, SLX4, TP53BP1, PRKDC, CENPE. Somatic variants 
within our cohort across these genes is presented in Table 6-3.  
As stated earlier, in a series of high risk cSCC, Pickering et al reported inactivating mutations 
of KMT2C in 39 cSCC, which encodes a histone methylation complex to alter transcriptional 
regulation. This mutation has been identified in other malignancies and was associated with 
increased incidence of bone invasion and a shorter time to recurrence in cSCC (Pickering, 
Zhou et al. 2014). Once again, in our series, it was a key MMR gene with a high rate of 
inactivating mutations. This confirms the earlier findings of a likely role in advanced and 
metastatic disease.  
 
 
 113 
5.5.4 Pathway impacts from short variants 
5.5.5 Canonical Wnt/ß-catenin and Hippo interaction  
The canonical Wnt/ß-catenin pathway is one of 3 Wnt pathways (canonical, non-canonical 
(cell polarity and calcium homeostasis). Wnt signalling is responsible for many regulatory 
and growth limiting effects with obvious cancer implications. Canonical Wnt pathway is 
activated via Wnt ligand binding to the Frizzled receptor (Fz) with subsequent 
intracytoplasmic accumulation of ß-catenin and translocation into the nucleus to act as a 
transcription factor for genes including c-myc and cyclin D1. When the Wnt ligand is not 
bound, ß-catenin does not accumulate, but rather is phosphorylated and ubiquinated to be 
degraded by proteasomes.  
 
Hippo is a pathway that acts to regulate the size of organs. It is impacted by cell density and 
so in a high cell density is in the activated state. Such a state is meant to regulate further cell 
division and organs growth. This is ultimately by phosphorylation (and degradation) of 
YAP/TAZ, the final drivers of anti-apoptotic and proliferation genes including diap1 and 
cyclin E (Kim and Jho 2014). 
 
Mechanisms for interaction between Wnt and Hippo pathways include the blocking of ß-
catenin’s nuclear localization (and therefore activation of regulators of proliferation) by 
YAP/TAZ, remembering that YAP/TAZ activation (non-phosphorylation and escape from 
degradation) occurs in the low-cell density state. Additionally, ß-catenin levels, and their 
ubiquitinisation complex levels may also impact on the levels of TAZ in the cytoplasm 
(Azzolin Cell 2012).  FAT4 is one of the previously unknown upstream activators of Hippo. 
Its deactivation should lead ultimately to less phosphorylation of YAP/TAZ with less 
resultant degradation. This would then replicate the low-cell density state and drive anti-
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apoptotic and proliferative genetic drivers. As reported earlier, FAT4 showed significant 
missense SNV in our cohort. Conversely, we have identified an amplification of DSP which, 
in NSCLC acts as tumour suppressor by inhibiting the Wnt/ß-catenin pathway. 
 
5.5.6 Notch signalling 
Of the 4 NOTCH receptor encoding genes, NOTCH1 showed the most variation in metastatic 
cSCC. Activation of the NOTCH pathway is highly conserved, and binding of ligands and 
activation of the transmembrane NOTCH receptor transfers the Notch Intracellular domain 
(NICD) to the nucleus to activate transcription of specific target genes and activation of 
downstream targets including PI3K, AKT and p21. 
 
5.5.7 Hedgehog pathway signalling 
PTCH1 was recurrently varied in metastatic cSCC although perhaps not to the same 
deleterious biological effect of some of the other highest impacting genes by SNV. 
Nonetheless, there is a degree of variant activity in this gene which is likely to impact on its 
role as a key transmembrane receptor in the Hh pathway. Inactivation of PTCH1 to disallow 
reception of the Hh ligand will impact disinhibition of SMO. SMO affect to induce expression 
and post translational modification of GLI zinc finger transcription factors (Karamboulas and 
Ailles 2013). 
 
5.5.8 Cell Cycle 
Genes in the cell cycle pathway predominate in the most recurrent single nucleotide variants 
in our samples. TP53 and CDKN2A are genes most impacted by high impact (eg stop gained 
and splice region) and missense variants. SMAD4 is the gene with the second highest rate of 
large scale deletion events. Crossover effects to the regulation of apoptosis magnify the loss 
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of not just the cell cycle but also programmed cell death as a result of these inactivating 
mutations. 
 
Figure 5-4 Cell cycle Kegg diagram highlighting TP53, CDKN2A and SMAD4 
interaction. Source https://www.kegg.jp/kegg-bin/show_pathway?hsa04110 
 
5.5.9 MAPK and MEK inhibition 
The Ras-Raf-MEK-Erk pathway starts with the bindings of a receptor tyrosine kinase and 
ends with the activation of transcription factors in the nucleus to drive cell growth, 
differentiation, proliferation, apoptosis and migration functions. Key genes within the 
pathway showing somatic variation in our cohort include the tyrosine kinase regulator 
PTPRD and PPPC6. In recognised key MAPK genes DUSP4, DUSP6, MAP2K1, MAP3K1, 
MAP3K2, MAP3K3, MAP3K7, MAP3K9, MAPK1, MAPK3, MAPK8, MAPK12, MAPK14 we 
found multiple missense variants across 10 of 15 samples. These were most prominent in 
DUSP4, MAP3K1, MAP3K3, MAP3K9 and MAPK14. No such mutations were seen in 
DUSP6, MAPK1 or MAP2K1.The usual targets of MEK pathway inhibition, BRAF and RAS 
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did not show significant variation, and there were no examples of V600E (or V600K) 
mutation in our samples. 
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6 Results: Non-coding regions 
6.1 TERT promoter variants 
TERT promoter mutations (TPM) were seen in 13 (93%) metastatic tumours (Figure 6-1). 
These included common and widely reported classic mutations C228T (chr5: 1295228) (n=3) 
and C250T (chr5:1295250) (n=8,), but also the less common but described variants 
A161C(chr5:1295262), C205T(chr5:1295205) (n=7), C242T(chr5:1295242), 
C243T(chr5:1295243) and C252T(chr5:1295252). Of those cases with TPM, 85% showed 
either C228T or C250T, but none showed both. 
 
The classic TPM C228T was seen in 21% of all samples and 23% of those with TPM. In this 
series the previously infrequently observed mutation C205T, was seen in 50% of all samples 
and 54% of samples with TPM (Figure 6-1).  
 
Amplification (CN=>4) of TERT itself was demonstrated in 13/15 samples (Figure 6-1), with 
a minimum block size of 5000bp.  
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Figure 6-1 TERT promoter variants by sample and prevalence. Percentage of samples 
exhibiting TP variant (blue) left of main body. Copy number variation of TERT below 
main figure (green).  
 
In order to understand whether any of the observed TPM impacted on telomerase expression, 
paraffin blocks of all metastatic tumour samples were cut and stained for 
immunohistochemical (IHC) assessment (TERT Antibody (A-6), Santa Cruz Biotechnology, 
California). Of those cases that had TPM, only 25% stained positive for telomerase (Figure 6-
2). The greatest association between TPM and positive IHC was for the C205T variant, 
whereby 75% of cases that stained positive had this mutation, and 43% of the C205T cases 
stained positive. Only 1 out of 8 cases with C250T stained positive, with this case also having 
C205T TPM. There was no correlation between positive IHC and clinicopathological 
features. Vinagre et al found a trend toward higher TERT expression as assessed by IHC in 
gliomas with TPM, but this failed to reach significance. Furthermore, there was no 
association between TPM or amplification pattern, and differentiation of tumours, nodal 
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ratio, resection status or survival in our cohort. Thus, telomerase IHC is unhelpful in 
considering TPM effect. 
 
 
Figure 6-2 Immunohistochemistry analysis showing positive telomerase staining in 
tumour cells of sample 35818 with no staining (negative control) of stroma evident. 35818 
had a TERT CN of 9 and was the only sample with C205T and A161C. TERT (A-6): sc-
393013 Santa Cruz Biotechnology Inc 
 
6.2 NFKBIE  
Across the NFKBIE promoter co-ordinates 6:44233377-6:44233437, SNVs were identified in 
9/15 specimens (60%), with 5 of these samples having more than one promoter variant. 
Chr6:44233400 C>T was seen in 5/15 (33%) samples with an average VAF of 0.25.  
In total, more than 50% of cases showed an amplification, one in combination with an LOH 
event. 
 
Noteworthy is that all samples with a CNV other than 48585 also had a promoter variant. 48585 
herein shows a major amplification over 370000bp with a CN of 6 (5:1).  
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6.3 MicroRNA 
We selected a group of microRNA(miRNA) that had been identified in SCC of the vulva 
(Melo-Maia, Lavorato-Rocha et al 2013) and cervix (Ding, Wu et al 2014) as potential 
biomarkers for progression of disease and also as potential serum biomarkers. These miRNA 
included miR-1246, miR-20a, miR-2392, miR-3147, miR-3162-5p miR-4484. To assess a 
wider block size (5000bp) than confined only to the miR co-ordinates (in the region of 22 
nucleotides each), manual co-ordinates were entered into Seave for analysis. These co-
ordinates were:  
miR-1246 Chr 2: 176817825-178208520 
miR-3147 Chr 7: 56738644-58335801  
miR-4484 Chr 10: 125523232-125649350 
miR-3162 Chr 11: 59265408-59409255 
miR-20a Chr 13: 91984898-92091600 
miR-2392 Chr 14: 101233633-101308604 
Copy number analysis of the regions spanning these miRNA showed both CN loss and gain. 
miR-3147 showed deletion in 5 samples (33%). This same miRNA was duplicated in 100% 
of samples with an average CN of 4.6 and average block size of 19.7 Mb. 13/15 samples 
showed a duplication of miR-2392 with an average CN of 3.7. 
 
A selection of microRNA implicated in cSCC (miR-21, miR-184, ,miR-31, miR-203 and 
miR-205) (Dziunycz, Iotzova-Weiss et al 2010) were analysed for CNV and SNV in our 
cohort. (Table 6.2). As discussed in Chapter 9.5.3, miR-203 and 205 are heavily amplified in 
our samples. In particular, miR-203 showed highly consistent amplification (in all but 1 
sample) and no evidence of deletion. Within this group miR-31 (known to suppress growth, 
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invasion and colony formation in metastatic cSCC cell lines (Wang, Landen et al 20140) had 
the highest average CN in those samples showing amplification.  
Table  6-1  cSCC associated microRNA Copy number variation. 
microRNA Amplified (n) Ave CN 
amplification 
Deleted (n) 
miR-21 6/15 3.5 4/15 
miR-184 5/15 3.9 2/15 
miR-31 6/15 4.5 2/15 
miR-203 14/15 3.7 - 
miR-205 10/15 3.6 3/15 
 
 
6.4 Long non-coding RNA 
A number of cancer associated lncRNAs , including HOTAIR, LINC00568, TERC, 
LINC00657 (NORAD), TCF7, TINCR, MALAT1 (Schmitt and Chang 2016) PVT1, HULC, 
,RP11-65J3.1(Xie, Jiang et al. 2018) and PICSAR (LINC00162) (Pipponen et al 2016)were 
analysed for both SNV and CNV. SNV (with minimum scaled CADD >5) were common 
across all samples (Table 6-2). 200971 was the least varied sample with only 2 SNV of 
lncRNA PVT1 and TINCR.  
 
Table  6-2  Frequency of lncRNA SNV in 15 metastatic cSCC specimens. Scaled CADD 
>5 
lncRNA SNV 
# samples (of 15) 
Average scaled CADD 
HOTAIR 5 10.8 
LINC00568 2 9.3 
TERC 1 6.7 
LINC00657 9 8.7 
TCF7 9 9.1 
TINCR 5 9.5 
MALAT1 12 9.9 
PVT1 15 7.7 
HULC 2 9.1 
LINC00162 0  
RP11-65J3.1 11 6.9 
MIRLET7A1 1 16.3 
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CNV of these lncRNA was predominantly amplification (Table 6-3).  In particular 13 of the 
15 samples had amplification in PVT1 with an average CN of 4.8 and no deletions.  
 
Table 6-3 Copy number variation long non-coding RNA 
lncRNA CN Amplification 
# samples (of 
15) 
Ave Size BP 
for Amp (Mb) 
Deletion 
# samples (of 
15) 
HOTAIR 3.5 8 24.61 2 
LINC00568 3.9 9 19.13 2 
TERC 4.1 11 14.47 0 
LINC00657 
(NORAD) 
4.2 9 12.88 1 
TCF7 3.2 5 36.12 3 
TINCR 3.2 8 9.89 2 
MALAT1 3.9 11 13.01 2 
PVT1 4.8 13 20.80 0 
HULC 4.0 10 19.13 0 
RP11-65J3.1 
(linc01503) 
4.0 8 15.64 0 
MIRLET7A1 4.0 8 32.02 0 
LINC00162 3.6 6 5.81 3 
 
 
 
6.5 Discussion: Non-coding Regions 
Most of the genome is non-coding. Non-coding regions include 3’ and 5’ untranslated 
regions (UTR), promoter and other regulatory regions, long non-coding RNA, introns, either 
in genes or intergenic with no clear functional role. Interrogating non-coding regions is a 
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mammoth task. This task is most sensibly approached either in piecemeal fashion targeting 
known hotspots or regions with transcription factor binding sites, or in conjunction with 
expression data which identifies over or under expressed regions not obviously the result of 
coding variants. And just as not all somatic variants are coding, not all expression changes 
will be the result of genomic variance, highlighting the impact of epigenetic modulation and 
stromal interaction. 
 
Non-coding regions discussed here are as a result of assessment of genes in interest only and 
are not presented as comprehensive. A further review of non-coding regions will follow a 
more thorough analysis of the expression pattern in cSCC generally. Promoter and enhancer 
variants probably impart effect by changing the affinity of transcription factor binding sites. 
Promoter and enhancer (regulatory) regions are rich in transcription factor binding sites. 
University of California Santa Cruz (UCSC) genome browser includes a track which includes 
TFBS in regulatory regions. From this resource, each TFBS can be interrogated for the 
evidence behind each claim, including the cell line or disease in which the enhancement is 
seen. Given the lack of genomic assessment of cSCC (moreover for metastatic cSCC), the 
application of data derived from ICGC or 1000 Genomes is not always clear.  
 
6.5.1 TERT promoter mutations 
Telomerase is a ribonucleoprotein polymerase, maintaining telomere ends by addition of the 
telomere repeat TTAGGG. In most normal somatic cells, telomerase is repressed allowing for 
progressive shortening of telomeres and eventual senescence. Telomerase is made up of an 
internal telomerase RNA template (encoded by gene TERC chr3) and the enzyme, telomerase 
reverse transcriptase (encoded by gene TERT chr5). The TERT promoter spans the 
coordinates chr5:1295154-1295376 (50-270BP upstream from the transcription start site). 
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Deregulation of telomerase expression in somatic cells may be involved in oncogenesis, and 
TPM are perhaps the most common variants in cancer. 
 
Vinagre et al (2013) evaluated the presence of TERT promoter mutations (TPM) across a 
number of malignant cell lines and tumours. They identified rates of TPMs in various 
malignancies; glioblastoma (49%), urothelial carcinoma of the bladder (59%), differentiated 
thyroid cancer (10%) and melanoma (29%). Corresponding upregulation of expression was 
noted in these groups. In the same study, no mutations were found in renal cell carcinoma, 
GIST or phaeochromocytoma. Within melanocytic tumours, only sun exposed cutaneous 
melanoma showed recurrent mutations, with no such evidence in either benign neavi or 
ocular melanoma. Huang (2013) in a study of 329 cell lines form various tissues and 
pathologies found a high rate of recurrent TERT mutations C228T and C250T within the 
melanoma group.   Most mutations observed were either C250T or C242T. Hugdahl, 
Kalvenes et al (2018) recently described the rate of TPM in matched primary and metastatic 
melanoma. They found a rate of 68% and 64% respectively, with 24% of mutations being 
discordant.   
 
Some telomerase activity persists in normal skin. Burnworth (2007) observed that over the 
spectrum from normal skin, through keratoacanthoma to invasive SCC, TERT expression was 
equally upregulated. In a focused examination of TERT promoter variants of SCC from 
various sites Cheng et al (2015) showed a similar pattern of recurrent and mutually exclusive 
mutations to that reported by Huang, but most marked in UV associated tumours. These 
mutations had no impact on clinicopathologic behaviour.  Scott et al (2013) surveyed TPM in 
primary skin cancers compared to benign skin conditions, without matched normal germline 
control. They found the highest rate of mutations in basal cell carcinoma (78%). Mutations 
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were found in SCC (50%) and Bowens Disease (cSCC insitu) (9%), but no TERT promoter 
variants were found in benign skin.  Zehir (2017) in 27 cases of metastatic nodal cSCC all 
with DNA extracted from FFPE samples and subjected to targeted NGS (including TERT 
promoter) found 32% of patients harboured TERT promoter variants; however, none of the 
patients exhibited C228T or c205T. TPM have been identified (Jung, Kim et al 2017) as a 
negative prognostic indicator in Non Small Cell Lung Cancer, being associated with both 
regional lymph node metastasis and worse overall survival. 
 
This mutual exclusivity of C228T and C250T was first described by Huang (2013). 
Breakpoint analysis showed no translocations or inversions effecting either promoter or 
TERT in any samples. One sample showed a 3Mb tandem duplication of TERC.  
 
The classic TPM C228T has not been previously described in metastatic cSCC.  Herein it 
was seen in 21% of all samples and 23% of those with TPM. In this series the previously 
infrequently observed mutation C205T, was seen in 50% of all samples and 54% of samples 
with TPM. In their collection of a variety of solid organ metastases, Zehir et al observed 
C205T mutation in only 0.05% of all cases (5 of 10336) and 0.4% of those cases with TPM 
(5 of 1232).  
 
TERT regulatory variants outside of the promoter region (total co-ordinates span 
chr5:263002-2208200 [Ensembl.org]) were identified in all samples with promoter region 
mutations. Some of these variants occurred in multiple samples. These occurred in Enhancer, 
TF, CTCF (CCCTC-binding factor) bindings sites, open chromatin and Promoter Flanking 
regions.  Of the 6 cases without TPM, 2 also had a variant in an open chromatin TERT 
regulatory region.   
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This high rate and novel pattern of TPM may be in response to the high mutational burden 
and may give rise to the high level of structural variation, including chromothripsis, although 
this paradoxical theory of telomere crisis is theoretical. Telomere crisis is characterised by 
the shortening of telomeres due to increased cell division (unregulated growth occurring early 
in carcinogenesis) to the extent that telomeres are completely lost to expose the chromosome 
proper (Chin, de Solorzano et al. 2004). Subsequent replication of isolated chromosomal 
fragments may give rise to chromothripsis and katagesis (Maciejowski, Li et al. 2015). 
 
ATRX can act to reduce telomere shortening via an alternate mechanism to the action of 
TERT. Its loss, by either mutation or deletion, might lead to telomere length loss. This 
process is described in glioma(Wiestler, Capper et al. 2013) to be mutually exclusive to TPM. 
In our series, this was not the case and the only coding mutation in ATRX was seen in a single 
sample that also had C250T TPM. Nonetheless, the missense mutation (C>T) with amino 
acid change (leucine to phenylalanine) seen was probably deleterious and had a scaled 
CADD of 29.8, and has been described in cholangiocarcinoma with COSMIC ID 
COSM4767440, COSM4767441. 
 
6.5.2 NFKBIE 
NFKBIE is a gene with 2 isoforms (Shain, Garrido et al. 2015). The longer isoform is present 
mainly in brain tissue, whereas the shorter isoform is present in all other tissues. Shain et al 
identified mutation hotspots within the promoter region of the shorter isoform, particularly in 
desmoplastic melanoma. One of these variants is chr6:44233400 C>T (G>A on coding 
negative strand). The mutation hotspots within the promoter of NFKBIE are within consensus 
binding sites for multiple transcription factors. Across the promoter co-ordinates 6:44233377-
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6:44233437, we identified SNV in 9/15 samples (60%), with 5 of these samples having more 
than one promoter variant. Chr6:44233400 C>T was seen in 5/15 (33%) samples with an 
average VAF of 0.25. In the original paper outlining this finding, 2 of 20 samples of 
desmoplastic melanoma also showed NFKBIE amplification.  
 
6.5.3 microRNA 
MicroRNA are small (19-25nt) fragments of the genome that are transcribed to a primer and 
then pre miRNA before exiting the nucleus as mature miRNA. In the cytoplasm they are 
activated by Dicer and then interact with mRNA in a complex known as the RNA-induced 
silencing complex (RISC). The effect of the RISC can be to either completely silence the 
translation of the mRNA or to reduce its expression and enhance its degradation, depending 
on the match of the miRNA and the 3’ UTR of the target gene/mRNA. The first human 
miRNA (let-7) was discovered in 2000 (Reinhart, Slack et al 2000). miRNA are often located 
in close proximity to genes (eg TP53 and miR-34) a trait that enables or augments their 
activity to reduce protein expression and in turn to potentially play a role in pathology. 
miRNA can be thought of in much the same fashion as cancer associated genes, ie having 
proto-oncogenic or tumour suppressing effect. Because miRNA through the RISC opposes 
gene expression by disabling mRNA (a miRNA may be involved in the RISC for a number of 
different genes), an over expression of a miRNA that bind to a tumour suppressor gene will 
have a pro-cancer effect, and similarly, under expression of a miRNA that binds to the 
mRNA of an oncogene will have the same effect. The converse would be the same in the 
tumour suppressing context. So miRNA are of interest in their interaction with cancer 
associated genes and might be able to be used as a biomarker or potentially as a therapeutic 
target. Not insignificant in assessing impact of miRNA in disease is the identification of the 
target genes for each. 
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Matched tumour and serum miRNA were investigated in oral SCC (OSCC) (Schneider, 
Victoria et al. 2018). They found amongst a group of 48 miRNA differentially expressed 
between healthy tissue and OSCC (25 down and 23 up-regulated), 30 were also able to be 
identified in the serum samples. They promoted the utility of miR-32 as it was up-regulated 
in both states compared to healthy tissue. miR-32 was identified as associated with colon, 
pancreas and prostate cancer in one of the earliest studies matching miRNA with solid 
tumour types (Volinia, Calin et al 2006). miR-32 is located on the long arm of chr1, near 
PTPN3, a protein tyrosine phosphatase which has been implicated in numerous solid organ 
malignancies, both to inhibit and to promote (Gao, Zhao et al. 2014, Li, Lai et al. 2015). In 
this context of liquid biopsy biomarkers, the microRNA miR-1246, miR-20a, miR-2392, 
miR-3147, miR- 3162-5p miR-4484 were identified as serum markers of metastatic cervical 
SCC(Chen, Yao et al. 2013). These miR cluster together in pathways by using miR-Path 
(Vlachos, Zagganas et al. 2015)  
 
In our cohort, copy number analysis of the regions spanning these miRNA showed both CN 
loss and gain. miR-3147 showed deletion in 5 samples (33%). This same miRNA was 
duplicated in al 100% of samples with an average CN of 4.6 and average block size of 19.7 
Mb. 13/15 samples showed a duplication of miR-2392 with an average CN of 3.7. 
 
A study of HPV negative vulval cSCC described overexpression of miR-3147 in cancers 
compared to non dysplastic adjacent skin. Levels of overexpression were proportional to 
depth of invasion, but not metastatic spread (Yang and Guo 2018).  
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We also identified a highly amplified state of miR-203, a miRNA previously identified as 
under-expressed in cSCC when compared to normal skin (Dziunycz, Iotzova-Weiss et al 
2010). This report did not analyse metastatic cSCC. Indeed in our samples, of the five 
miRNAs analysed in Dziunycz et al (miR-21, miR-184, miR-31, miR-203 and miR-205) 
miR-203 stood out due to there being no deletion events but having sizeable amplification in 
14/15 specimens. In SNV terms, miR-203 showed downstream SNV in 10/15 samples, 
though of debatable impact without total RNASeq data.  
 
This amplification of miR-203 in metastatic cSCC is at odds with most of the body of 
evidence surrounding this microRNA. In colorectal cancer for example, depletion of miR-203 
is associated with a higher grade and lymph node metastasis (Deng, Wang et al 2016). 
Conversely, overexpression was associated with improved survival and suppression of 
growth in vitro on CRC cell lines. Using a bioinformatic algorithm called TargetScan, Deng 
et al inferred the target of the miR-203 blockade was EIF5A2.  Expression of miR-203 and 
EIF5A2 were essentially opposite. The one exception from the published series is that of 
epithelial ovarian cancers, which generally displayed the opposite effect, that miR-203 levels 
are proportional to aggressiveness and are prognostically adverse (Iorio, Versone et al 2007). 
In our cohort, with significant amplification of miR-203, we found that EIF5A2 (located on 
3q – a highly amplified region – see above) was amplified in 11/15 samples with an average 
CN of 4.2 in the amplified samples. There were no deletions of this gene. This is not the same 
as either transcription influence or protein translation, but the amplification of both seems to 
suggest there is more to this story, particularly in our cohort.  
 
TP63 is a target of miR-203 in effect reducing p63 expression (Yi, Poy 2008). This means 
that in vitro it reduces stemness in the suprabasal epithelial layers and promotes 
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differentiation. Conversely, miR_205 is thought to target E-cadherin expression, and in doing 
so, be associated with a less well-differentiated form. In comparing miR-203 and miR-205 
and their expression in high risk cSCC, again, miR-203 was more likely to be expressed in 
better outcome disease, when compared to miR-205, which was associated with more 
aggressive biology in terms of recurrence and locoregional metastasis (Canueto, Cardenoso-
Alvarez et al 2017). Again, in terms of purely genomic observations of amplification and 
deletion, this difference is not seen in our cohort, with amplification of miR-203 being the 
most prominent amplified cSCC associated microRNA. Total RNA Seq will qualify and 
quantify any expression difference.  
 
Also within the list of miRNA of Dziunycz is miR-31. It has been further analysed by Wang 
et al (Wand, Landen et al 2014) wherein they describe its apparent role in both primary and 
metastatic cSCC, utilizing a previously described metastatic cSCC cell line UT-SCC-7. They 
found that blocking of miRNA expression reduces invasion, migration and colony formation 
of UT-SCC-7. miR-31 was not overexpressed in normal tissue or actinic keratosis. Within 
our samples, miR-31 amplification was seen in 6/15, with an average CN of 4.5 (Table 6-1), 
perhaps providing genomic evidence of over-expression. 
 
6.5.4 Long non-coding RNA 
lncRNA are a type of noncoding RNA that have transcripts greater than 200 nucleotides in 
length without protein coding function. These are thought to be highly specific to 
differentiated tissues and diseases including cancer. lncRNA influence gene expression by a 
variety of mechanisms. The physiological and pathological mechanism  of miRNA action is 
more fully understood and there are a number of miRNA inhibitors and mimics currently 
being developed for use in cancer and chronic diseases (Matsui and Corey 2017). lncRNA 
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situated between genes are referred to as long intergenic ncRNA, and there is a subclass of 
lincRNA that is termed very long intergenic non-coding RNA as their size is greater than 
50kb.  
PVT1 (lincRNA) upregulation is associated with worse prognosis and a more aggressive  
phenotype in many cancers. It shares a locus with the known oncogene MYC on chr8. There 
is significant correlation between amplification of PVT1 and MYC due to their close 
proximity. In breast cancer, PVT1 may interact with the miRNA-200 family to promote early 
disease events (Colombo, Farina et al. 2015). It may exert its role in gastric cancer by 
interfering with the ubiquitinisation of STAT3 to reduce it degradation, and in doing so, to 
promote angiogenesis (Zhao, Du et al 2018).   
 
In this study, we have shown amplification in chr8q24.21 which includes both MYC and 
PVT1. In addition, CNV identified PVT1 as amplified (to an average CN of 4.8) in 13/15 
samples of metastatic cSCC (87%). There was no evidence of any deletions in this lincRNA. 
The highest rate of amplification frequency seen in TCGA data is for ovarian cancer at 43% 
(Colombo, Farina et al. 2015). Of note is that all samples with amplification of PVT1 showed 
corresponding amplification of MYC presumably due to the block size (average size of 
amplified element affecting PVT1 20.80 Mb) covering both regions in the long arm of chr8. 
PVT1 holds some promise, not just in cSCC, as a potential biomarker of disease and/or 
progression.  
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7 Germline variants 
While the focus of this study has been an analysis of the landscape of somatic variants in 
metastatic cSCC, we have, in the process of interrogation of genes of interest, identified a 
number of recurrent inherited variants that may be implicated in the development of cSCC, 
and may play a role in the progression of cSCC.  
 
7.1 Mismatch repair genes 
 
In our cohort, significant germline events were identified in 14/19 whole blood samples. The 
most recurrent of these variants, seen in 9/20 samples, was a splice region SNP of MSH2 
(chr2:47641560 (A>C) (dbSNP ID rs11309117), with a scaled CADD of 11.63.  This SNP 
was not identified in any of the more than 4000 genomes sequenced in the Medical Genome 
Reference Bank healthy elderly adult germline database, compiled and curated by the, 
Kinghorn Centre for Clinical Genomics/Sydney Genomics Collaborative. 
(https://www.garvan.org.au/research/kinghorn-centre-for-clinical-genomics/research-
programs/sydney-genomics-collaborative/mgrb). One other SNP, effecting one specimen, 
had a probably damaging and deleterious variant in PMS2 (chr7:6045634 T>C) rs63750123 
(scaled CADD 26.9), seen in 1% of MGRB samples. This SNP also has a COSMIC ID 
(COSM601786), catalogued as a missense somatic variant in tumour sample of a sample of 
metastatic cSCC (Li, Hanna et al. 2015) 
 
7.2 TERT promoter 
 
Germline analysis of all included samples reveals recurrent Chr5p15.33 SNPs. We identified 
3 recurrent and novel variants in the TERT/CLPTM1L super-enhancer SE_66421 in 16 of 19 
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samples. The incidence of these events in normal elderly healthy adult genome library 
(MGRB – as discussed above) (n=5678) are 43%, (rs466502/Chr 5:1325767 A>G), 40% 
(rs31488/Chr 5:1342156 A>G) and 44% (rs27070/Chr 5:13465303 G>C). This combination 
of SNPs has not been previously described and they have neither independently nor in 
combination been described in cSCC.  
 
These germline events occur less than 1500BP upstream of the TSS of CLPTM1L, which in 
turn is immediately upstream of TERT. They also sit within the bound region of 
ENSR00000177543 which is the CLPTM1L regulatory element with binding sites for 
promoting transcription factors including PKNOX1 and ATF1.  
 
Germline analysis reveals 93% of our cases have a G>C SNP at 5:1346303 (rs27070), less 
than 1500BP upstream of the TSS of CLPTM1L, within the TERT associated super-enhancer 
SE_66421. This SNP also sits within the bound region of ENSR00000177543 which is the 
CLPTM1L regulatory element with binding sites for promoting transcription factors including 
PKNOX1 and ATF1. This SNP is present in 43% of 5678 sequenced germlines in our 
database of healthy subjects. SNPs in the TERT/CLPTM1L.  
 
7.3 Discussion 
 
Much effort in this analysis of cSCC has been on tumour variation. We know, using 
xeroderma pigmentosum as a model (see above Chapter 1.2) that predisposing inherited 
conditions can mirror the effect of drug induced immunosuppression in increasing the 
incidence of cSCC. There has been previously no investigation into whether novel inherited 
predisposing genetic factors might play a role in determining a landscape for either a more 
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aggressive form of cSCC or for disease which readily metastasizes. These initial results 
suggest peculiarities in the germline of this cohort of patients with metastatic disease and 
offers an avenue for a more formal interrogation. This idea is supported by recent work by 
Ioannides and Wang et al (2018) who have identified through genome wide and 
transcriptome wide analysis loci of likely predisposition for cSCC. These genes include 
CTSS, HORMAD1, GOLPH3L and ANXA9 at 1q21, CASP8 at 2q33, AHI1 at 6q23, HAL at 
12q23, and ORMDL3 at 17q21. Further analysis of larger germline samples within an 
expanded group of our cases will allow some insights into any relevance of these genes in 
susceptibility in the metastatic disease setting. 
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8 Expression analysis 
The Nanostring platform using the Pancancer Progression Gene Panel for multiplex gene 
expression analysis was used. This catalogue of cancer associated genes (n=770) was selected 
to match best with predicted patterns of variants associated with the metastatic process.  The 
genes analysed in the panel are listed in Appendix 6 and are known drivers of carcinogenesis, 
metastasis or epithelial mesenchymal transition.  
8.1 Results 
Expression data for across all 770 genes is shown in Figure 8-1. The samples and genes are 
clustered in an unsupervised manner and show considerable variation in gene expression 
across all genes and specimens. 
 
Within each of the following heatmaps, sample 34943 shows significant difference from the 
remained of the cohort. This sample is from a patient who had left sided parotid lymph node 
metastasis. Of all the patients included, this patient was the only to have previously had a 
mucosal SCC, in addition to the included metastatic cSCC. They had undergone a 
contralateral maxillary resection for an alveolar SCC 6 years prior to the emergence of their 
cutaneous disease. It is unclear as to the significance of the observed expression difference 
and how much previous treatment may have influenced subsequent behavior of a new, 
anatomically related, malignancy. 
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Figure 8-1 Heatmap analysis of expression of all 770 genes in the Nanostring Pancancer 
Progression panel for all 15 metastatic cSCC specimens. Lower panel shows (log2)*gene 
expression. 
 
 
Next, gene expression analyses of tumour samples based on genes with recurrent short 
variants across our cohort (refer to Figure 5-2) that are also included in the Nanostring 
Pancancer Progression Panel was performed (Figure 8-2). For each of these genes, there was 
demonstrable expression changes for high impact SNV. Within TP53, the only samples with 
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high impact SNV (eg stop-gained or deletion) were 321773, 48585 and 4699. Conversely, 
193958 had no high or medium impact SNV in TP53. With respect to PTPRD, while 38532 
has evidence herein of decreased expression, and while it does have a high/medium impact 
variant is a missense SNV, the SNV is classified as benign and tolerated, but with a scaled 
CADD of 23. Within each sample, SNVs can be implicated in some of what is observed in 
the expression analysis, but certainly not all. This supports the conventional wisdom that 
expression is the summation of multiple influences including both genetic and epigenetic.  
 
 
 
  
 
 
Figure 8-2 Heatmap analysis of expression of genes with recurrent short variants across 
15 metastatic cSCC specimens. Lower panel shows (log2)*gene expression 
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Expression of those genes that are included in the Nanostring Pancancer Progression Panel 
with significant CNV as reported in Figure 5-3 is shown in Figure 8-3. DCC and SMAD4 
show recurrent deletions, all other genes were amplified.  
 
 
 
 
 
 
 
Figure 8-3 CNV and expression effect for the genes listed in Figure 5-3  that were 
included in the 770 gene Cancer Progression Panel. Samples with SMAD4 and DCC 
deletions listed beneath the heatmap. The samples in which SMAD4 is deleted include 
321773, 183410 and 184577. The samples which showed deletion of DCC include 34366, 
321773, 183410 and 184577. 
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As discussed earlier (Chapter 1.8), many genes are potentially implicated in EMT. 
Expression differences in these genes are not necessarily driven by genetic variants. 
Epigenetic influence may be a key driver of EMT. We examined a group of genes previously 
identified as exhibiting expression differences in cSCC animal models (Pastushenko, 
Brisebarre et al. 2018). This study defined tumour cells on the basis of their expression of 
EPCAM markers CD61, CD51 and CD106, and differential expression of genes including 
CDH1, EPCAM, KRTN14, ASPN, MMP1, TWIST1, VCAM, ZEB1, LOX.  
The expression heatmap of these genes across our cohort is presented in Figure 8-4.   
 
 
 
 
Figure 8-4 Expression of EMT genes  
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MYLK, EPHB1 and PTK2 were amongst the genes that were shown to have gene break points 
in more than one sample. To examine the effect of these coding break points and/or gene 
fusions, all samples were tested for MYLK, EPHB1 and PTK2, as these genes were amongst 
the 770 genes included in our Nanostring Pan Cancer Progression Panel. The findings are 
presented in Figure 8-5.  
 
 
 
 
 
Figure 8-5 Expression of genes with breakpoints (samples with breakpoints highlighted 
in blue for given gene). Samples with MYLK breakpoints were 9120 and 184577. 
Samples with EPHB1 breakpoints were 4699 and 321773.Samples with PTK2 
breakpoints were (including sample 34934 which had gene fusion with SLA2). These 
expression differences are inconclusive. 
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8.2 Discussion 
It is ultimately expression that determines a biological effect. Variants in the genome may be 
transcribed and translated in an altered fashion to affect a pathological outcome. Various 
methods exist for the correlation of genomic observations with gene expression. These 
include formal sequencing of the entire transcribed RNA (transcriptome), a more limited 
coding RNA sequencing, PCR (polymerase chain reaction) of isolated regions of transcribed 
RNA by identification using primers, newer digital counting technologies and more clinical 
means such as immunohistochemical assessment and in situ hybridization. There are pros and 
cons to each platform, derivatives mainly of cost and technical demands, and within any 
experiment, one or more of these may be applicable to different components of the analysis.  
 
NanoString NCounter technology uses a hybrid probe to allow RNA in solution to be identified 
with a capture probe and subsequently reported by a reporter probe. This highly automated 
process delivers molecule counts for each gene of interest as a measure of expression. The 
molecule counts are compared and calibrated to that of several housekeeping genes.  
 
The extent of intracohort variability for selected genes with either CNV or high impacting 
SNV was significant. Some of these findings were counterintuitive. For example, in Fig 8-2, 
the sample with the least expression of TP53, relative to other samples, was 48585, which 
showed TP53 amplification. However, it is worth noting that this sample also harboured a 
high impact SNV, so the expression affect could be due to, for example, a premature stop-
gained or a splice variant curtailing transcription. The correlation between our identified 
genomic events and the NanoString expression is not linear, and ultimately the employment 
of RNASeq to more accurately measure the entire transcriptome will provide for greater 
assurance around discrepancies. There are other instances where a clear expression change 
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cannot be accounted for with only genomic data, without an understanding of transcriptional 
translational influences beyond the observed variation. 
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9 Conclusion and reflections 
9.1 Conclusion  
Cutaneous squamous cell carcinoma (cSCC) ranks as the most common lethal malignancy. 
Primary cSCC ranks second only to BCC in prevalence, and together they comprise more 
numbers than all other cancers combined. But most cSCC are able to be treated with simple 
excision with clear margins. This is made more complex in head and neck regions, given 
anatomical constraints and aesthetic considerations. Nonetheless, less than 5% of cSCC will 
ever metastasize.  
 
There are no clinicopathologic predictors of risk of metastasis. Large databases of high risk 
and metastatic cSCC, such as that maintained at the Sydney Head & Neck Cancer Institute, 
support the idea that tumours of the lip and ear are more likely to spread to cervical lymph 
nodes. However, by no means do all tumours behave in this aggressive way, and therefore 
most can be treated simply and not subjected to rigorous surveillance, other than for further 
primary cutaneous lesions. 
 
The impact of metastasis on the patient with cSCC is profound. Spread to lymph nodes 
usually requires multimodal treatment including the surgical resection of effected lymph node 
basins and adjuvant external beam radiotherapy. A large study of the effect of such therapy 
reveals the quality of life costs (Wang, Palme et al 2013).  The issue is not the metastasis per 
se, but rather that most patients with metastatic disease have not been the subject of 
surveillance to risk and with the aim of identifying regional disease spread. This is not due to 
some dereliction of care, but rather that no reliable means of prediction of risk, and therefore 
application of surveillance, has been established. The result of this clinical dilemma impacts 
not just the individual patient, whereby lymph node metastases are often only identified at an 
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advanced stage, but also the community, where effective strategies for surveillance and pre-
emptive management could save not just morbidity to individuals but could more effectively 
and efficiently use public money and resources. 
 
The gaps in our knowledge of the genomic landscape of cSCC have lagged behind that of 
many other less common cancers. In particular, as a marker of activity, publications in cSCC 
compare unfavourably to those on melanoma (Figure 9.1) despite far greater prevalence. 
 
Figure 9-1 Publication rates per year for the last 10 years comparing cSCC, Skin SCC 
and Melanoma (PubMed). 
 
This project is the first dedicated examination of the whole genome in metastatic cSCC. This 
disease has the highest somatic genomic mutational burden of any disease ever described. 
The overwhelming majority of this variation is in the non-coding genome. Within the coding 
genome, the observed mutational burden provides evidence for the application of checkpoint 
inhibiting immunotherapeutics. Metastatic cSCC is characterized by a highly disrupted 
genome with significant structural variation. The predominant structural variation is 
amplification. Within the coding genome, a pattern of highly impacting and recurrent SNV of 
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both tumour suppressor genes and oncogenes is evident. Within the non-coding genome, 
novel patterns of variation have been identified within the TERT promoter and also within 
noncoding RNA. 
 
This project is an exploration of the genomic landscape of metastatic cSCC. This subject 
underpins the work now commenced on looking at expression changes in metastatic versus 
primary disease, with a view to eventually providing validated biomarkers to discriminate 
cancer behaviour and identify those tumours at greatest risk of metastasis from those at little 
risk.  
The suite of genes with high impact variants, and subject to copy number variation and or 
structural rearrangement is significant, both in terms of synergy with other disease, and for 
their potential to provide both a measurable biomarker, and a potential for therapy for 
advanced or unresectable disease, or indeed for distant metastatic disease.  
 
The subjects of investigation that have become obvious future areas if interest from this work 
include: 
Interrogation of non-coding variants- of note was the extent to which WGS illuminates the 
variation in the non-coding genome. We have herein identified some noteworthy regions 
which have stemmed from findings in other diseases, including the TERT promoter and 
miRNA and lncRNA. This is however by no means an exhaustive list and a concentration on 
these findings as well as other known hotspots of influence must be undertaken.  
Analysis of germline variants – this project was not designed as an investigation of the 
germline looking for predisposing inherited variants. However, even within the 
CLPTM1L/TERT super-enhancer, we were able to identify SNPs of unusual combination and 
recurrence. We understand the role of the immune system in predisposing to cSCC. It would 
therefore seem illogical to imagine that components of the genetic makeup of individuals 
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could not play a role in predisposing to an exaggerated effect of UV exposure, either through 
innate immunodeficiency or through stromal variation. 
Transcriptome analysis – this work must be combined with a thorough analysis of the 
transcription and expression of the genomic events we have discovered. Outside of using 
circulating DNA remnants as a biomarker of disease, an examination of the genomic state of 
tumours does not provide any targets of use as a tool for assessing risk. Certainly the 
discoveries herein provides clues to targets, but the transcriptome will potentially provide a 
more useful picture of high risk and metastatic cSCC.  
Already planned future work with this dataset will include the abovementioned transcriptome 
analysis and integration and will also need to be enhanced by increasing the overall numbers 
of both primary and metastatic deposits, including those cases that have synchronous primary 
and metastatic disease.  
 
9.2 Reflections 
It has not been possible to extrapolate from the genomic analysis of 15 samples any particular 
clinicopathologic behaviour attributable to somatic variation, other than to observe that the 
metastatic stage of cSCC has a high mutational burden with prominent amplification. Within 
our patient group, there was a wide variation in age, comorbid disease and 
immunocompetency, all of which potentially confound a direct line between any given 
genomic event and a clinical effect. So it would be fair to say that small numbers in this study 
have not helped overcome the challenge of drawing specific conclusions with regard to 
clinicopathologic behaviour.  
 
Studies such as this need to be based on a watertight and meticulously archived tumour bank. 
It is very challenging, even for a dedicated clinical team, to annotate and care for specimens 
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to that level required of such a project. At every stage, we have been reminded of the absolute 
requirement for record keeping and sample movement rigour, and have, on occasions, needed 
to repeat experiments and retrace our steps, with time and money sacrificed. During this 
project, the establishment of a highly sophisticated and research enabling tumour bank 
(CONCERT) has taken over the ongoing collection and curation of our precious clinical 
specimens and combines this with a prospective clinicopathologic database.  
 
A single sequencing facility and team would have reduced opportunities for error and overall 
would have reduced the work of sample delivery and downstream processing. Whilst the 
AFP at ANU were as helpful and accommodating as the geographic dislocation allowed, the 
delivery of tissues overseas to Macrogen did incur delay and further handling steps. 
Subsequent delivery of raw data to allow for alignment, variant calling and eventual 
bioinformatics analysis was more cumbersome than would have been afforded had we done 
all the sequencing and processing at the KCCG, or any other single quality assured 
sequencing provider.  
 
I would have spent more time and consulted more widely in the establishment of an exact 
protocol for cellularity estimation. I failed to discuss this process with other groups who may 
have been in the position to help with a protocol to diminish the rate of poor tumour 
cellularity and subsequent unusable sequencing effort. We had designed a system that relied 
too heavily on potentially inexact and subjective measures, based on tissue samples that may 
not have eventually matched exactly that which was subsequently used for DNA extraction 
and sequencing. The protocol we eventually landed on was to take a small block of tissue 
either side of that to be sequenced (30mg blocks) and to then have a Specialist Pathologist 
give a tissue cellularity. If the tissue is assessed at >50%, the extracted DNA should then be 
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submitted to a SNP array to confirm the suitability for WGS. One WGS undertaken on low 
cellularity (unusable) tissue would pay for 15 SNP arrays. This modification of process has 
educated a subsequent round of WGS of DNA extracted from primary cSCC. 
 
Despite the learning curve associated with the technical and cognitive gains required, this 
project has been transformative. It has allowed me to further understand the biology of a 
challenging disease, to appreciate the scientific method and to build a strong collaboration of 
interested clinicians and scientists to progress this work.  
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Appendix 1 AJCC Staging 8th Edition Head and Neck SCC 
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Appendix 2 Nucleic acid extraction results 
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Appendix 3 Gel Electrophoresis 
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Appendix 4 Gene List 
AHNAK, BMP1, CALD1, CDH2 , COL1A2, COL3A1, COL5A2, FN1, FOXC2, GNG11, GSC, 
IGFBP4, ITGA5, ITGAV, MMP2 MMP3, MMP9, MSN, SERPINE1, SNAI1, SNAI2, SNAI3, 
SOX10, SPARC, STEAP1, TCF4, TIMP1, TMEFF1, TMEM132A, TWIST1, VCAN, VIM, 
VPS13A, WNT5A, WNT5B, CAV2, CDH1 , DSP, FGFBP1, IL1RN, KRT19, MITF, MST1R, 
NUDT13, PPPDE2, RGS2, SPP1, TFPI2, TSPAN13, AKT1,, CAV2, CDH2 CTNNB1, FN1, 
FZD7, GNG11, GSK3B, IGFBP4, ILK, ITGA5, MAP1B, MITF, RGS2, SNAI1, SNAI2, 
SPARC, TCF4, TGFB1, TGFB2, TGFB3, TIMP1, TMEFF1, TSPAN13, VIM, VPS13A, 
WNT5A, AKT1, BMP2, BMP7, CTNNB1, DSP, ERBB3, F11R, FZD7, GSC, KRT14, MITF, 
MST1R, NODAL, NOTCH1, PTP4A1, SMAD2, TGFB2, TGFB3, TMEFF1, TWIST1, VCAN, 
WNT11, WNT5A, WNT5B, CTNNB1, PPP3R1, RAC1, SMAD2, SOX10, TGFB1, TGFB2, 
TGFB3, TWIST1, WNT11, WNT5A, AKT1, BMP2, BMP7, CAV2, CTNNB1, EGFR, ERBB3, 
FGFBP1, HIF1A, IGFBP4, ILK, MST1R, NODAL, PDGFRB, TGFB1, TGFB2, TGFB3, 
TIMP1, VCAN, CAV2, EGFR, FN1, ITGB1, MSN, MST1R, NODAL, PDGFRB, RAC1, 
STAT3, TGFB1, VIM, BMP2, BMP7, CDH1, CDH2 , CTGF, CTNNB1, DSC2, EGFR, 
ERBB3, F11R, FN1, ILK, ITGA5, ITGAV, ITGB1, PTK2, RAC1, SPP1 , TGFB1, TGFB2, 
TIMP1, VCAN, CAV2, ESR1 , KRT19, TGFB3, NOTCH1, EGFR, ERBB3, PDGFRB, RGS2, 
SPARC, BMP2, BMP7, , SMAD2, SMAD4, TGFB1, TGFB2, TGFB3 CCT3, CENPF, 
KCNK1, CCL14, GREB1, ADH1B, ANLN  RELN AAMP ABI3BP ACHE ACTG2 ACVR1 
ACVR1C ACVRL1 ADAM15 ADAM17 ADAM28 ADAM8 ADAM9 ADAMTS1 ADAMTS12 
ADAMTS8 ADAP1 ADD1 ADM2 ADRA2B AEBP1 AGGF1 AGR2 AGRN AGT AKAP12 
AKAP2 AKT1 AKT2 AKT3 ALB ALDOA ALOX5 AMH ANG ANGPT1 ANGPT2 ANGPTL2 
ANGPTL4 ANPEP ANXA2 AP1M2 APC APOD APOE APOH AQP1 ARAP2 AREG 
ARHGAP32 ARHGDIB ASPN ATPIF1 B3GNT3 BAD BAG2 BAI1 BAI3 BCAS1 BGN BICC1 
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BMP4 BMP5 BMP7 BMPER BMPR1A BMPR1B BMPR2 BNC2 BRMS1 BTG1 C1S C3 
C3AR1 CADM1 CALCRL CAMK2A CAMK2B CAMK2D CAMP CASP8 CAV1 CBLC 
CCBE1 CCDC80 CCL11 CCL21 CCL5 CCL7 CCL8 CCR2 CCR3 CD163 CD24 CD2AP 
CD34 CD36 CD44 CD46 CD82 CDC42 CDH1 CDH11 CDH13 CDH2 CDK14 CDKN1A 
CDKN2A CDS1 CEACAM1 CEACAM5 CEACAM6 CEP170 CEP295 CFP CGN CHAD 
CHD4 CHI3L1 CHP1 CHP2 CHRDL1 CHRNA7 CIB1 CKMT1A CLDN1 CLDN3 CLDN4 
CLDN7 CLEC2B CLEC3B CLIC4 CLU CMA1 CNN1 COL18A1 COL4A1 COL4A2 COL4A6 
COL5A1 COL6A1 COL6A2 COL6A3 COL7A1 COMP CREBBP CRIP2 CRISPLD2 CSF2RB 
CSPG4 CST7 CTNNB1 CTNND1 CTSG CTSH CTSK CTSL CUL1 CX3CL1 CXADR 
CXCL10 CXCL11 CXCL12 CXCL13 CXCL17 CXCL8 CXCR2 CXCR3 CXCR4 CYB561 
CYBB CYP1B1 DAG1 DCC DCN DDR2 DENND5A DENR DESI1 DICER1 DLC1 DLG1 
DLL4 DPT DPYSL3 DSC2 DST ECM1 ECM2 ECSCR EDN1 EGF EGFL7 EGFR EGLN2 
EGLN3 EIF2AK3 EIF4E2 EIF4EBP1 ELF3 ELK3 EMCN EMILIN1 EMILIN3 EMP3 ENO1 
ENO2 ENO3 ENPEP ENPP2 EP300 EPAS1 EPCAM EPHA1 EPHA2 EPHB1 EPHB3 
EPHB4 EPN3 EPS8L1 ERBB2 ERBB2IP ERBB3 EREG ERMP1 ESRP1 ETV4 EVI2A EVPL 
F11R F3 FAM174B FAP FASLG FBLN1 FBLN5 FBN1 FBN2 FBP1 FERMT2 FGF18 FGF2 
FGF9 FGFR1 FGFR2 FGFR3 FGFR4 FGL2 FHL1 FIGF FLI1 FLT1 FLT4 FMOD FN1 
FOXO4 FRAS1 FREM1 FREM2 FST FSTL1 FUT3 FXYD6 GALNT7 GATA4 GDF15 GDF5 
GDF6 GIMAP4 GIMAP6 GJA5 GLYR1 GPI GPR124 GPR56 GPX1 GREM1 GRHL2 GSN 
GTF2I GZMK HAPLN1 HAS1 HDAC5 HDHD3 HEG1 HGF HIF1A HIPK1 HIPK2 HK2 
HK3 HKDC1 HLA-DPB1 HMOX1 HOXA5 HOXA7 HOXB13 HOXB3 HPSE HRAS 
HSD17B12 HSP90B1 HSPB1 HSPG2 HUNK IBSP ICAM1 ID1 ID2 ID4 IFNG IGF1 
IGFBP4 IGFBP7 IL10RA IL11 IL13RA2 IL15 IL18 IL1A IL1B IL1RL1 IL1RN IL6 ILK 
INHBA INHBE IRF6 ISL1 ISLR ITGA1 ITGA11 ITGA2 ITGA3 ITGA5 ITGA6 ITGA7 ITGA8 
ITGA9 ITGAM ITGB1 ITGB1BP1 ITGB2 ITGB3 ITGB4 ITGB6 ITGB7 ITGB8 ITM2A JAG1 
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JAM2 JAM3 JUN KCNJ8 KDM1A KDR KIAA1462 KISS1 KLK3 KRAS KRIT1 KRT1 KRT14 
KRT19 KRT7 LAD1 LAMA1 LAMA3 LAMA4 LAMA5 LAMB3 LAMC1 LAMC2 LDHA 
LEFTY1 LGALS1 LHFP LIFR LLGL2 LOX LOXL2 LRG1 LTBP4 LUM LY96 MAF MAP2K1 
MAP2K2 MAP2K4 MAP3K7 MAPK1 MAPK3 MAPKAPK3 MCAM MED1 MED23 MEG3 
MEOX2 MET MFAP4 MGAT5 MGP MISP MMP1 MMP10 MMP12 MMP13 MMP14 
MMP17 MMP2 MMP24 MMRN2 MPDZ MRC1 MS4A4A MS4A6A MT3 MTA1 MTBP 
MTDH MTOR MUC1 MYC MYCL MYH11 MYLK MYO1D MYO5C NAA15 NAP1L3 
NCAM1 NCL NDNF NDP NDRG1 NF1 NF2 NFAT5 NFATC2 NFKB1 NID2 NME1 NME4 
NODAL NOS2 NOS3 NOTCH1 NOTCH2 NOX5 NPR1 NR3C1 NR4A1 NR4A3 NRCAM 
NRP1 NRP2 NRXN1 NRXN3 NTRK1 OAS1 OCLN OGN OLFML2B OVOL2 P3H1 P3H2 
PCOLCE PDCD10 PDCL3 PDGFA PDGFC PDGFRB PDK1 PDPN PEBP4 PECAM1 
PFKFB1 PFKFB4 PGK1 PIK3CA PIK3CD PIK3CG PIK3R1 PIK3R2 PIK3R5 PIK3R6 
PITX2 PKM PKN1 PKNOX1 PLA2G10 PLA2G2A PLA2G2D PLA2G3 PLAU PLAUR 
PLCG1 PLCG2 PLEKHO1 PLS1 PLXDC1 PLXNC1 PLXND1 PMP22 PNPLA6 POPDC3 
POSTN PPFIBP2 PPL PPP1R16B PPP2CB PPP2R1A PPP3R1 PRELP PRF1 PRKCB 
PRKCG PRKCZ PROK2 PROM1 PRR15L PRSS22 PRSS8 PTEN PTGDS PTGIS PTGS2 
PTK2 PTK2B PTK6 PTPRB PTPRC PTPRM PTRF PTTG1 PTX3 PXDN PYCARD QKI 
RAB25 RAC1 RAC2 RAF1 RAMP1 RAMP2 RB1 RBL1 RBL2 RBM47 RBPJ RBX1 RELN 
RGCC RHOA RNH1 ROBO4 ROCK1 ROCK2 RORA RORB RPS27A RPS6KB1 RPS6KB2 
RRAS RTN4 RUNX1 RUNX1T1 S100A14 S100A7 S1PR1 SACS SAMSN1 SCG2 SCNN1A 
SDC4 SELE SEMA3E SERINC5 SERPINA1 SERPINF1 SERPING1 SERPINH1 SET SETD2 
SFRP1 SFRP2 SH2B3 SH2D3A SH3YL1 SHB SIRT1 SKP1 SLC12A6 SLC2A1 SLC35A3 
SLC37A1 SLC44A4 SLIT2 SLPI SMAD1 SMAD2 SMAD3 SMAD4 SMAD5 SMAD9 SMC3 
SMOC1 SMURF1 SMURF2 SNRPF SOD1 SOS SORD SOX17 SOX2 SOX9 SP1 SPARC 
SPARCL1 SPDEF SPHK2 SPINK5 SPINT1 SPOCK3 SPP1 SRC SRF SRGN SRPK2 SRPX2 
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SSTR2 ST14 STAB1 STAB2 STAT1 STAT3 SULF1 SV2B SYK SYNE1 TACSTD2 TAL1 TBX1 
TBX4 TBXA2R TCEB1 TCEB2 TCF20 TCF3 TCF4 TDGF1 TEK TF TFDP1 TFPI2 THBS1 
THBS2 THBS4 THY1 TIE1 TIMP1 TIMP2 TIMP4 TJP2 TJP3 TLR4 TMC6 TMEM100 
TMEM30B TMPRSS2 TMPRSS4 TMPRSS6 TNC TNF TNFRSF12A TNFRSF1A TNFSF10 
TNFSF12 TNFSF13 TNMD TNN TNS1 TNXB TOM1L1 TP53 TPM2 TPSB2 TPSD1 TSHR 
TSPAN1 TWIST1 TWIST2 TXNIP TYMP UBA52 UTS2 VAMP8 VASH1 VAV2 VAV3 VCAM1 
VCAN VEGFA VEGFB VEGFC VEZF1 VHL VIM VIT VPS13A VSIG4 VWA1 VWA2 WARS 
WIPF1 WNT5A WNT5B WWTR1 ZC3H12A ZCCHC24 ZEB1 ZEB2 ZFPM2 ZFYVE16 
ZFYVE9 AGK AMMECR1L CC2D1B CNOT10 CNOT4 COG7 DDX50 DHX16 DNAJC14 
EDC3 EIF2B4 ERCC3 FCF1 GPATCH3 HDAC3 MRPS5 MTMR14 NOL7 NUBP1 
PRPF38A SAP130 SF3A3 TLK2 TMUB2 TRIM39 USP39 ZC3H14 ZKSCAN5 ZNF143 
ZNF346, CDH2 , FN1, FOXC2, GNG11, GSC, IGFBP4, ITGA5, ITGAV , MSN, SOX10, 
SPARC, STEAP1, TCF4, TIMP1, TMEFF1, TMEM132A, TWIST1, VCAN, VIM, VPS13A, 
WNT5A, WNT5B, CAV2, CDH1 , DSP, FGFBP1, IL1RN, KRT19, MITF, MST1R, NUDT13, , 
RGS2, SPP1, TFPI2, TSPAN13, , AKT1, , CAV2, CDH2 CTNNB1, FN1, FZD7, GNG11, 
GSK3B, IGFBP4, ILK, ITGA5, MAP1B, MITF, RGS2, SPARC, TCF4, TGFB1, TGFB2, 
TGFB3, TIMP1, TMEFF1, TSPAN13, VIM, VPS13A, WNT5A, AKT1, BBMP2, 
BMP7CTNNB1, DSP, ERBB3, F11R, FOXC2, FZD7, GSC, KRT14, MITF, MST1R, NODAL, 
NOTCH1, PTP4A1, SMAD2, SOX10, TGFB2, TGFB3, TMEFF1, TWIST1, VCAN, WNT11, 
WNT5A, WNT5B, CTNNB1, FOXC2, PPP3R1, RAC1, SMAD2, SOX10, TGFB1, TGFB2, 
TGFB3, TWIST1, WNT11, WNT5A, AKT1, BMP2, BMP7, CAV2, CTNNB1, EGFR, ERBB3, 
FGFBP1, FOXC2, HIF1A, IGFBP4, ILK, MST1R, NODAL, PDGFRB, TIMP1, VCAN, 
CAV2, EGFR, FN1, ITGB1, MSN, MST1R, NODAL, PDGFRB, RAC1, STAT3, TGFB1, VIM, 
BMP2, BMP7, CDH1, CDH2 , COL5A2, CTGF, CTNNB1, DSC2, EGFR, ERBB3, F11R, 
FN1, FOXC2, ILK, ITGA5, ITGAV, ITGB1, MMP3, PTK2, RAC1, SPP1 , TGFB1, TGFB2, 
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TIMP1, VCAN, CAV2, ESR1 , KRT19, TGFB3,  PDGFRB, RGS2, SPARC, SMAD4, CCT3, 
CENPF, KCNK1, CCL14, GREB1, ADH1B, ANLN  RELN PCLO, CSMD3, MUC16, ST18, 
USH2A, AMPH, FAT4, PDE1C, SHANK1, ABCA13, APOB, THSD7B, CYP2C8, DNAH10, 
SEMA3D, IL1RAPL1 
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Appendix 5 Nanostring Pancancer Progression Panel Gene 
List 
ZFYVE9,ZFYVE16,ZFPM2,ZEB2,ZEB1,ZCCHC24,ZC3H12A,WWTR1,WNT5B,WNT5A,WIPF1,WAR
S,VWA2,VWA1,VSIG4,VPS13A,VIT,VIM,VHL,VEZF1,VEGFC,VEGFB,VEGFA,VCAN,VCAM1,VAV3,
VAV2,VASH1,VAMP8,UTS2,UBA52,TYMP,TXNIP,TWIST2,TWIST1,TSPAN1,TSHR,TPSD1,TPSB2,
TPM2,TP53,TOM1L1,TNXB,TNS1,TNN,TNMD,TNFSF13,TNFSF12,TNFSF10,TNFRSF1A,TNFRSF1
2A,TNF,TNC,TMPRSS6,TMPRSS4,TMPRSS2,TMEM30B,TMEM100,TMC6,TLR4,TJP3,TJP2,TIMP
4,TIMP2,TIMP1,TIE1,THY1,THBS4,THBS2,THBS1,TGFBR2,TGFBI,TGFB2,TGFB1,TFPI2,TFDP1,TF
,TEK,TDGF1,TCF4,TCF3,TCF20,TCEB2,TCEB1,TBXA2R,TBX4,TBX1,TAL1,TACSTD2,SYNE1,SYK,SV
2B,SULF1,STAT3,STAT1,STAB2,STAB1,ST14,SSTR2,SRPX2,SRPK2,SRGN,SRF,SRC,SPP1,SPOCK3,
SPINT1,SPINK5,SPHK2,SPDEF,SPARCL1,SPARC,SP1,SOX9,SOX2,SOX17,SORD,SOD1,SNRPF,SNA
I3,SNAI2,SNAI1,SMURF2,SMURF1,SMOC1,SMC3,SMAD9,SMAD5,SMAD4,SMAD3,SMAD2,SM
AD1,SLPI,SLIT2,SLC44A4,SLC37A1,SLC35A3,SLC2A1,SLC12A6,SKP1,SIRT1,SHB,SH3YL1,SH2D3A
,SH2B3,SFRP2,SFRP1,SETD2,SET,SERPINH1,SERPING1,SERPINF1,SERPINE1,SERPINA1,SERINC5
,SEMA3E,SELE,SDC4,SCNN1A,SCG2,SAMSN1,SACS,S1PR1,S100A7,S100A14,RUNX1T1,RUNX1,
RTN4,RRAS,RPS6KB2,RPS6KB1,RPS27A,RORB,RORA,ROCK2,ROCK1,ROBO4,RNH1,RHOA,RGCC
,RELN,RBX1,RBPJ,RBM47,RBL2,RBL1,RB1,RAMP2,RAMP1,RAF1,RAC2,RAC1,RAB25,QKI,PYCA
RD,PXDN,PTX3,PTTG1,PTRF,PTPRM,PTPRC,PTPRB,PTK6,PTK2B,PTK2,PTGS2,PTGIS,PTGDS,PTE
N,PRSS8,PRSS22,PRR15L,PROM1,PROK2,PRKCZ,PRKCG,PRKCB,PRF1,PRELP,PPP3R1,PPP2R1A,
PPP2CB,PPP1R16B,PPL,PPFIBP2,POSTN,POPDC3,PNPLA6,PMP22,PLXND1,PLXNC1,PLXDC1,PL
S1,PLEKHO1,PLCG2,PLCG1,PLAUR,PLAU,PLA2G3,PLA2G2D,PLA2G2A,PLA2G10,PKNOX1,PKN1
,PKM,PITX2,PIK3R6,PIK3R5,PIK3R2,PIK3R1,PIK3CG,PIK3CD,PIK3CA,PGK1,PFKFB4,PFKFB1,PEC
AM1,PEBP4,PDPN,PDK1,PDGFRB,PDGFC,PDGFA,PDCL3,PDCD10,PCOLCE,P3H2,P3H1,OVOL2,
OLFML2B,OGN,OCLN,OAS1,NTRK1,NRXN3,NRXN1,NRP2,NRP1,NRCAM,NR4A3,NR4A1,NR3C1
,NPR1,NOX5,NOTCH1,NOS3,NOS2,NODAL,NME4,NME1,NID2,NFKB1,NFATC2,NFAT5,NF2,NF
1,NDRG1,NDP,NDNF,NCL,NCAM1,NAP1L3,NAA15,MYO5C,MYO1D,MYLK,MYH11,MYCL,MYC,
MUC1,MTOR,MTDH,MTBP,MTA1,MT3,MS4A6A,MS4A4A,MRC1,MPDZ,MMRN2,MMP9,MMP
3,MMP24,MMP2,MMP17,MMP14,MMP13,MMP12,MMP10,MMP1,MISP,MGP,MGAT5,MFA
P4,MET,MEOX2,MEG3,MED23,MED1,MCAM,MAPKAPK3,MAPK3,MAPK1,MAP3K7,MAP2K4,
MAP2K2,MAP2K1,MAF,LY96,LUM,LTBP4,LRG1,LOXL2,LOX,LLGL2,LIFR,LHFP,LGALS1,LEFTY1,L
DHA,LAMC2,LAMC1,LAMB3,LAMA5,LAMA4,LAMA3,LAMA1,LAD1,KRT7,KRT19,KRT14,KRT1,K
RIT1,KRAS,KLK3,KISS1,KIAA1462,KDR,KDM1A,KCNJ8,JUN,JAM3,JAM2,JAG1,ITM2A,ITGB8,ITG
B7,ITGB6,ITGB4,ITGB3,ITGB2,ITGB1BP1,ITGB1,ITGAM,ITGA9,ITGA8,ITGA7,ITGA6,ITGA5,ITGA
3,ITGA2,ITGA11,ITGA1,ISLR,ISL1,IRF6,INHBE,INHBA,ILK,IL6,IL1RN,IL1RL1,IL1B,IL1A,IL18,IL15,I
L13RA2,IL11,IL10RA,IGFBP7,IGFBP4,IGF1,IFNG,ID4,ID2,ID1,ICAM1,IBSP,HUNK,HSPG2,HSPB1,
HSP90B1,HSD17B12,HRAS,HPSE,HOXB3,HOXB13,HOXA7,HOXA5,HMOX1,HLA-
DPB1,HKDC1,HK3,HK2,HIPK2,HIPK1,HIF1A,HGF,HEG1,HDHD3,HDAC5,HAS1,HAPLN1,GZMK,G
TF2I,GSN,GRHL2,GREM1,GPX1,GPR56,GPR124,GPI,GLYR1,GJA5,GIMAP6,GIMAP4,GDF6,GDF
5,GDF15,GATA4,GALNT7,FXYD6,FUT3,FSTL1,FST,FREM2,FREM1,FRAS1,FOXO4,FOXC2,FN1,F
MOD,FLT4,FLT1,FLI1,FIGF,FHL1,FGL2,FGFR4,FGFR3,FGFR2,FGFR1,FGF9,FGF2,FGF18,FERMT2,
FBP1,FBN2,FBN1,FBLN5,FBLN1,FASLG,FAP,FAM174B,F3,F11R,EVPL,EVI2A,ETV4,ESRP1,ERMP
1,EREG,ERBB3,ERBB2IP,ERBB2,EPS8L1,EPN3,EPHB4,EPHB3,EPHB1,EPHA2,EPHA1,EPCAM,EP
AS1,EP300,ENPP2,ENPEP,ENO3,ENO2,ENO1,EMP3,EMILIN3,EMILIN1,EMCN,ELK3,ELF3,EIF4E
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BP1,EIF4E2,EIF2AK3,EGLN3,EGLN2,EGFR,EGFL7,EGF,EDN1,ECSCR,ECM2,ECM1,DST,DSC2,DPY
SL3,DPT,DLL4,DLG1,DLC1,DICER1,DESI1,DENR,DENND5A,DDR2,DCN,DCC,DAG1,CYP1B1,CYBB
,CYB561,CXCR4,CXCR3,CXCR2,CXCL8,CXCL17,CXCL13,CXCL12,CXCL11,CXCL10,CXADR,CX3CL1,
CUL1,CTSL,CTSK,CTSH,CTSG,CTNND1,CTNNB1,CST7,CSPG4,CSF2RB,CRISPLD2,CRIP2,CREBBP,
COMP,COL7A1,COL6A3,COL6A2,COL6A1,COL5A2,COL5A1,COL4A6,COL4A2,COL4A1,COL3A1,
COL1A2,COL1A1,COL18A1,CNN1,CMA1,CLU,CLIC4,CLEC3B,CLEC2B,CLDN7,CLDN4,CLDN3,CLD
N1,CKMT1A,CIB1,CHRNA7,CHRDL1,CHP2,CHP1,CHI3L1,CHD4,CHAD,CGN,CFP,CEP295,CEP170
,CEACAM6,CEACAM5,CEACAM1,CDS1,CDKN2A,CDKN1A,CDK14,CDH2,CDH13,CDH11,CDH1,C
DC42,CD82,CD46,CD44,CD36,CD34,CD2AP,CD24,CD163,CCR3,CCR2,CCL8,CCL7,CCL5,CCL21,C
CL11,CCDC80,CCBE1,CBLC,CAV1,CASP8,CAMP,CAMK2D,CAMK2B,CAMK2A,CALD1,CALCRL,CA
DM1,C3AR1,C3,C1S,BTG1,BRMS1,BNC2,BMPR2,BMPR1B,BMPR1A,BMPER,BMP7,BMP5,BMP
4,BICC1,BGN,BCAS1,BAI3,BAI1,BAG2,BAD,B3GNT3,ATPIF1,ASPN,ARHGDIB,ARHGAP32,AREG,
ARAP2,AQP1,APOH,APOE,APOD,APC,AP1M2,ANXA2,ANPEP,ANGPTL4,ANGPTL2,ANGPT2,AN
GPT1,ANG,AMH,ALOX5,ALDOA,ALB,AKT3,AKT2,AKT1,AKAP2,AKAP12,AHNAK,AGT,AGRN,AG
R2,AGGF1,AEBP1,ADRA2B,ADM2,ADD1,ADAP1,ADAMTS8,ADAMTS12,ADAMTS1,ADAM9,AD
AM8,ADAM28,ADAM17,ADAM15,ACVRL1,ACVR1C,ACVR1,ACTG2,ACHE,AAMP 
 
 
